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IDENTIFICATION OF SMALL EXTRACELLULAR RNA FRAGMENTS OF 
MYCOBACTERIUM TUBERCULOSIS  
 
In 2012, the World Health Organization reported 8.6 million estimated incident cases of 
tuberculosis, 1 million deaths among HIV-negative people, and 0.3 million deaths from HIV-
associated tuberculosis.  The Stop TB Partnership has a 2015 goal of reducing the 1990 
prevalence rates by half.  In order to accomplish this goal, there is a large effort to develop new 
vaccines, diagnostics, treatment, and therapeutics.  Understanding how the pathogen, 
Mycobacterium tuberculosis, interacts with the host is critical to the development of these goals.  
An emerging area of interest is how host cells respond to bacterial nucleic acids; there are several 
bacteria that produce nucleic acids that impact pathogenesis through recognition by host pattern 
recognition receptors. 
Previous work by Obregón-Henao et al. found that the culture filtrate (CF) of M. 
tuberculosis was able to induce apoptosis in monocytes, and the material was identified as small 
stable RNAs. Through cloning, the M. tuberculosis small RNA present in the CF was found to 
predominantly consist of tRNA and rRNA with lengths between 30 and 70 bases.  The goal of 
this work was to further understand the composition of the small, stable, extracellular RNA of M. 
tuberculosis. 
The first step in further elucidating the extracellular RNA population was to develop an 
RNA isolation method, allowing for the reliable purification of RNA from the CF of M. 
tuberculosis H37Rv.  The method developed previously was not optimized for RNA purification, 
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and a more streamlined method was needed.  Available commercial kits did not fit the specific 
needs of the project as a method was needed to isolate small RNAs from large volumes of CF.   
The method developed resulted primarily in small RNAs and allowed for isolation of 
extracellular RNA free of contaminants that could interfere with biological assays, including 
DNA, protein, LAM, and LPS.  The kinetics of RNA release into the CF was examined, 
comparing the rate of RNA release to that of protein.  The RNA and protein were found to have 
parallel release rates, which could indicate active release rather than passive release of the RNA.   
Once a reliable RNA isolation method was developed, the composition of the 
extracellular RNA was interrogated utilizing Next Generation Sequencing as a high-throughput 
method.  A pilot study was developed to determine the optimal concentration of extracellular 
RNA for sequencing.  The Next Generation Sequencing provided a better understanding of the 
components of the secreted or released RNA. Ribosomal RNA and transfer RNA fragments were 
found to be present in the extracellular RNA, correlating to what was found by Obergón-Henao 
et al.  A third group of small RNAs were also identified in this study, many of which 
corresponded to small RNAs previously reported in the literature, however novel small RNA 
sequences were also identified. 
The possibility of bias in the sequencing technology was investigated using synthesized 
tRNA DNA oligonucleotides (stDNA oligos) added at specific concentrations.  The quantitation 
bias study indicated that some bias occurs, although the cause is unknown.  All of the stDNA 
oligos in the sample were identified, giving some confidence in the qualitative nature of this 
technology.  However, based on the possibility of bias, it may be too generous to state that the 
technology is truly quantitative.  Based on these studies, it is possible to say with confidence that 
what is identified is present, but not that things are not missed. 
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The long-term goals of this work are to fully understand how the extracellular RNA 
interacts with the host at a molecular level and to understand the mechanism of RNA release.  In 
order to accomplish these goals, it will be necessary to evaluate more M. tuberculosis 
extracellular RNA using Next Generation Sequencing.  A time course study with Next 
Generation Sequencing should also be done to see if the RNA composition changes over time, as 
well as for comparison to intracellular small RNAs.  It would also be important to develop an 
assay to confirm fragments found using the Next Generation Sequencer, as well as to evaluate 
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1.1 General Introduction to Mycobacteria, Mycobacterium tuberculosis and Tuberculosis 
1.1.1 Mycobacterium spp. 
 The genus Mycobacterium is made up of many different species, which are often broadly 
divided into two categories: Mycobacterium tuberculosis complex (MTBC) and nontuberculosis 
mycobacteria (NTM).  The classification of these organisms is based on several defining 
characteristics including rate of growth and virulence [1].  While the topic of this thesis focuses 
on M. tuberculosis, it is important to acknowledge other important species in this genius.  Some 
are obligate human pathogens, while others are considered opportunistic.  Table 1.1 lays out a 
few of the Mycobacterium spp., dividing them into pathogenic and opportunistic, also identifying 
each organism as slow or rapid growers. 
 
1.1.2 Mycobacterium tuberculosis general characteristics and physiology  
 
 Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) and is a highly 
effective pathogen that has plagued humans for centuries.  TB is a disease that has shaped our 
past and continues to shape our future.  Despite the efforts of the WHO, it is still the second 
leading cause of death from an infectious disease worldwide [6]. 
In 1882, Robert Koch was the first to isolate M. tuberculosis and establish it as the 
causative agent of TB.  Prior to this event, TB was believed to be an inherited disease [7].  M. 
tuberculosis is an acid-fast, Gram-positive bacillus with a unique and complex cell envelope 
along with a G/C rich genome [8].  As noted in Table 1.1, M. tuberculosis is a slow growing 
bacterium, which is due, in part, to the cell wall, reviewed in the next section [9].   
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Table 1.1 Prominent Mycobacterium species.  Shows prominent Mycobacterium species separated by 
pathogenicity and rate of growth.  Adapted from references [1-5]. 
 
1.1.2.1 Cell wall 
M. tuberculosis has a unique and complex cell wall, which plays a role in pathogenesis, 
especially because it is the first thing that comes into contact with an antigen-presenting cell 
(APC).  The extensive cell wall structure is important in protecting M. tuberculosis from the host 
immune response, and adds increased resistance to degradation by lysosomal enzymes in the 
phagosome [9].  The basic features of the M. tuberculosis cell wall will be briefly reviewed in 
this section, focusing on pathogenic aspects. 
Because of the unique cell wall, M. tuberculosis is not a true Gram-positive bacterium, 
possessing Gram-negative attributes, including an outer membrane-like structure [10].  M. 
tuberculosis has an outer layer in addition to the typical Gram-positive peptidoglycan that 
  Mycobacterium species Growth 
Pathogenic 
Mycobacterium tuberculosis Slow 
Mycobacterium leprae Slow 
Mycobacterium africanum Slow 
Mycobacterium bovis Slow 
Mycobacterium abscessus Rapid 
Opportunistic 
Mycobacterium avium Slow 
Mycobacterium ulcerans Slow 
Mycobacterium kansasii Slow 
Mycobacterium intracellulare Slow 
Mycobacterium scrofulaceum Slow 
Mycobacterium marinum Slow 
Mycobacterium malmoense Slow 
Mycobacterium simiae Slow 
Mycobacterium szulgai Slow 
Mycobacterium xenopi Slow 
Mycobacterium haemophilum Slow 
Mycobacterium smegmatis Rapid 
Mycobacterium chelonae Rapid 
Mycobacterium fortuitum Rapid 
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contains lipids, glycolipids, and polysaccharides.  Figure 1.1 shows a simplified schematic of the 
M. tuberculosis cell wall, which includes some of the most biologically important structures.   
 
Figure 1.1 Mycobacterial cell wall.  Figure shows some of the most biologically important structures within the 
plasma membrane and the outer membrane (Adapted from Chatterjee et al., 1998 [11] and Minnikin et al., 2002 
[12]; permissions obtained). 
 
The plasma membrane is surrounded by peptidoglycan covalently linked to 
arabinogalactan (AG) and mycolic acids (MA), both of which are unique to the actinomycete 
line of bacteria including the Cornebacterium-Mycobacteria-Nocardia (CMN) branch [9, 11, 13, 
14].  The hydrophobic mycobacterial MAs are long-chain fatty acids that are mainly oriented 

























lipomannan (LM), and lipoarabinomannan (LAM) are all known to exist in a plasma membrane-
bound form as well as in the outer layer [9, 14, 19-21].   
In order to determine the pathogenic implications of the cell wall components of M. 
tuberculosis, researchers performed early studies by separating the various molecules and testing 
them individually.  Using purified components, LAM has been implicated in multiple 
immunologic functions including abrogation of T cell activation [22], the inhibition of IFNγ-
induced functions [23], scavenging of cytotoxic oxygen free radicals [24], and the production of 
macrophage associated cytokines including TNF-α [25-29].  Unlike M. smegmatis and M. 
chelonae, LAM in M. tuberculosis is mannose-capped, referred to as ManLAM, and has been 
considered an important virulence factor [30, 31].  Mannose caps are thought to be involved in 
both the attenuation of the host immune response and mycobacterial entry into macrophages 
[11].  Studies on the importance of ManLAM in virulence were preformed using purified product 
and studies often yielded conflicting results [20, 23, 32-37].  Mannose capping is not restricted to 
virulent strains of M. tuberculosis, indicating that ManLAM may not be an important virulence 
factor on its own [38-40].     
Sulfolipids and trehalose dimycolates (TDM) are located in the outer layer of the cell 
wall, and have been found to be important in the survival of M. tuberculosis in the host cell 
(Section 1.2) although like ManLAM, early studies were done using purified products [41-51].  
The outer layer also contains the lipid phthiocerol dimycocerosate (PDIM), which has been 
shown to be necessary for virulence in mouse models [52-55].  M. tuberculosis mutants rendered 
unable to synthesize or translocate PDIM are attenuated in vivo, although the exact role has not 
yet been identified [54, 56-59].  The mode of action and importance in virulence is not known 
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for many of these cell wall components and the development of mutants will be important in 
determining the true biological importance of these components. 
  
1.1.2.2 Protein Secretion and translocation systems of M. tuberculosis  
 Secreted mycobacterial proteins make up a critical component of the host-pathogen 
interaction that occurs in TB, and the systems responsible for export or secretion are important 
mechanisms of virulence.  This section briefly reviews four methods M.tuberculosis utilizes for 
export or secretion; the Sec pathway, the twin-arginine transporter (TAT) pathway, Type VII 
secretion system (T7SS), and production of membrane vesicles (MV).   
The Sec pathway is a translocation system that is highly conserved in bacteria, and serves 
to translocate proteins containing N-terminal signal sequences in an unfolded state across the 
cytoplasmic membrane.  One of the major components of the Sec secretion pathway is SecA, and 
M. tuberculosis is one of the few pathogenic bacteria that has two copies of the SecA protein, 
secA1, and secA2 [8].  Deletion mutants were used to evaluate the roles of these two 
components, and secA2 was found to be nonessential, as the ΔsecA2 mutant is not able to prevent 
phagosome maturation, which is so critical to M. tuberculosis survival in the host cell [60-62].  
SecA2 does contribute to the pathogenesis of M. tuberculosis, as it has been found to be the 
secretion mechanism for the protein superoxide dismutase A (SodA), which helps the pathogen 
elude oxidative attack by macrophages [61]. 
The TAT pathway is also a translocation system, which serves to translocate folded 
proteins across the cytoplasmic membrane.  The TAT pathway is essential to M. tuberculosis, 
although the role in pathogenesis is not fully understood [63]. 
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M. tuberculosis has five T7SS, also termed Esx 1-5, which are responsible for 
transporting proteins without a typical signal sequence.  The Esx-1 secretion system is the best 
understood of the T7SS, and is involved in virulence.  Esx-1 is encoded on the region of 
difference 1 (RD1), which is deleted in the attenuated vaccine strain Mycobacterium bovis 
Calmette-Guérin (BCG).  The absence of RD1 and Esx-1 in BCG is associated with the 
decreased virulence of this vaccine strain [64].   
There are several effectors secreted by the Esx-1 system also encoded on the RD1, 
including early-secreted antigenic target 6 (ESAT-6) (Esx-A) and culture filtrate protein 10 
(CFP10) (Esx-B) [65].  ESAT-6 and CFP10 have effects on the innate as well as the adaptive 
immune response.  ESAT-6 is important in the recruitment of uninfected macrophages to the site 
of infection, and both M. tuberculosis antigens are recognized by CD4+ and CD8+ T cells [66, 
67].  ESAT-6 can also make pores in host membranes, which are responsible for three main 
consequences in the host cell.  The first result of pore formation is host cell death, which is 
imperative for inducing formulation of necrotic granulomas [68].  The second is mycobacterial 
escape from the phagosome, which allows access to the cytoplasm after prolonged infection [69].  
The third is secretion of bacterial effector molecules into the host cytoplasm like mycobacterial 
DNA, discussed in section 1.3.3.6 [69, 70].  
In addition to the other methods of secretion and translocation, M. tuberculosis is also 
able to release products through active MVs [71].  MVs are released from bacteria through a 
process of budding from the outer membrane can contain genetic material, lipids, proteins, DNA, 
and RNA [72-76], which are used as a way for the bacteria to interact with it’s environment [75, 
77].  Many different mycobacterial species have been found to form and release MVs including 
M. ulcerans, M. tuberculosis, and BCG, although only the virulent species were found to possess 
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lipoprotein agonists of TLR2 [71].  When the MVs were given to mice before infection with M. 
tuberculosis, there was an increase in the bacterial replication in the lungs and spleens after 
infection [71].  MVs from BCG and M. tuberculosis were also found to induce a strong humoral 
immune response in TB patients [78].  Pardos-Rosales et al. later found that iron limitation, 
which occurs in the host cell environment, affects MV production, stimulating release and 
changing the lipid content, further implicating MVs in M. tuberculosis cell communication, 
modulated by the host environment [77].  Membrane vesicles provide a way for M. tuberculosis 
to release immunologically active factors into the host, which could help this pathogen survive 
and persist [77, 78]. 
 
1.1.3 Pathology, Epidemiology, and Control of M. tuberculosis 
 
 M. tuberculosis is spread through aerosol, and generally infects the lungs, termed 
pulmonary TB.  Infection is not limited to the lungs however, and can affect other parts of the 
body, termed extrapulmonary TB.  Within M. tuberculosis infection, there are two TB-related 
conditions: latent TB infection and active TB disease.  In latent TB infection, the patient is 
infected with the bacterium, although they are not infectious and show no outward symptoms.  In 
TB disease the bacteria are actively growing, causing the patient to become infectious and 
develop symptoms [79].  In general, a relatively small proportion of people infected with M. 
tuberculosis will develop active TB disease, although for people with weak immune systems or  
human immunodeficiency virus (HIV), the risk is much higher [80, 81]. 
 In 2012, the World Health Organization (WHO) reported 8.6 million estimated incident 
cases of tuberculosis, 1 million deaths among HIV-negative people, and 0.3 million deaths from 
HIV-associated tuberculosis [6].  Geographically, 58% of the world’s TB cases in 2012 were in 
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South-East Asia and the Western Pacific Regions [6].  The African region accounts for one 
fourth of the world’s cases, India 26%, China 12%, and the Americas with only 3% [6].  There 
are multiple factors to this including areas with high rates of HIV, poverty, and population 
density.  
In 1995, the WHO introduced and expanded a strategy for tuberculosis control termed 
DOTS (Directly Observed Treatment, Short-Course).  DOTS operates using five key technical as 
well as managerial elements involving diagnosis, administration of anti-tuberculosis drugs, 
securing sufficient resources and political commitment, and a system for data monitoring [82].  
In 1998, the Stop TB Partnership was formed in part to help accelerate DOTS implementation 
[82].  Since 1995, 56 million people have been successfully treated for TB in countries that have 
adopted DOTS [6].  The Stop TB Partnership has a 2015 goal of reducing the 1990 prevalence 
rates by half.  Since 1990 the TB mortality rate has fallen by 45% globally, and incidence rates 
are falling in most parts of the world [6].  Because of the large number of people affected by 
tuberculosis, research to develop new drugs, diagnostics, and vaccines is extremely important. 
 
1.1.3.1 Treatment 
The thick cell wall, described in section 1.1.2.1, allows for decreased permeability 
contributing to inherent drug resistance [31].  TB can be cured by standard drug therapy, 
although the treatment times are long, due in part, to the slow rate of M. tuberculosis growth and 
the complex cell wall.  The current regimen involves two months of treatment with first-line 
drugs: rifampicin (RIF), isoniazid (INH), ethambutol (EMB), and pyrazinamide (PZA); followed 
by four months of RIF and INH [6].  When first line drugs are ineffective, a group of second-line 
drugs are available; this includes thiamides, cycloserine, aminoglycosides, p-aminosalicylic acid 
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(PAS), fluorquinolones, and cyclic peptides [83].  Second-line drugs are more harmful to 
patients, often having severe side effects and long treatment times. 
There are many reasons why new TB drugs are needed, including the rise of MDR-TB 
(discussed in the next section).  Current drug regimens require long treatment times and often 
have toxicity associated with use, resulting in a need for drugs that are able to shorten the 
treatment time as well as improving efficacy and tolerability [6].  Because patients with HIV are 
more likely to develop TB disease [6] it is also important to consider HIV patients when 
developing new drugs.  Any anti-TB treatments used for these patients need to be used in 
conjunction with antiretroviral therapy (ART) for HIV [6, 84].  The drugs at a physician’s 
disposal for treating TB are around 50 years old, although recently, bedaquiline, a new anti-TB 
drug was approved by the FDA for use as part of combination drug therapy in adults [6, 85]. 
According to the 2013 WHO Global Tuberculosis Report, there a currently ten new or 
repurposed drugs in the late phases of clinical development [6].  
In addition to drug toxicity and resistance, there are many socioeconomic factors that 
impact the treatment of TB.  Socioeconomic factors include immigration, poverty, malnutrition, 
war, and limited access to medication/medical care [86].  The cost of drugs is a concern for 
treating impoverished patients and, second-line drugs are even more expensive than first-line 
drugs [87].  Getting the cost of current drugs or new drugs down would have an impact on the 
number of patients that are treated for TB.  Many other obstacles in treatment exist that would 
require social change, and Stop TB Strategy aims to find resolutions for these issues [6].  One 
such obstacle is the need close follow-up and patient adherence to therapy [86], and that it can be 
difficult for individuals in rural and poor communities to get formal health care [87].  The Stop 
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TB Partnership aims to help accomplish it’s goal by finding ways to improve health policies and 
finding ways to deliver necessary supplies and information [6].  
 
1.1.3.2 Drug resistance 
The development of drug resistant M. tuberculosis strains can be attributed in part, to 
poor TB control, a lack or misuse of drugs, and lack of patient follow-up [88].  In 2012 the WHO 
reported 450,000 incident cases and 170,000 deaths due to Multi-drug resistant TB (MDR-TB), 
with the highest levels in eastern Europe and central Asia [6].  Only 81 total confirmed cases of 
MDR-TB were reported in the US in 2012, comprising only 0.018% of the MDR-TB cases world 
wide [6].  Of the documented MDR-TB cases, 9.6% were recorded as Extensively drug-resistant 
TB (XDR-TB) [6].  MDR-TB is resistant to at least INH and RIF [6]. XDR-TB is resistant to at 
least INH and RIF, along with fluroquinolones, and more than one second-line drug [89]. 
A new category of resistant TB has been identified in Iran, India, and Italy, termed either 
extremely drug-resistant (XXDR), or totally drug-resistant (TDR); strains in this category are 
resistant to all first- and second-line drugs, along with additional drugs [89-91].  The rise in 




There is also a need for an effective TB vaccine to help prevent spread of the disease.  
There is only one vaccine that is currently available to protect against TB, Mycobacterium bovis 
bacillus Calmette-Guérin (BCG).  BCG was found to have varied levels of protection in adults 
ranging from 0-80% [92].  While not entirely effective, BCG is able to protect against 
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disseminated TB in infants, so it is still widely used [93, 94].  There are two major strategies 
being used in the development of a new vaccine for TB.  The first strategy is to produce a 
vaccine that is more efficient than BCG, and the second is to utilize a ‘prime-boost’ strategy [6].  
The ‘prime-boost’ strategy for vaccine development is attractive, as many of the populations 
most in need of a vaccine already immunize with BCG [95].  There are currently 12 anti-TB 
vaccine candidates in Phase I, Phase II, or Phase IIb trials [6].  New vaccines fall into two major 
categories: live mycobacterial vaccines, and subunit vaccines [92].   
A prominent example of one of these candidates is the recombinant modified vaccinia 
virus Ankara, which expresses the M. tuberculosis antigen 85A (Ag85A), named MVA85A [96].  
MVA85A follows the ‘prime-boost’ strategy, and BCG vaccination followed by a boost with 
MVA85A was shown to improve protection in animals [97-100].  MVA85A was also found to 
be immunogenic and safe in South African adults [95].  Proof of concept Phase IIb trials to show 
safety and evaluate efficacy in infants for this candidate began in South Africa in 2009, and 
study results were recently published [6].  Despite encouraging early studies, MVA85A was not 
successful in providing additional protection from TB disease or M. tuberculosis infection in 
infants, although no concern of safety was raised [96, 101].  Further studies are necessary to 
evaluate MVA85A, as it may be more effective in a different age group such as adults, 
adolescents, or older children [6, 96].  Researchers also wish to investigate whether the vaccine 
would work better as a booster for adolescents and adults, further studying the interaction with 
BCG [101].  MVA85A is currently being tested on HIV positive adults in Senegal and South 
Africa to determine the efficacy with HIV patients [101].  Although the results of the MVA85A 
trial were not as positive as many had hoped, there may still be a use for this vaccine once other 
questions have been investigated [101, 102]. 
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1.1.3.4 Diagnostics 
 Early detection and treatment are important in TB control, and can reduce the rate of 
transmission [103].  Current diagnostics for TB are often time consuming, and it is especially 
difficult to identify patients with latent TB [6].  This section discusses the available methods for 
diagnosis including the pros and cons to each method.   
The conventional method of TB diagnosis is sputum smear microscopy and bacterial 
culture [6].  Unfortunately, this method takes a considerable amount of time, making the 
development of rapid diagnostic tests important for TB control.  Sputum smear microscopy also 
relies on the acquisition of a good sample, which can be difficult to obtain, especially in children 
and HIV positive patients, as they do not produce sputum [104, 105].  Sputum acquisition also 
introduces a risk to healthcare workers because of the possibility of aerosolization during sample 
collection [106].  Sputum can have a low concentration of TB bacilli, rendering the sample 
smear negative [104].  The detection limit for microscopy is approximately 5x103 bacilli per ml 
of specimen [107, 108].  Sample quality is greatly improved when patients are given specific 
instructions on sputum production, limiting the collection of saliva rather than sputum and 
increasing the volume of sample obtained, especially in women [109-112]. 
Chest radiography is another method used to look for TB, although it is not specific to 
TB, identifying abnormalities that could be attributed to other diseases.  There are still uses for 
chest radiography as it can be a cost-effective solution and more readily available than other 
methods of diagnosis [113].   
The Tuberculin skin test (TST) is a widely used diagnostic test, first developed by Robert 
Koch in the 1880s [114].  The TST involves intradermal injection of purified protein derivative 
(PPD), which contains a mixture of M. tuberculosis antigens [115].  When a patient has been 
 13 
exposed to M. tuberculosis, they develop cell-mediated immunity to tuberculin antigens in PPD. 
The patient will have a delayed-type hypersensitivity skin reaction to PPD at the injection site, 
testing for the presence of a cellular immune response within 48 to 72 hours [115].  The TST is 
far from an ideal diagnostic, as it can only give an indication of TB disease or latent disease, and 
should not be the only method used.  A positive result does not diagnose, as it could be a result 
of exposure to environmental mycobacteria, or previous BCG immunization.  The impact of 
BCG vaccination on a TST depends on multiple factors including when the vaccination was 
given, and how many doses were administered [115].  A negative result does not rule out TB, as 
immunosuppressed patients may not react, leading to an incorrect interpretation of results [115].  
The TST is still the preferable method for the serial testing of health care workers in the United 
States [116]. 
Interferon gamma (IFN-γ) release assays (IGRA) are another diagnostic platform used to 
test for active TB disease or latent TB infection, although it cannot distinguish between the two.  
Like the TST, IGRAs also test for the presence of a cellular immune response.  One of the 
downsides to IGRAs is that we don’t know how long adaptive immune responses to 
mycobacterial antigens last when mycobacteria are no longer present [117].  These assays use 
antigens that are specific to M. tuberculosis like ESAT-6 and CFP10 to stimulate T cells, and 
measure the release of IFN-γ [115].  These assays have lower sensitivity in immunocompromised 
patients, including patients with HIV and children.  IGRAs are not affected by BCG vaccination 
status, and results can be available within 24 hours, relatively quickly when compared to the TST 
[115].  There are two main tests, the QuantiFERON-TB Gold In-Tube (QFT) (Cellestis/Qiagen, 
Carnegie, Australia) and the T-SPOT.TB (Oxford Immunotec, Abingdon, United Kingdom) 
[115].  QFT is an enzyme-linked immunosorbent assay (ELISA) that uses ESAT-6, CFP-10, and 
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TB7.7 to test whole blood [115].  TSPOT.TB is an enzyme-linked immunosorbent spot 
(ELISPOT) assay that uses PBMCs rather than whole blood [115].  PBMCs are incubated with 
ESAT-6 and CFP-10 to look for the number of IFN-γ producing T cells, or spot-forming cells 
[115].  
Drug susceptibility testing (DST) is an important step once a diagnosis has been made in 
order to determine if the bacterium is resistant to first- or second-line anti-TB drugs.  This 
determination is especially important in MDR-TB cases [6].  In 2010, the WHO recommended 
the rapid molecular test Xpert® MTB/RIF, which tests for pulmonary TB as well as rifampicin 
resistance [6].  New diagnostics are necessary for TB, especially tests that can be done quickly, 
inexpensively, and instrument free [6].  
 
1.2 The host-pathogen interactions of M. tuberculosis 
 
M. tuberculosis is a complex organism that is notoriously difficult to study for many 
reasons, including its ability to live undetected in its host for prolonged periods of time.  M. 
tuberculosis has evolved with humans, and as such the bacterium has devised mechanisms to 
ensure its survival.  Because of the need for new drugs and vaccines, there is an emphasis on 
studying the initial host-pathogen interactions and the initial stages of infection leading to 
disease.  This section aims to describe some notable interactions between M. tuberculosis and the 
host immune system, including both the innate and adaptive immune response.  
Following infection with a bacterial pathogen, the type of immune response is determined 
in part by the initial interaction between the pathogen and the host innate immune system.  
Pathogen associated molecular patterns (PAMPs), are molecules on microbial pathogens that 
bind to specific host pattern recognition receptors (PRRs), resulting in the activation of the innate 
immune response [118].  The binding of PAMPs to specific PRRs initiates signaling pathways 
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leading to the phosphorylation and activation of transcription factors.  These transcription factors 
are capable of inducing production of many cytokines that are important in the innate immune 
response of the host.  The type of innate immune response triggered by the interaction between 
PAMPs and PRRs tailors the type of adaptive immune response in the event that the innate 
immune response is unsuccessful on its own [118].  A few bacterial components that are 
recognized by PRRs and the innate immune system include: bacterial lipopolysaccharide (LPS), 
lipoproteins, peptidoglycan, flagellin, and teichoic acid [119].  These PAMPs are highly 
conserved among microbial pathogens and are not readily made by mammalian cells; over time, 
various receptors of the innate immune system have evolved to recognize these microbial 
products [118].  
Initial interactions between M. tuberculosis and the host cell primarily occur with 
alveolar macrophages and dendritic cells (DCs), although some in vitro model systems use 
monocytes to study immunological interactions.  The bacilli enter mononuclear phagocytes 
through receptor mediated phagocytosis and there are several M. tuberculosis products that can 
be recognized by PRRs during phagocytosis [120, 121].   
M. tuberculosis can be opsonized by host molecules including immunoglobulins (Ig), 
complement, and lectins [122, 123].  Opsonization allows for enhanced phagocytosis, host cell 
activation, and microbicidal activity.  Non-opsonized M. tuberculosis can be recognized by a 
number of different PRRs including: C-type lectin receptors (CLRs), scavenger receptors (SRs), 
Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLR), and complement receptor 3 (CR3) [124-130].   
C-type lectin receptors (CLRs) are a class of receptors on phagocytic cells and four 
different types are involved in the binding and uptake of M. tuberculosis: the mannose receptor, 
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dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN), 
Mincle, and Dectin-I [126, 131].  The mannose residues on ManLAM allow for M. tuberculosis 
detection by the mannose receptor on macrophages and dendritic cells (DCs) [132-137].  DC-
SIGN is a transmembrane receptor located on the surface of immature DCs, which is also able to 
detect ManLAM, mediating ManLAM induced production of IL-10 [130, 138, 139].  Mincle is 
expressed on the surface of macrophages and is an essential receptor for TDM, although there is 
some redundancy with other PRRs also able to recognize TDM including the one of the SRs 
[140-144].  Dectin-I has been shown to work in concert with TLR2 in mediating production of 
TNF-α [145, 146].  Additionally, Dectin-I has a role in the production of IL-12p40, which is 
important in the formation of granulomas [147].   
NOD1 and NOD2 are PRRs that are able to detect peptidoglycan [148].  NOD2 has been 
found to be required for the optimal production of proinflammatory cytokines [149, 150], as well 
as play a role in the recognition and control of infection found by using knockout mice [151].  
Polymorphisms associated with NLRs are more susceptible to M. tuberculosis infection [152-
154].   
TLRs 1, 2, 4, and 9 have been implicated in the host response and recognition to M. 
tuberculosis and will be discussed in greater depth in section 1.3.2 [155-159].  Lipoproteins of 
M. tuberculosis are TLR2 agonists and TLR2 is important for macrophage production of 
proinflammatory cytokines TNF-α, IL-1, IL-6, and IL-12 [160, 161].  
In the course of many bacterial infections, phagocytosis by a macrophage causes death of 
the pathogen as a result of phagosome and lysosome fusion, or phagosomal maturation, leading 
to an acidic, hydrolytically active environment.  M. tuberculosis and other intracellular 
pathogens are able to survive inside the macrophage by inhibiting this event.  Inhibition of 
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phago-lysosome fusion requires live M. tuberculosis and only occurs with pathogenic bacteria.  
Mycobacteria-containing phagosomes stall at an early stage of maturation, retaining a pH of 6.4 
[162].  Molecules that are proposed to modulate phagosome maturation are the cell wall 
glycolipids ManLAM, TDM, and sulfolipids, along with the bacterial phosphatase SapM and 
serine/threonine kinase PknG [162].  Modulation of the phagosome by M. tuberculosis is critical 
to the success of this pathogen.  The early endosome provides a favorable environment that 
protects M. tuberculosis from serum immunoglobulins and complement, also giving the bacteria 
access to nutrients including iron through recycling endosomes [163].   
Once M. tuberculosis becomes established inside the host cell, a localized 
proinflammatory response attracts immune cells including mononuclear cells and T cells 
resulting in a granuloma [164].  The formation of a granuloma becomes important for both the 
host and the bacteria, keeping the infection at bay, while providing the bacteria with protection 
from the immune system along with nutrient sources [164].  The granuloma is made up of 
macrophages, multinucleated giant cells (MGCs), foamy macrophages, T cells, B cells, and 
fibroblasts [131, 165].  When T cells fail to maintain the granuloma, as occurs with HIV, 
reactivation of the bacilli is promoted and active TB disease can progress [164].  The granuloma 
is also a place where cell-to-cell spread of M. tuberculosis occurs via release of bacilli from host 
cells through apoptosis and phagocytosis by uninfected cells, allowing for further spread of 
infection [131]. 
Despite the ability of M. tuberculosis to live inside macrophages, host cells possess 
methods of eliminating the bacilli.  T cells and a T helper 1 (Th1)-type response are important 
for the host adaptive immune response and are critical for controlling M. tuberculosis during 
latent, or containment stages of disease. Cell mediated immunity is important for control of M. 
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tuberculosis largely because it is an intracellular organism, making antibodies less effective 
[165].  Although the adaptive immune response is important for the control of M. tuberculosis 
growth, it is not sufficient to abolish the infection [166].  T cells that secrete IFN-γ are important 
to granuloma formation and maintenance [117]. Exposure to IFN-γ before phagocytosis of M. 
tuberculosis allows the macrophage to overcome mycobacterial inhibition of phagosome 
maturation [162].  IFN-γ can activate autophagy, or delivery of the bacilli to the lysosome [131].  
TNF-α works with IFN-γ to activate macrophages and modulate apoptosis [167].  NK cells are 
an important source of IFN-γ [168] and express granulysin, which has direct antimycobacterial 
activity.   
There are several subsets of CD4+ T cells: Th1 cells, Th17 cells, and T regulatory cells 
(Tregs); and all have a role in the host response to M. tuberculosis.  Tregs secrete the anti-
inflammatory cytokine IL-10 and TGFβ [165].  Th17 cells initiate the recruitment of Th1 cells to 
the lung through up regulation of chemokines [95].  
  T helper type 1 (Th1) cells are essential for primary resistance to infection and 
protective immunity in humans [131].  TNF-α is important early on in granuloma formation and 
the protective host response [34], and acts as a mediator of macrophage activation [165]. 
Th1 cells recognize peptide antigens that are bound to major histocompatibility complex 
(MHC) class II molecules. M. tuberculosis is able to diminish the ability of macrophages to 
present antigens to CD4+ T cells, which makes it more difficult for the host to eliminate 
infection, down regulate MHC class II on the surface [165].  M. tuberculosis  is also able to 
inhibit MHC II peptide loading and trafficking to the cell surface [169].  Resting macrophages 
express low levels of MHC class II molecules on the surface, once a macrophage is activated, 
antigen presentation is up regulated, increasing MHC II on the surface [162].  Antigen presenting 
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cells (APCs) are able to produce TGFβ, IL-6, and IL-10, which can directly and indirectly affect 
T cell function and proliferation [165]. 
The role of CD8+ T cells in M. tuberculosis infection has been debated through the years 
and the details have not been fully elucidated.  Many studies show that CD8+ T cells are an 
important component in protection and control of TB infection [170-178].  CD8+ T cells 
contribute to protection through secretion of IFN-γ [179, 180] as well as their ability to initiate 
cytotoxic lysis of host cells [181-183].  There are also studies suggesting CD8+ T cells are not 
necessary during infection and have no protective role [184-187].  It is possible for CD8+ T cells 
to arise, which can secrete the immunosuppressive IL-10 during a chronic M. tuberculosis 
infection, although the significance of this particular cell type is unclear [188].  CD8+ T cells do 
not optimally produce IFN-γ without the presence of CD4+ T cells, and this interaction between 
the two types requires further study [173, 189-192].   
CD8+ T cells recognize peptide epitopes bound to MHC class I, cytoplasmic antigens.  
MHC class I restricted and nonclassically restricted CD8+ T cells (CD1).  CD1b presents 
mycolic acid, LAM, PDIM, glucose monomycolate, and CD1c presents isoprenoid glycolipids.  
CD8+ T cells are able to lyse infected cells by producing perfoin, granzymes, and granulysin, and 
produce cytokines like IFN-γ to recruit cellular effector cells [165]. 
Apoptosis and autophagy are two additional host cell mechanisms for controlling M. 
tuberculosis infection [164].  Apoptosis can also benefit M. tuberculosis depending on what 
stage of infection it occurs in [166].  Apoptosis promotes cross-presentation of antigens by CD8+ 




Type I Interferon Response and M. tuberculosis 
 Type I IFNs (IFN-α/β) were originally described and thought of as a part of the antiviral 
type response, although it is found more and more in response to bacterial infection as well.  
Type I IFNs induce the transcription of a large group of genes, and the products of these genes 
enhance the host’s ability to resist viral infections.  This class of IFNs are produced by many 
different cell types in response to stimulation by transmembrane and cytosolic receptors which 
will be discussed in more detail later [193].   
Depending on stage of infection, type I IFNs could be either detrimental or beneficial to 
the host.  They are important in activating components of the innate and adaptive immune system 
including APC maturation, activation of T cells, B cells, and NK cells [194, 195].  Because of 
their role in regulation, type I IFNs can suppress the innate immune response to bacterial 
infections and also play a role in apoptosis, increasing the susceptibility of different cell types 
[70, 193]. 
M. tuberculosis has been shown to induce a type I IFN response in macrophages although 
its role in susceptibility to disease has not been fully elucidated [70, 196].  The ability to induce a 
type I IFN response by specific M. tuberculosis clinical strains has been correlated with 
virulence, and The Esx-1 secretion pathway is necessary for this response to occur [197, 198].  
The induction of the type I IFN response limits the host’s ability to clear M. tuberculosis from 
the spleen and lungs [199, 200].  Mice deficient in the type I IFN receptor were found to have 
decreased mortality when compared to wild type mice, although the bacterial load in the lungs 
was similar [198].  IFN-α/β have been found to modulate IL-12-dependent IFN-γ production and 
impair Th1 responses in mice [198, 201].   
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Individually, IFN-α is able to prime macrophages to produce IL-10 and impair the 
mycobacteriostatic activity, and has been shown to enhance mycobacterial replication in human 
macrophages infected with BCG that could normally control infection [201].  IFN-α can be 
produced by macrophages; DCs, promoting both Th1 and DC maturation [34]; and lymphocytes 
[202].  IFN-α has also been shown to increase apoptosis in monocytes [201].  Figure 1.2 shows 
an overview of the basic mechanisms involved in the interaction between M. tuberculosis and the 
host cell. 
 
Figure 1.2 Basic molecular pathogenesis of M. tuberculosis.  Overview of the basic molecular mechanisms 
induced by M. tuberculosis in the host cell.  The host cell has pattern recognition receptors on the outside of the cell 
and inside the phagosome/early endosome.  Inhibition of phagolysosomal fusion allows M. tuberculosis to survive 
intracellularly.  Mycobacterial antigens can be released from the cells through exosome formation.  After infection, 
the host cell is induced to produce proinflammatory cytokines like TNF-α, IL-1, IL-6, IL-12, as well as a type I IFN 
























 Ribonucleic acid, or RNA, is an essential building block of life, and is likely the earliest 
genetic material in evolutionary history [203-207].  It is critical for the function of prokaryotic 
cells, eukaryotic cells, and viruses.  RNA has a wide range of functions including storing and 
transmitting genetic information, and aiding in the synthesis of essential proteins for cell survival 
[206, 208-210]. 
 RNA is composed of molecules containing a ribose sugar, a phosphate group, and a 
ribonucleotide base [209, 210].  Ribonucleotides are similar to the dioxynucleotides of DNA; 
both have adenine (A), guanine (G), and cytosine (C), but in place of the thymidine (T) of DNA, 
RNA contains uracil (U) [211].  The RNA of eukaryotic and prokaryotic cells is generally single-
stranded (ssRNA).  Some viruses are unique in that they contain double-stranded RNA (dsRNA) 
[212-214].  Typical ssRNA is able to fold or coil back on itself to form complex secondary and 
tertiary structures; the most common of which are hairpins with complementary base pairing and 
helical organization [209, 210, 215]. 
 One of the most important roles of RNA in a cell is its involvement in transcription and 
translation [208].  In order to accomplish this, there are three main types of RNA: messenger 
RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA).  These differ in their 
functions, location in the cell, and structure [209].  rRNA, mRNA, tRNA are considered “classic 
RNAs” [216]. 
 The template for protein synthesis is mRNA, the only coding RNA, transcribed from the 
template strand of DNA [210].  The primary function of mRNA is to carry the information from 
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the nuclear DNA to the ribosome, where mRNA will guide amino acid assembly, forming a 
functional protein [217]. 
 rRNA and tRNA are part of the protein-synthesizing machinery [210, 218, 219], and are 
both non-coding RNA [220].  rRNA has three major roles: it contributes to ribosome structure, it 
helps position the mRNA on the ribosome, and it also plays a catalytic role in protein synthesis 
[209, 218].  rRNA is a major component of the ribosome, along with polypeptides, and is the 
most abundant type of RNA [221].  The translation process occurs on the ribosome with complex 
assemblies of rRNAs [210, 218].  The bacterial ribosome is made up of a 30S subunit and a 50S 
subunit.  The 30S subunit contains 16S rRNA, and the 50S subunit contains 5S and 23S rRNA, 
each of which contains a translational domain [209]. 
 tRNA forms a cloverleaf-like structure generally consisting of a D arm and loop, a T arm 
and loop, an acceptor stem, a variable loop, and an anticodon loop (Figure 1.3) [222, 223].  This 
structure makes tRNA more stable than some of its other RNA counterparts, especially mRNA 
which degrades easily [224].  tRNA functions as the adaptor in protein synthesis, carrying 
activated amino acids to the ribosome to form proteins [219, 220].  The anticodon region 
recognizes the codon on the mRNA, and attaches the correct amino acid [225]. 
RNA is notoriously difficult to study.  It is generally not very stable in solution due in 
part to the activity of ribonucleases (RNases), which are enzymes that process and degrade RNA 
[227].  Because of these difficulties, there are many aspects of how bacterial RNA affects 
biological systems that are not fully understood. 
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Figure 1.3 tRNA Secondary Structure. Circles represent nucleotides and lines represent bases.  White circles in 
the D-loop represent residues present in some, but not all tRNAs.  Red circles represent anticodon residues, and light 
blue circles represent the 3’ CCA end (adapted from Phizicky et al., [226], permissions obtained).  
 
1.3.1.1 Small RNA 
Small RNAs (sRNA) have become a popular topic of research across multiple organisms.  
sRNA research was originally focused on cancer biology, but has more recently become a 
growing topic in the study of bacterial pathogens.  Many bacterial sRNAs have been found 
through bioinformatic predictions.  When bioinformatics screens are preformed several key 
elements are examined including promoter and terminator motifs in intergenic regions (IGR), 
phylogenetic conservation, and RNA structure similarities [228].    
There are many types of sRNA including micro RNA (miRNA), pico RNA (piRNA), 
small-interfering RNA (siRNA), and non-coding (ncRNAs), ranging from 50 to 400 nucleotides 
in size [216].  These RNAs are typically not translated into proteins and have been shown to 
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shown to modulate numerous stress responses in bacteria as well as important components in 
microbial physiology including: catabolism, intracellular iron homeostasis, cell cycle, quorum 
sensing, toxicity, secretion system, cellular stress, and persistence [216].  sRNAs often act by 
base-pairing with specific target mRNAs altering their translation or stability, while others 
associate with specific proteins and modulate their function; allowing bacteria to quickly adjust 
to new environments [216].  sRNAs interact with regulatory proteins; possess specialized 
housekeeping functions; and interact with specific mRNAs in a regulatory manner affecting 
transcription, translation, and stability [216].  sRNAs can be further divided into two categories 
that are based on the mode of base pairing.  Cis-encoded and trans-encoded.  Cis-encoded 
sRNAs are within the target-encoding mRNA and are transcribed in an antisense orientation to 
the target mRNA [229].  Trans-encoded sRNA is typically in the IGR and often has multiple 
targets [230].  Many sRNAs have been identified although only a few have been studied in 
detail. 
In 2009 Arnvig and Young published the first experimental evidence for sRNAs in M. 
tuberculosis [231].  The sRNAs were found by making cDNA libraries from low-molecular 
weight M. tuberculosis RNA.  Nine putative sRNA molecules were found and differential 
expression was observed between exponential and stationary phases of growth, as well as in 
stress conditions [231].  This initial study was followed by a next generation sequencing analysis 
of the M. tuberculosis transcriptome [232].  The sequencing approach revealed a large number of 
sRNAs.  Over one fourth of the sequence reads were ncRNA, with more intergenic regions than 
annotated coding sequences.  The sRNAs were again monitored in exponential and stationary 
growth, with an increase in the stationary phase cultures.  They also preformed a mouse study, 
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finding large amounts of the sRNAs in the lungs of infected mice, indicating a possible role in 
pathogenesis [232]. 
Using both a cloning technique and computational techniques, DiChiara et al. identified 
34 novel sRNAs in BCG [233].  For the sRNAs found in BCG, homologues were identified in 
M. tuberculosis and M. smegmatis.  Eight of the sRNAs were found in M. tuberculosis and BCG 
only, three were found in BCG and M. smegmatis only, 12 were found in all three species, and 
14 were found in BCG alone [233].  The differential expression between the different species 
could be an indicator that some participate in pathogenicity. 
 Pelly et al. preformed a screen for ncRNAs in M. tuberculosis by cloning size-selected 
sRNAs from total RNA of M. tuberculosis [234].  Using this method, 12 clones were identified 
within intergenic regions.  Of the 12 clones, four were novel sRNAs, and eight colones contained 
sequences from a region of the genome between MT1302 and MT1303, termed ncrMT1302, 
which had previously been found by DiChiara et al [233, 234].  Further study showed that 
ncrMT1302 is expressed at high levels in M. tuberculosis. Low pH, the addition of rifampicin, 
and supplementation with cAMP can modulate the levels of ncrMT1302 y [234].  Additionally, 
this was the first report to identify an expression of an M. tuberculosis sRNA in vivo [234].  
 The host has many miRNAs that are important in the immune response to M. 
tuberculosis.  Host miRNAs have been found to be important in the regulation of T cell 
differentiation, the function of macrophages, DCs, and NK cells.  There is research being 
conducted to use specific miRNAs as a biomarker for tuberculosis [235].  The following sections 





1.3.2 Receptors that recognize nucleic acid 
  
Nucleic acids are conserved throughout all life forms, and the recognition of viral nucleic 
acid by mammalian cells is well described [236].  There are several types of PRRs involved in 
the recognition of foreign nucleic acids.  These PRRs include: toll-like receptors (TLRs), 
protein-kinase-RNA-regulated receptors (PKRs), retinoic acid-inducible gene-1-like RNA 
helicases (RLH), and the nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLR) family.  Each of the previously mentioned types of PRRs plays a different role in various 
types of nucleic acid detection. 
 
1.3.2.1 Toll-like receptors 
 
TLRs are transmembrane receptors that play a major role in pathogen nucleic acid 
recognition in the host, and are among the most well described PRRs.  TLRs are expressed in 
DCs, macrophages, B cells, and non-immune cells like fibroblasts and epithelial cells [237].  The 
TLR family is able to recognize both bacterial and viral products, and are involved in targeting 
and eliminating intracellular pathogens in the innate immune response [119, 238].  When a 
ligand is recognized by a TLR, a formation of homodimers or heterodimers occurs, and the 
cytoplasmic domain of TLRs interact with adaptor molecules and transmit signals initiating a 
signaling cascade.  These signaling cascade can have different outcomes depending on the TLR, 
including leading to the transcription of NF-κB and MyD88 [239].  The interaction of a TLR 
with its specific ligand results in the activation of transcription factors. 
TLRs 3, 7, 8, and 9 recognize nucleic acids and reside in intracellular compartments 
including the endosome, lysosome, and endoplasmic reticulum (ER) of host cells [240, 241].  
When an intracellular TLR detects foreign nucleic acid, it triggers what is historically known as 
an anti-viral type response through these transcription factors.  This response produces type I 
 28 
IFNs and inflammatory cytokines such as interleukin-12 (IL-12), IL-1, and IL-6 [236, 241]. TLR 
polymorphisms can alter host susceptibility to human pathogens [242, 243]. 
 
 
1.3.2.1.1 TLR 3 
 
TLR3 recognizes polyinosine-polycytidylic acid (poly (I:C)), a synthetic analogue of 
dsRNA, and natural dsRNA [236].  dsRNA is produced by many viruses during their replication 
[236].  The lysis of virally infected cells can lead to the release of dsRNA, which can be taken up 
by a transmembrane receptor and delivered to the intracellular compartment where TLR3 
resides.  Viruses inside cells can also release dsRNA during their replication which can then be 
detected by TLR3 [236]. 
TLR3 recognizes dsRNA partially by the ionic and hydrogen bonds associated with the 
sugar-phosphate backbone of the dsRNA [241].  Host RNA has a low affinity for TLR3 due to 
RNA modifications which include polyadenylation (poly-A tails) and nucleotide methylation 
[238].  Selective recognition of dsRNA by TLR3 leads to the activation of NF-κB and the 
production of IFN-α/β [236], which exert antiviral and immunostimulatory activities [119].  
Activation of TLR3 also leads to production of immunoregulatory and antiviral cytokines IL-6 
and IL-12, which help elicit cytotoxic responses needed for the elimination of intracellular 
pathogens [236, 244].  These cytokines can help control the replication of viruses and contribute 
to the initiation of the adaptive immune response [244]. 
 
1.3.2.1.2 TLR7 and TLR8 
 
TLRs 7 and 8 are phylogenetically similar to one another, and for this reason, they are 
often studied together [241].  They were originally found to recognize synthetic anti-viral and 
anti-tumor compounds such as imidazoquinolines and guanine nucleoside analogues, as well as 
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whole RNA from viruses, and certain synthetic singe-stranded oligoribonucleotides (ORNs) 
[241, 245].  TLR7 and 8 have also been shown to sense short dsRNAs [246].  They were also 
originally thought to function for detection of viral RNA only, although more recent research has 
shown that they can also detect bacterial RNA [246].  Bacterial RNA contains less frequently 
modified nucleosides than human RNA, which limits TLR7 and 8 sensing of phagocytosed self-
RNA [246].  Despite their similarities, TLR7 and 8 are not identical, and more research has led 
to discoveries of their differences.  TLR7 is highly expressed in plasmacytoid dendritic cells 
(pDCs) and B cells [241, 246].   
TLR8 is primarily, although not exclusively expressed in monocytes [246].  TLR8 
preferentially recognizes bacterial RNA and ssRNA derived from HIV, vesicular stomatitis virus 
(VSV), and influenza A virus [245].  It is possible that ssRNA makes its way to the endosomes 
of cells through receptor-mediated endocytosis, where viral particles are degraded [241].  When 
RNA is detected by TLR8 in monocytes it leads to the production of IL-12p70, which then 




TLR9 recognizes unmethylated 2’-deoxyribo-cytidine-phosphate-guanosine (CpG) DNA 
motifs and synthetic CpG oligodeoxynucleotides (ODNs) [239, 241].  CpG DNA is present in 
prokaryotes, but is rare in eukaryotes [247].  In prokaryotic DNA, the cytosines are rarely 
methylated, unlike those in eukaryotic DNA.  This difference helps to prevent the innate immune 
system from recognizing host DNA [248].  Recognition of DNA occurs independently of the 
base sequence, as the sugar backbone 2’-deoxyribose is what allows the DNA to be recognized 
by TLR9 [241].   
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TLR9 is generally localized in the ER, and then migrates to the endosome where it 
recognizes its ligand [249].  The intracellular location of TLR9 is likely another factor that helps 
prevent recognition of self DNA and subsequent autoimmunity [239].  TLR9 is expressed in 
various cell types including plasmacytoid dendritic cells (pDCs), conventional DCs (cDCs), and 
macrophages [241].  When TLR9 is stimulated, different cytokines or transcription factors are 
produced depending on the type of CpG-DNA stimulation [239].  When TLR9 molecules in 
pDCs encounter their ligands, large amounts of type I IFNs are produced, which can directly 
activate T cells, linking the innate and the adaptive immune systems [239]. 
 
1.3.2.2 Protein kinase-RNA-regulated receptors 
 
 While TLRs are an important part of the pathogen recognition system, there are many 
TLR-independent mechanisms for recognizing foreign nucleic acids including the PKRs.  PKRs 
are serine/threonine protein kinases, located in the cytosol, which are induced by IFNs and 
activated by dsRNA [250, 251].  PKRs contain two conserved dsRNA binding domains in their 
N-terminal region [194].  The recognition of dsRNA can induce PKR to activate the IκB kinase 
(IKK) complex, leading to the release of NF-κB, resulting in an inflammatory response and the 
production of type I IFNs [250].  Induction of these pathways helps to kill virally infected cells 
aiding the host in its defense against viral infections. 
 
1.3.2.3 Retinoic acid-inducible gene-1-like RNA helicases 
The retinoic acid-inducible gene-I (RIG-I)-like RNA helicase (RLH) family is also able 
to recognize nucleic acid in a TLR-independent manner, and includes: RIG-I, melanoma 
differentiation associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (Lgp2) 
[241, 252, 253].  These receptors are found in the cytoplasm of both immune and non-immune 
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cells, where they survey for the presence of viral RNA [241].  When members of the RLH family 
recognize the appropriate ligand, dsDNA for example, a typical antiviral-like response ensues, 
with induction of type I IFN.  The dsDNA can be derived from viruses, bacteria, or even self. 
 RIG-I is a viral and bacterial PRR able to recognize short sequences of cytoplasmic 
dsRNA as well as various ssRNA viruses [194, 241, 254].  MDA5 is required for the recognition 
of some RNA viruses as well as poly (I:C) and binds long sequences of dsRNA [241].  Lgp2 is 
also able to bind dsRNA, and was recently found to be required for antiviral responses mediated 
by RIG-I and MDA5 by Satoh et al. [255]. 
 
1.3.2.4 Nucleotide-binding oligomerization domain (NOD)-like receptors 
 
 The Nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) family is 
divided into five subfamilies, each with a different function.  NOD2 binds viral RNA, which 
leads to the production of type I IFNs [237].  Some of the NLRs are capable of forming multi-
protein complexes called inflammasomes that can secrete IL-1 family cytokines [241].  One of 
these inflammasomes is called NALP3, which is required for caspase-1 activation in response to 
dsRNA and bacterial RNA as well as other ligands [256].  The interaction between PAMPs and 
NALP3 is thought to be indirect, as no direction between the two has been shown [241].  The 
NALP3 inflammasome is important in the secretion of pro-inflammatory cytokines to help 




1.3.3 Specific microbes and the role of nucleic acids in the innate immune response 
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 The previous section outlines multiple nucleic acid receptors and begins to show how 
pathogen RNA can modulate the immune response and possibly help a pathogen establish 
infection.  The role of nucleic acids and their impact on the immune system has been more 
broadly studied in viruses, and there are many examples of this interaction.  One nice example is 
from Moon et al., where they found that a noncoding RNA from a flavivirus is able to disrupt 
cellular mRNA decay in the host cell [257].  This mRNA decay causes interference with 
regulation of cellular gene expression that may influence the cell’s ability to mount an effective 
immune response [257].  This section will outline specific microbes and the role of nucleic acids 
in pathogenesis. 
 
 1.3.3.1 Listeria monocytogenes 
 
 Listeria monocytogenes is the causative agent of listeriosis, a food-borne disease that can 
cause sepsis and meningitis in immunocompromised patients.  This disease can also cause severe 
fetal infections or abortion in pregnant women [258, 259].  L. monocytogenes is a Gram-positive 
bacterium that infects and resides in macrophages [194, 260].  It gains access to the cytoplasm of 
macrophages by disrupting the phagosomal membrane using a pore-forming toxin called 
listeriolysin O (LLO), allowing the bacteria to replicate in the cytosol [260].  Once in the cytosol, 
the bacteria induce a type I IFN response, although the mechanism by which L. monocytogenes 
induces the response is still largely unknown [261].  The induction of type I IFN is independent 
of TLR and cytoplasmic RNA-sensing pathways [260], but seems to be related to multidrug 
resistance pathways [262].  These multidrug resistance pathways cannot transport large RNA or 
DNA polymers, but may be able to transport small RNA molecules [260].  Five novel ncRNAs 
were found in L. monocytogenes that are only found in pathogenic L. monocytogenes, and are 
likely involved in virulence [263].  Like M. tuberculosis, L. monocytogenes has two copies of the 
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SecA protein, as well as an Esx-1-like secretion system [264, 265].  L. monocytogenes was 
recently found to actively secrete small RNAs through the Sec secretion system, relying on 
SecA2 [65].  The secretion of small RNAs resulted in strong activation of RIG-I [65].  Hagmahn 
et al. were able to visualize the bacterial RNA being secreted into the cytosol of human cells 
[266]. 
 L. monocytogenes is a good example of a pathogen that uses the type I IFN response to its 
benefit.  The role of type I IFN in apoptosis could be of great importance in the pathogenesis of 
L. monocytogenes [70].  Studies conducted with mice lacking the type I IFN receptor found that 
these mice were more resistant to L. monocytogenes infection than wild-type mice [259, 267, 
268].  The decreased survival of wild-type mice is likely a result of IFN-mediated apoptosis of 
splenocytes [259].  In this case, the type I IFN is not acting against the bacteria, but is instead 
acting against the host, allowing the bacteria to survive the innate immune response. 
 
1.3.3.2 Legionella pneumophila 
 
 Legionella pneumophila is a Gram-negative bacterium that is ubiquitous in freshwater 
and soil amoebae.  When humans inhale contaminated water, especially from air-conditioning 
units, the bacterium can cause a type of pneumonia called Legionnaires’ disease [269, 270].  L. 
pneunophila replicates in the vesicles of alveolar macrophages, which helps it elude the immune 
response [270].  This bacterium is one of the only bacteria known to induce a type I IFN 
response through the MDA5 cytosolic RNA-detection pathway [271]. 
 The interferon regulatory factor 3 (IRF3) and interferon-β promoter stimulator 1 (IPS-1) 
are critical for the IFNβ response, and are also important for the control of intracellular 
replication by L. pneumophila in lung epithelial cells [271].  In an experiment done by Opitz et 
al., mice lacking the IPS-1 gene had reduced induction of type I IFN by L. pneumophila [271].  
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In this experiment, the replication of L. pneumophila in mouse alveolar macrophages decreased 
with increasing IFNα/β [271].  The exact mechanism of how this occurs is unclear; one 
hypothesis is that L. pneumophila DNA is translocated into the host cells, which leads to the 
production of RNA ligands through DNA-dependent RNA polymerase III (Pol III) transcription 
[272].  There is however, no direct evidence that DNA translocation occurs during infection 
[260].  Another study showed that transfection of macrophages with L. pneumophila RNA, but 
not DNA, is able to induce a RIG-I-dependent type I IFN response [260].  This study also found 
a that MDA5 made a contribution to RIG-I in induction of type I IFNs.  Unlike L. 
monocytogenes, the induction of the type I IFN response seems to have a protective effect 
against L. pneumophila.   
 
1.3.3.3 Group B Streptococcus 
 
 Group B Streptococcus (GBS) is a group of Gram-positive extracellular bacteria that 
causes sepsis, meningitis, or pneumonia in human neonates [273, 274].  Transmission occurs 
prior to, or during birth, when the mother is colonized by GBS.  The bacterium can also cause 
meningitis when acquired perinatally, although this sequale is less common [274]. 
 GBS is another example of the induction of a type I IFN response that is beneficial to the 
host.  When GBS is phagocytosed by conventional DCs (cDCs) and macrophages, the bacteria 
undergo degradation and lysis in the phagolysosome.  The degraded bacterial products remain in 
the phagolysosme and it is there that nucleic acids from GBS act as ligands for TLR7 and TLR9 
[273, 275].  RNA from GBS can be sensed by TLR7 in the endosome of cDCs [237].  In 
macrophages however, GBS activates a different pathway that is independent of TLR signaling 
[275].  In this pathway, liberated bacterial genomic DNA activates an unknown cytosolic DNA 
sensor [273].   
 35 
1.3.3.4 Helicobacter pylori 
 Helicobacter pylori is a Gram-negative bacterium that can cause peptic ulcer disease, 
non-cardia adenocarcinoma of the stomach, as well as gastro-esophageal reflux disease.  H. 
pylori is able to colonize the stomach despite harsh environmental conditions, and can maintain 
persistence throughout the life of host [276].  There is evidence suggesting H. pylori is a human-
specific pathogen [277], and that co-evolution of the microbe and the host has likely occurred 
[278].  
In order to survive for a prolonged period of time in the stomach of infected patients, H. 
pylori needs to evade the host immune system, and some of the methods are similar to those of 
M. tuberculosis.  H. pylori is also able to inhibit phagosome maturation and persist in the early 
endosome [279].  H. pylori has a high rate of mutation as well as a high frequency of 
recombination, leading to a versatile population in a single host, which contributes to its ability 
to evade the host adaptive immune system [276].  H. pylori is also able to interfere with the 
uptake and processing of antigens as well as the activation of immune cells [280]. 
The role of TLR8 polymorphisms in M. tuberculosis, which will be discussed later, 
prompted Gantier et al. to investigate TLR8 signaling in H. pylori [279].  Infection with H. pylori 
promotes the induction of IFN-γ, which induces expression of TLR8 [279].  This study was the 
first evidence that TLR8 is able to function after phagocytosis of bacteria [279].  Additionally, 
Rad et al. used DCs to look at nucleic acid activation by H. pylori and found that TLR9 
recognizes H. pylori DNA [281].  They also showed that H. pylori RNA induces 
proinflammatory cytokines in a TLR-independent manner, identifying RIG-I as the receptor for 
the bacterial RNA.  Recognition of H. pylori RNA by RIG-I induces type I IFN production and 
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DC activation.  These studies were the first evidence that bacterial RNA could be recognized by 
RIG-I to produce type I IFNs [281].  
  
1.3.3.5 Borrelia burgdorferi 
 Borrelia burgdorferi is the spirochetal causative agent of Lyme disease, which is a public 
health problem in the United States [282] as well as Europe [283].  The primary route of 
transmission is by Ixodes scapularis ticks [284].  Lyme disease is a complex illness ranging from 
a local skin rash, called erythema migrans, to systemic problems including meningitis, 
encephalitis, arthritis, and carditis [285].  Activation of the innate immune system is an important 
component to the pathogenesis of B. burgdorferi, and a great deal of research has been done to 
better understand this response. 
Phagocytosis of live B. burgdorferi leads to the transcription of IFN-β in human 
monocytes, which was previously solely attributed to TLR1/2 stimulation by B. burgdorferi 
lipoproteins [242].  It was later found that the type I interferon response could not be from 
TLR1/2 alone and that the induction of IFN-β was a result of TLR8-mediated signaling [286, 
287].   Cervantes et al. recently discovered that B. burgdorferi RNA serves as the ligand for 
TLR8 [242].  Their studies show that activation occurs in the phagosome and that bacterial 
nucleic acids are not transferred into the cytosol.  This is the first known example of bacterial 
RNA as an activator for TLR8 in human cells [242]. 
 
 
1.3.3.6 Mycobacterium tuberculosis 
 The previous sections help to illustrate the biological role nucleic acid can play in the 
pathogenesis of an organism.  Although much of this research is fairly recent and needs to be 
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elucidated, it provides us with possibilities of how this may occur in other organisms.  As 
discussed in section 1.3.1.1, sRNAs have been found in M. tuberculosis, and the following 
section discusses the possibility of nucleic acid playing a role in its pathogenesis as well. 
 Studies by Stanley et al. and Pandey et al. indicate that TLR signaling may not be 
involved in the induction of the type I IFN response against M. tuberculosis [70, 288].  Instead, 
these studies show that the presence of nucleic acids, like RNA and/or cell fragments in the 
cytosol may be of greatest importance.  The type-VII secretion system may be involved in 
directly translocating these molecules or permeabilizing the phagosomal membrane, which 
would allow bacterial molecules to enter the cytosol [260].  This is a benefit for the organism, as 
it is able to elude the host immune response inside the macrophage. 
 Manzanillo et al. found extracellular M. tuberculosis DNA is able to trigger the cytosolic 
surveillance pathway (CSP) in macrophages and that this cytosolic signaling was required for 
virulence [69].  This response was found to be independent of TLR/NOD, and RNA-sensing 
molecules.  They propose that the Esx-1 system is utilized to deliver ESAT-6 to cause conduits 
in the phagosomal membrane, allowing the DNA to come in to contact with cytosolic receptors.  
There are a few ideas as to how the DNA becomes extracellular, which include bacterial lysis, 
naturally occurring DNA on the surface of the bacterium, and active or passive release through 
outer membrane vesicles [69].  
The role of M. tuberculosis nucleic acid and its interaction with the immune system has 
been explored recently.  Obregón-Henao et al. investigated the finding that RNA in the culture 
filtrate (CF) of M. tuberculosis was able to induce early apoptosis in human monocytes [289].  
Additional work showed that the apoptosis was a caspase-8 dependent, TNF-α and caspase-1 
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independent mechanism.  The RNA affected the ability of human monocytes to control 
mycobacterial infection [289].  
 Although it has been shown that M. tuberculosis RNA detection in the host cell is linked 
to caspase-8, the exact mechanism is not known.  Based on the information discussed above 
about receptors that recognize RNA, there are several possible ways in which the M. tuberculosis 
RNA could be interacting with the host cell.  TLRs 3, 7, and 8 are located in the early endosome 
and are able to detect RNA, making them possible candidates.  TLR8 can also lead to apoptosis, 
and is therefore a likely candidate based on the previous studies.  TLR8 polymorphisms in 
humans have been studied and are associated with increased susceptibility to TB [243], although 
the mechanism used for TLR8 to recognize M. tuberculosis is unknown [290].   
It is also possible that the RNA is able to move out of the early endosome into the cytosol 
to activate receptors like RIG-I, MDA5, and Lgp2.  As discussed earlier, M. tuberculosis has also 
been shown to form exosomes, and the RNA could be packaged in these, where it could then be 
released and recognized by other cells [71].  Because of there was a lack of caspase-1 
involvement in the apoptotic pathway studied by Obregón-Henao et al., it is not likely that the 
CF RNA is inducing an inflammasome response, such as the NALP3 inflammasome [289].  
Figure 1.4 shows the various ways described in this section in which M. tuberculosis RNA could 
be interacting with the host cell. 
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Figure 1.4 Ways in which M. tuberculosis RNA could be interacting with the host cell.  TLR7/8, 3 are located in 
the early endosome and are able to detect RNA.  Activation of TLR7/8 can also lead to apoptosis, which is 
important based on previous studies.  Bacterial RNA could get out into the cytosol and activate a receptor like RIG-
I.  RNA could also be packaged in exosomes where it could then be released and recognized by other cells. 
 
 
1.3.4 Specific RNA sequences recognized 
 
 Specific RNA sequences have been identified that bind to TLR7 and 8.  These sequences 
are natural viral and eukaryotic RNA with U-rich sequences [291, 292].  Studies have coupled 
these sequences with synthetic ORNs to determine the immune response triggered by each one 
[291].  The GU-rich ORNs induce substantially stronger IFN-α production from human 
peripheral blood mononuclear cells (PBMCs) than other combinations of nucleotides tested 
















required to stimulate cytokine responses.  The major sequences found to activate TLR7 and 8 
are: UUGU, GUUC, GUUU, UUUC, UGUU, and UCUC.  Some sequences are specific to 
TLR8, and are generally AU-rich, including: AUGU, UAUA, AUAU, AUAC, UAUU, UUAC, 
CUAC, GUAC, or UAUC [291].  It is now thought that immune stimulation could be due to the 
specific motifs impact on secondary structure, rather than the sequence itself [246].  All of the M. 
tuberculosis tRNAs have sequence homology to sequences found to activate both TLR7 and 8, 
and many have sequence homology to TLR8 specific reactive sequences [291]. 
 
1.4 Project Rationale 
 
 After discovering that the CF of M. tuberculosis was able to induce early apoptosis in 
human monocytes, Obregón-Henao et al. set out to find what material was responsible.  Because 
the CF of M. tuberculosis is largely protein based, it was hypothesized that the apoptosis was the 
result of released or secreted proteins.  The CF was column fractionated and the active fraction 
was tested with Proteinase K, DNase, and RNase.  Activity was lost when the fraction was 
treated with RNase, and unfractionated CF behaved in the same manner.  To determine what 
type of RNA was present in the CF, a classical siRNA cloning technique was adopted.  The M. 
tuberculosis RNA present in the CF was found to predominantly consist of tRNA and rRNA 
with lengths between 30 and 70 bases.  Because of the possibility that the RNA could be 
degraded to 30-70 bases, the material in the CF was also immediately precipitated with acetone, 
indicating that the RNA is fairly stable in the CF [289].  
 In order to address the question of if the RNA was released as a result of active or passive 
release, the kinetic accumulation of RNA in the CF over time was also assessed.  RNA was 
detected in the CF as early as two days of growth, and the accumulation paralleled that of protein 
secretion [289].  This is important since the presence of protein in the CF of early log phase 
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culture has been shown to be a result of active release [293].  The presence of RNA in early 
culture indicates that M. tuberculosis could be actively releasing these RNAs. 
 These previous findings lead to the hypothesis that this RNA population will be of 
biological importance.  Before the biological importance can be evaluated, it is necessary to 
further understand the composition of the small, stable, extracellular RNA of M. tuberculosis.  
The study of small RNAs in M. tuberculosis will facilitate long-term goals of understanding how 
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Development of Culture Filtrate RNA Isolation Protocol 
 
2.1 Introduction 
The first step in further evaluating the CF RNA population was to develop a more facile 
RNA purification scheme.  Although the method used by Obregón-Henao et al. was effective in 
identifying the biologically active component of the M. tuberculosis CF, it was originally 
designed to look for protein and therefore not optimized for RNA purification [1].  A more 
streamlined method specifically designed for isolating RNA from large amounts of M. 
tuberculosis CF was needed.   
In the previous studies, CF was initially treated with ConcanavalinA (ConA) to remove 
ManLAM, which had been shown to inhibit macrophage apoptosis [2-4].  The ManLAM 
depleted CF was then fractionated using DEAE-Sephadex and a stepwise gradient of sodium 
chloride, yielding seven fractions.  The fractions were evaluated for apoptotic activity and the 
most active fraction, fraction seven, was then treated with Proteinase K, DNaseI, and RNaseVI.  
As mentioned in Chapter I, the activity of fraction seven was abolished with RNaseVI treatment, 
leading to the conclusion that RNA was the apoptotic factor.  Fraction seven was further purified 
by treatment with DNaseI and, Proteinase K, followed by phenol:chloroform:isoamyl alcohol 
extraction (IAA).  The CF RNA was then gel purified from a denaturing urea-polyacrylamide gel 
[1].   
Many commercial kits are available for the purification of total RNA and sRNA.  While 
these kits are effective for many applications, they did not fit the specific needs of this project.  
Kits are typically designed for the isolation of RNA from relatively small amounts of material 
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including cells and tissue; for this project it was important to develop a method that could be 
used to isolate RNA from large volumes of M. tuberculosis CF.  RNA isolation kits generally 
utilize a guanidinium thiocyanate-phenol-chloroform (TRIzol) extraction method which can be 
coupled with a column based purification.  Both the TRIzol and column based methods would be 
problematic for this project as they are inefficient for large volumes of sample.   This chapter 
details the development of a purification scheme for RNA from large batches of H37Rv CF. 
 
2.2 Materials and Methods 
2.2.1 Bacterial Strains and growth conditions 
M. tuberculosis H37Rv was grown from glycerol stocks on 7H11 agar plates (Difco, 
Detroit, MI) before passing into 100 ml glycerol alanine salts (GAS) medium at 37°C [5].  After 
14 days of incubation with agitation, each culture was passed into one-liter of GAS medium.  
After an additional 14 days of incubation with agitation, one-liter cultures were used to upscale 
for large batch cultures.  Each one-liter culture was split into five separate one-liter cultures, for a 
total of eight to ten one-liter cultures.  Large batch cultures were harvested at day 14, late log 
phase. 
For the time-course studies, one-liter cultures were split into five separate one-liter 
cultures, with two liters per time point.  Before inoculating time course cultures, cells were 
centrifuged at 3,000 rpm and washed three times with GAS medium before inoculating two one-





2.2.2 Culture filtrate 
 CF was obtained by removing the cell pellet from all cultures and running remaining 
medium through a 0.2 µm VacuCap™ bottle top filter (Pall Life Sciences, Port Washington, 
NY).  
 Large batch CF (8L) was concentrated by decreasing the volume to 150 ml using the 
Millipore Pellicon tangential flow filtration system and Pellicon 2 Ultrafiltration cassettes (EMD 
Millipore, Billerica, MA).  The Pellicon system was cleaned with 0.1M sodium hydroxide for ten 
minutes, followed by a water flush for ten minutes.  During the water flush, the pump speed and 
feed pressure of the system were adjusted to achieve a flux rate of 30%.  The flux rate was 
calculated by measuring the retentate and permeate volume after 30 seconds and dividing the 
permeate volume by the total volume.   Before concentrating CF, 10 mM ammonium bicarbonate 
(Sigma-Alderich, St. Louis, MO) was run through the system until the pH matched that of the 
ammonium bicarbonate buffer (pH 7.8).  After concentration, CF was dialyzed against 10 mM 
ammonium bicarbonate. 
Time course CF (2L) was concentrated by decreasing the volume to 50 ml using the 
Amicon Ultrafiltration Cell (EMD Millipore, Billerica, MA) with a Ultracel 10 kDa molecular-
weight cutoff, regenerated cellulose membrane (EMD Millipore, Billerica, MA).  Membranes 
were hydrated with 90% isopropanol for ten minutes followed by diH2O for 30 minutes. 
 
2.2.3 RNA Purification 
Concentrated large batch samples were lyophilized, reconstituted in 15 ml RNase-free 
water, and dried twice using the Savant SPD2010 SpeedVac Concentrator.  After the last drying 
step, samples were resuspended in 60 ml of 50 mM Tris HCl, 150 mM NaCl buffer.  
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Concentrated time course samples were reconstituted in 1 ml RNase-free water and suspended in 
3 mL of the Tris NaCl buffer. 
CF was then digested for two hours at room temperature with 1mM MgCl2 at a final 
concentration of 0.4 mg/ml, with 10 µg/µl RNase-free DNaseI (Sigma-Aldrich, St. Louis, MO).  
DNase digestion was followed by incubation with 100 µg/ml RNase-free Proteinase K (IBI 
Scientific, Peosta, IA) and 10% RNase, DNase-free sodium dodecyl sulfate (SDS) (Fisher 
BioReagents, Fair Lawn, NJ), for a final concentration of 0.5%, for 8 hours at 55°C.  
Proteinase K digestion was followed by the addition of an equal volume of 
phenol:chloroform:isoamyl alcohol (IAA) (25:24:1) to separate layers.  Layers were separated by 
centrifugation at 3000 x g.  The aqueous layer was transferred to a new tube and an equal volume 
of chloroform:IAA (24:1) was added to separate any remaining phenol.  After centrifugation, the 
aqueous layer from this step was taken and used for further RNA isolation. 
 
2.2.3.1 Removal of LAM 
Four different methods were tested for the removal of LAM from the CF RNA: ethanol 
precipitation, isopropanol precipitation, passing over a ConA column, and passing over a C18 
column. 
For ethanol precipitation, three volumes of 100% ethanol (EMD Millipore, Billerica, 
MA) were added for every one volume of sample and put on ice to incubate for one hour.  After 
incubation, samples were centrifuged at 14,000 x g for 30 minutes at 4°C to pellet RNA.  
Supernatant was removed, and RNA was washed twice with cold 70% ethanol and centrifuged at 
14,000 x g for 10 minutes at 4°C.  After the final wash the supernatant was removed, and ethanol 
was allowed to dry.  Isopropanol precipitation was performed in a similar mannor except that 
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two volumes of isopropanol were used for every one volume of CF RNA; washes were also 
performed with 70% isopropanol.   
For the ConA method, two ml of ConA Sepharose resin (GE Healthcare, Germany) was 
prepared and mixed with one ml of the CF RNA, after the chloroform:IAA extraction, for four 
hours at room temperature.  After incubation, the CF RNA/ConA mixture was added to a 
column, and flow-through was collected.  After initial flow-through was collected, the column 
was washed with ConA buffer, followed by ConA elution buffer. 
For the C18 method of removing LAM, Sep-Pak Vac RC 500 mg and 100 mg C18 
cartridges were used (Waters, Ireland).  Columns were prepared for use by hydrating using one 
volume of LC-MS grade Methanol (Honeywell Burdick & Jackson, Muskegon, MI), and were 
subsequently washed four times with sterile, RNase free H2O.  For the large batch RNA 
purification, five ml of CF RNA were added to the 500 mg C18 column, and the flow-through 
was collected.  For the time course RNA purification, one ml of CF RNA was added to the 100 
mg C18 column, and the flow-through was collected.  Each column was washed at least one time 
with an equal volume of 50 mM Tris HCl, 150 mM NaCl buffer to remove any remaining RNA. 
 
2.2.3.2 CF RNA ethanol precipitation  
After removal of LAM using the C18 method, CF RNA from each column was further 
concentrated and purified through ethanol precipitation (as described above).  Once ethanol was 
removed, CF RNA pellets were re-suspended in 150 µl RNase-free water, combining the flow-




2.2.4 RNA Quality assurance/quality control 
2.2.4.1 SDS-PAGE Gels: Silver Stain and Western Blot 
 NuPAGE 4-12% Bis-Tris (Invitrogen, Carlsbad, CA) SDS-Polyacrylamide gel 
electrophoresis (SDS-PAGE) gels were used for Western blotting to address LAM contamination 
and silver staining to address protein contamination. CF RNA samples were added to a sample 
reducing agent and LDS Sample Buffer before loading onto the SDS-PAGE gel (Invitrogen, 
Carlsbad, CA).  A pre-stained protein standard was run on each gel to indicate protein size (Bio-
Rad, Hercules, CA).  MES SDS Running Buffer was used to run the SDS-PAGE gels at 200 
Volts (V) for approximately 45 minutes (Invitrogen, Carlsbad, CA).  Silver staining was 
performed as previously described [6] to ensure protein had been removed during the RNA 
purification process. 
SDS-PAGE gels were transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, 
CA) at 50 V for 80 minutes.  After transfer, membranes were blocked for one hour at room 
temperature with 3% BSA in 10 ml TBS.  Membranes were then probed with a LAM-specific 
monoclonal antibody CS-35 overnight at 4°C, to test CF RNA for the presence of LAM [7].  
Following primary antibody incubation, membranes were washed with 0.5% Tween-20 in TBS 
(TBS-T) three times for five minutes each.  The membranes were then subjected to the secondary 
antibody, an Anti-Mouse IgG alkaline phosphatase, developed in goats, diluted 1:1000 in TBS.  
Membranes were incubated for 45 minutes with the diluted secondary antibody, followed by 
washes, as before, with TBS-T.  Finally, membranes were developed using NBT/BCIP alkaline 




2.2.4.2 TBE-Urea Gels: Ethidium bromide staining  
Novex 15% Tris Borate EDTA (TBE)-Urea gels were used for Ethidium bromide 
staining of RNA to visualize size and purity (Invitrogen, Carlsbad, CA).  RNA was added to 
TBE-Urea Sample Buffer before loading onto the TBE-Urea gels, and run using TBE Running 
Buffer at 200 V for approximately one hour (Invitrogen, Carlsbad, CA).  RNA size was 
estimated using the RNA Century size marker (Invitrogen, Carlsbad, CA). 
 TBE-Urea gels were stained in a 1 µg/ml Ethidium bromide (EtBr) bath for 15 minutes 
and de-stained for 10 minutes in water.  EtBr stained gels were imaged on a Bio-Rad Gel Doc at 
302 nm (Bio-Rad, Hercules, CA). 
 
2.2.4.3 NanoDrop 
The NanoDrop Spectrophotometer ND-1000 was used to determine the concentration of 
RNA.  All samples were run in triplicate at three concentrations (undiluted, 1:10, and 1:100), 
along with two different standard curves of tRNA.  Standard curves were made using tRNA from 
E. coli MRE600 (Roche, Mannheim, Germany).  Standard Curve 1 consists of tRNA at:  4000 
ng/µl, 3000 ng/µl, 2000 ng/µl, 1000 ng/µl (Figure 2.1 A).  Standard Curve 2 consists of tRNA at: 
750 ng/µl, 500 ng/µl, 250 ng/µl, 100 ng/µl, 75 ng/µl, 50 ng/µl, 25 ng/µl (Figure 2.1 B). The 
amount of RNA was calculated based on the appropriate tRNA standard curve.  
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Figure 2.1 NanoDrop tRNA standard curves.  NanoDrop standard curve with tRNA standards ranging between 
A) 25-750 ng/µl and B) 1000-4000 ng/µl. 
 
2.2.4.4 Bioanalyzer 
The Agilent 2100 bioanalyzer was used to perform on-chip gel electrophoresis, using 
different chips to detect different types of samples in different size ranges.  The Small RNA chip 
(Agilent Technologies, Germany) detects RNA between 6-150 nucleotides (nt) in length, and 
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was used to look at sRNA.  The small RNA chips have a concentration range of 50-2000 pg/µl, 
so the RNA samples were run at the appropriate dilution based on NanoDrop results.   
CF RNA samples were also tested on an Agilent Technologies 12000 DNA chip to detect 
possible DNA contamination.  The DNA chips are able to detect DNA between 100-12000 base 
pairs (bp) in length with a concentration range of 0.5-50 ng/µl. 
 
2.2.4.5 LAL 
 Endotoxin levels were measured using the Limulum Amebocyte Lysate (LAL) Kinetic-
QCL (Lonza, Walkersville, MD) according to the manufacturer’s instructions.  Each sample was 
tested using at least two different dilutions. 
 
2.2.5 Kinetics of Release 
 In order to assess the accumulation of RNA in the CF over time compared to the rate of 
protein release, protein concentrations were measured using the Micro Bicinchoninic acid (BCA) 
Protein Assay (Thermo Scientific, Rockford, IL) following the manufacture’s procedure.  96 
well plates with bovine serum albumin (BSA) standards, samples, and working reagent were 
incubated at 37°C for 30 minutes and read using the BioTek Synergy 2 plate reader (Winooski, 
VT) at 562 nm.  Comparing sample optical densities to the BSA standard curve using the Gen5 
BioTek Software determined protein concentration. 
 
2.2.6 Intracellular Small RNA Extraction 
 The FastRNA Pro Blue Kit (MP Biomedicals, Santa Ana, CA) was used to extract total 
M. tuberculosis RNA from day 14 late log phase cells, according to the manufacturer’s 
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instructions.  This kit uses a bead-beating cell membrane disruption, in combination with 
solutions to inactivate cellular RNases during cell lysis to prevent RNA degradation.  Bead-
beating is followed by purification and isolation by chloroform extraction and ethanol 
precipitation. 
 Once total RNA had been isolated, the PureLink miRNA Isolation Kit (Invitrogen, 
Carlsbad, CA) was used to isolate the sRNA.  The kit was used according to the manufacturer’s 
instructions, followed by a second extraction using a modified protocol.  For the second 
extraction, one ml TRIzol reagent (Life Technologies, Carlsbad, CA) was added to the sample 
and incubated for five minutes at room temperature.  After incubation, 0.2 ml chloroform was 
added and mixed by vortexing, followed by a two-minute incubation at room temperature.  
Samples were centrifuged at 12,000 x g for 15 minutes at 4°C, and the resulting aqueous layer 
was transferred to a new tube along with an equal volume of 70% ethanol.  The sample was then 
added to the kit spin column, and the manufacturer’s instructions were followed from step four. 
 Bioanalyzer RNA Nano chips (Agilent Technologies, Germany) were used to determine 
if rRNA had been removed, leaving only the sRNA.  RNA samples were diluted based on the 
NanoDrop, as the RNA Nano chips have a concentration range of 25-500 ng/ul. 
 
2.3 Results 
2.3.1 RNA purification 
 The first critical step in the purification of CF RNA was to concentrate the large amount 
of CF harvested.  The Pellicon tangential flow filtration system allows for large amounts of 
material to be concentrated quickly and efficiently (8-10 L in approximately two hours).   
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Once the material had been concentrated and reconstituted in buffer, DNase and 
Proteinase K digestions were done in order to digest DNA and protein in the concentrated CF.  
EtBr stained TBE-Urea gels were used to show the removal of DNA after DNase digestion 
(Figure 2.2 A), and silver-stained SDS-PAGE gels were used to confirm removal of protein 
(Figure 2.2 B).  During method development, a faint band around the size expected of LAM was 
observed on the silver stained gel (Figure 2.2 B).  LAM is typically not seen on silver stained 
gels unless the staining procedure includes a periodic acid oxidation step, used to view 
carbohydrates [8].  Despite the lack of the periodic acid oxidization step, a large amount of LAM 
can sometimes appear as a faint band.  The presence of LAM in the CF samples was confirmed 
using the CS-35 monoclonal antibody for LAM in a Western blot (Figure 2.2 C), although the 
LAM detected through Western blotting (Figure 2.2 C) appears at a higher molecular weight 
than the faint band seen in the silver stained gel (Figure 2.2 B).  The band seen through silver 
staining could also be lipomannan (LM), which is often associated with LAM and is smaller in 
size [9].  
 Discovery of LAM contamination in the CF RNA led to the evaluation of several 
methods for their ability to remove LAM (Figure 2.2 C).  Ethanol precipitation and isopropanol 
precipitation were not successful in removing LAM.  The C18 and ConA columns were both 
able to remove LAM from the CF RNA without greatly reducing RNA yield.  Because they are 
commercially available and easy to use, the C18 column method was chosen for LAM removal 




Figure 2.2 Gel based analysis of Purified CF RNA. A) Ethidium bromide stained PAGE gel shows the removal of 
DNA. Lane 1, CF before lyophilization; lane 2, CF after lyophilization; lane 3, CF diluted in Tris/NaCl buffer; lane 
4, CF after phenol:chloroform:IAA and chloroform:IAA. B) Silver-stained PAGE gel shows the removal of protein, 
as well as the presence of LAM. Lane 1, CF before lyophilization; lane 2, CF after lyophilization; lane 3, CF diluted 
in Tris/NaCl buffer; lane 4, CF after phenol:chloroform:IAA and chloroform:IAA. C) Western blot with CS35 anti-
LAM showing that C18 solid phase extraction and ConA chromatography efficiently removed LAM from the CF. 
Lane 1, CF after concentration; lane 2, CF after phenol:chloroform:IAA and chloroform:IAA; lane 3, after ethanol 
precipitation; lane 4, after isopropanol precipitation; lane 5 C18 flow-through; lane 6, after ConA chromatography. 
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Figure 2.3 RNA purification protocol with rational.  Workflow of CF RNA purification protocol developed with 
the rational for each step. 
 
2.3.2 RNA quality assurance/quality control  
Several methods of QA/QC were used to determine the concentration and purity of RNA 
in each batch including: silver staining, Western blotting, EtBr staining, NanoDrop, and 
Bioanalyzer analysis.  The silver staining, Western blotting for LAM, and EtBr staining were all 
used during the method development, and were later used as visual confirmation of purity, 
ensuring the RNA preparations were free of protein, LAM, and DNA contaminants.  The silver 
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stain was used to confirm the removal of protein after Proteinase K digestion, and EtBr staining 
was used to show removal of DNA as well as the approximate size of RNA. 
For down-stream studies, it was critical to ensure consistency and exact concentration.  
The NanoDrop spectrophotometer was used to obtain an accurate concentration of the RNA.  
The secondary structure of tRNA was a concern in the gaining accurate concentrations.  In order 
to account for the affect secondary structure may have on the accuracy of NanoDrop readings, 
two tRNA standard curves were used in order to calculate the concentration of the RNA, rather 
than the values given by the NanoDrop software.  Using the NanoDrop and tRNA standards, a 
typical large batch of CF will yield 2-3 mg of purified RNA.  It is important to note that yield 
can vary, as RNA can be lost throughout the isolation process. 
The Bioanalyzer small RNA chip was used as an additional method of verifying the 
concentration given by the NanoDrop, as well as a way of obtaining a more accurate reading of 
the RNA size seen in the EtBr stained gel.  The Bioanalyzer 12000 DNA chip was used to 
confirm the absence of DNA seen in the EtBr stained gel.  Table 2.1 shows four different 
purified CF RNA samples to demonstrate the differences in concentration measurements 
obtained using the NanoDrop with and without the tRNA standards as well as the Bioanalyzer 
small RNA chip.  Without the tRNA standard curves the NanoDrop calculates the concentration 






Table 2.1 Purified CF RNA sample concentrations.  Shows the differences between three different methods of 
quantifying CF RNA sample concentration: NanoDrop without tRNA standards, NanoDrop with tRNA standards, 
small RNA Bioanalyzer chip. 
 
 
The CF RNA samples displayed in Table 2.1 are also shown in Figure 2.4 using a small 
RNA Bioanalyzer chip and an EtBr stained gel.  The Bioanalyzer traces shown in Figure 2.4 A 
reflect both the concentrations calculated with the tRNA standards as well as the size seen in the 
EtBr gel (Figure 2.4 B).  All of the CF RNA samples shown have similar peaks with the size 
predominantly between 30-70 bases.   
 
CF RNA 
Concentration given by 
NanoDrop without tRNA 
standards (µg/µl) 
NanoDrop concentration 
calculated using tRNA 
standard curve (µg/µl) 
Concentration given by 
Bioanalyzer small RNA 
chip (µg/µl) 
CF RNA 1 2.7 1.7 1.1 
CF RNA 2 1.5 0.6 0.6 
CF RNA 3 2.0 1.1 1.1 
CF RNA 4 3.5 2.4 1.9 
Average 2.4 1.5 1.2 
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Figure 2.4 Bioanalyzer and EtBr stained gel RNA analysis. A) Bioanalyzer trace of four CF RNA samples.  B) 
EtBr stained gel of four CF RNA samples. 
 
 The LAL endotoxin assay was used to ensure LPS had not been introduced during the 
purification process, which could have an effect on down stream biological studies.  The amount 
of endotoxin in CF RNA samples was expressed in ng of endotoxin per µg of RNA.  The average 
amount of endotoxin detected in the purified CF RNA samples was 2.6 ng/µg. 
 
2.3.3 Time course CF RNA 
Smaller cultures were evaluated for time course studies to evaluate RNA release into the 
CF over time.  Time course studies showed low levels of CF RNA starting as early as day three, 
increasing over time, which is illustrated by the Bioanalyzer trace overlay in Figure 2.5.  The 
size of the extracellular RNA is consistent throughout the time course and the large batch.  The 
main peak is between 30 and 70 bases in length, corresponding to what was seen previously [1]. 
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Figure 2.5 Bioanalyzer analysis of purified RNA.  Bioanalyzer chip technology showed similarity between 
multiple batches of purified secreted RNA, including RNA purified at different times during the growth of M. 
tuberculosis.  
 
2.3.4 Kinetics of release  
The identification of extracellular RNA in the CF as early as day three lead to the 
investigation of the kinetics of release.  To assess the kinetics of release, the rate of RNA release 
into the CF was compared to the rate of protein release in the CF. Protein release was measured 
using the BCA, and RNA release was measured using the Bioanalyzer small RNA chip.  When 
plotted together (Figure 2.6), there is parallel trend between the rate of protein and RNA release 
into the CF. 
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Figure 2.6 Kinetics of release.  The release of RNA was measured over time using the Bioanalyzer, and compared 
to the release of protein in the culture filtrate, measured using the BCA.  The rate of accumulation of both RNA and 
protein increases over a 20-day period. 
 
 While the protein has a fairly linear release rate, the RNA release is not linear.  RNA 
from day 7-21 is more linear, so it is possible that day three could be a technical issue.  The 
concentration of RNA in the CF of a day three culture is much lower than the other time points, 
which can be seen in Figure 2.5.  It is possible that the concentration of day three was so low that 
it was outside the optimal range for the Bioanalyzer and therefore read inaccurately.  By running 
known concentrations of tRNA on the Bioanalyzer, the instrument was found to be less accurate 
at lower concentrations, which could explain why the time point for day three is a trend outlier. 
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2.3.5 Intracellular Small RNA Extraction 
 The whole-cell RNA resulting from the FastRNA Pro Blue Kit was run on the 
Bioanalyzer showing total RNA with rRNA (Figure 2.7 A).  The first isolation with the PureLink 
miRNA kit resulted in a decreased amount of rRNA.  Because the rRNA had not been 
completely removed, a second isolation was preformed using a modified form of the miRNA kit 
protocol; after which the rRNA had been removed and only the sRNA remained (Figure 2.7 B).  
The workflow for the intracellular small RNA purification is depicted in Figure 2.7 C.  The 




Figure 2.7 Intracellular small RNA extraction.  A) Bioanalyzer RNA Nano chip results for intracellular M. 
tuberculosis RNA after the FastRNA Pro Blue kit and first PureLink miRNA Isolation kit.  B) Bioanalyzer Nano 
chip results for intracellular M. tuberculosis RNA after the second miRNA kit isolation, resulting in purified, 
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 The development of a reliable RNA isolation was critical to moving forward with studies 
of extracellular RNA.  The method described here allows for reliable purification of RNA from 
the CF of M. tuberculosis; free of DNA, protein, LAM, and LPS.  Using the Bioanalyzer for 
analysis, the RNA was shown to be small in size, ranging from 30 to 70 bases in length, as was 
previously found [1].  
 The C18 solid-phase extraction binds nonpolar and moderately polar compounds, 
allowing the negatively charged RNA to pass through.  The C18 is able to remove both LAM 
and LPS, two biologically active components that could potentially interfere with downstream 
biological assays.  The ConA method was also successful in removing LAM, although the C18 
method was ultimately chosen based on ease of use. 
 A method for removing sRNA from whole M. tuberculosis was developed for 
downstream analysis and comparison to the extracellular sRNA, which will be discussed in 
Chapter IV.  The FastRNA Pro Blue Kit was chosen as it was used previously in whole-cell 
RNA isolation from M. tuberculosis [10, 11].  The PureLink miRNA isolation kit was used in an 
effort to remove the rRNA.  It is important for rRNA to be removed for downstream studies, 
especially Next Generation Sequencing (discussed in Chapter III).  There is a concern that the 
rRNA would overpower some of the small RNA fragments, and would need to be removed 
computationally.  The PureLink miRNA kit is designed to isolate high-quality sRNA molecules, 
based on the selective binding of sRNA molecules to a silica-based membrane in the presence of 
70% ethanol.   
 CF contains a diverse population secreted protein antigens that accumulate over time, 
starting as early as day two [12].  To evaluate the release of RNA in the CF, the kinetics of 
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release was compared to that of proteins, similar to what was done by Obregón-Henao et al. [1].  
The RNA and protein have parallel release rates, which could indicate active release rather than 
passive release of RNA.  Because the concentration of RNA in the CF at early time points is so 
low the kinetics of release of the RNA could be inconclusive for the early time points.  It will 
become important to future studies to develop a method to measure specific products over time.  
The replication rate of M. tuberculosis is typically about 24 hours [13], which is important to 
note in looking at the kinetics of growth and the release of RNA into the CF.  It has also been 
documented that the highest content of RNA and protein is present in two-week cultures, 
indicating logarithmic phase growth [14].  Because the concentration of RNA in the CF at early 
time points is so low the kinetics of release of the RNA could be inconclusive for the early time 
points.  It will become important to future studies to develop a method to measure specific 
products over time.   
H37Rv is a virulent strain of M. tuberculosis, although it is now considered a laboratory 
strain.  CF RNA was also detected in M. tuberculosis clinical isolates HN878 and CDC1551, as 
well as the avirulent M. smegmatis (data not shown).  These findings indicate that RNA release 
into CF is common among Mycobacterium spp., although it may not be a characteristic of 
virulence. 
The development of the method described in this chapter was critical for experiments to 
further elucidate the composition of the small-extracellular RNA from M. tuberculosis, described 
in Chapter III.  This procedure can also be used for down-stream studies to determine the 
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Analysis of Extracellular RNA by Next Generation Sequencing 
 
3.1 Introduction   
 In Chapter I, the ability of mycobacterial extracellular RNA to induce an apoptotic 
response in human monocytes was discussed.  The work described here is a continuation of 
previous studies, in an effort to further define the extracellular RNA population of M. 
tuberculosis.  Information gained from this research will allow for the further definition of the 
biological importance of the extracellular RNA, as well as its contribution in the pathogenesis of 
M. tuberculosis.  
In order to better understand the biologically active RNA found in the CF, it is important 
to fully define the RNA population.  While there are several methods that could be utilized for 
the further definition of the extracellular RNA, Next Generation Sequencing (NGS) was the most 
appropriate for the needs of this study.  Microarrays can be used to detect large numbers of RNA 
species, and are often used in transcriptional studies.  However, microarrays were not ideal in 
this situation, as the probes on the chip must be defined, and this study seeks to find any type of 
RNA that may be present.  Similarly, for a PCR based method of detection, targeted DNA 
sequences are needed as probes.  Microarray or PCR could be used to investigate previously 
described M. tuberculosis extracellular RNA, although that does not meet the needs of this study.  
For these reasons, NGS technology was used to further elucidate the extracellular RNA 
population.   
NGS technologies provide large volumes of data with more accurate sequence 
information than conventional Sanger sequencing approaches [1].  The nature of the NGS 
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technology minimizes false positives, giving confidence in the sequences identified.  It is 
possible for bias to be introduced, with library preparation and PCR amplification increasing 
specific RNA species to unrepresentative levels, which could influence the experiment in a 
detrimental fashion.  The possibility of bias was investigated using a quantitation bias study of 
DNA oligonucleotides at specific concentrations.  What is generally accepted with confidence is 
that nothing will be sequenced that was not initially present, meaning the results are somewhat 
qualitative although not necessarily quantitative. 
Previous studies and Bioanalyzer analyses, discussed in Chapter II, indicated the RNA of 
interest was small in size, between 30-70 bases in length, and made up primarily of tRNA and 
rRNA fragments [2].  For most NGS involving sRNA, total RNA is used and subsequently size 
selected.  Because the extracellular RNA from M. tuberculosis was already small in size, and the 
entire population was to be interrogated, no size selection was necessary. To determine the 
optimal concentration of CF RNA for NGS, a pilot study was done with a range of CF RNA 
concentrations.  The goal of these experiments was to determine the composition of the CF RNA 
samples and the relative abundance of the various types of RNA present.   
NGS of the CF RNA confirmed the presence of tRNA and rRNA fragments found 
previously [2], also revealing a third group of small RNAs (sRNA).  As discussed in Chapter I, 
there have been recent research efforts to investigate the sRNAs of M. tuberculosis [3-8].  The 
first experimental evidence of sRNAs in M. tuberculosis was published in 2009 [3], and has 
since been the focus of several research groups.  The first evidence was quickly followed by a 
NGS study of sRNA from M. tuberculosis total RNA, reveling a large number of previously 
unknown sRNAs [4].  Since these initial studies, other groups have identified additional sRNA 
candidates either through experimental evidence or bioinformatic prediction [5, 7, 8].  Despite 
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the identification of many previously unknown sRNAs, little is known about their function, and 
research is ongoing.  The wealth of recent information on M. tuberculosis sRNAs was beneficial 
to the study discussed here, as the products identified by NGS could be compared to the 
literature. 
 
3.2 Materials and Methods 
3.2.1 Library preparation for SOLiD sequencing: CF RNA 
Purified CF RNA (Chapter II) was used for NGS on the Applied Biosciences Support 
Oligonucleotide Ligation Detection (SOLiD) Sequencer (Life Technologies, Grand Island, NY).  
A range of concentrations was used from large batch and time course CF RNA samples.  For the 
large batch CF RNA (harvested at day 14), 100 ng, 50 ng, 10 ng, 5 ng, 1 ng, 0.5 ng, and 0.1 ng 
were used.  For samples from the time course experiment, days 3, 7, 10, and 14, were tested with 
5 ng and 1 ng concentrations for each time point. The only exception was day 14, which was 
only tested at 1 ng because the data for the 5 ng concentration were encapsulated within the large 
batch samples.  Sequencing libraries were prepared using the Applied Biosciences SOLiD Total 
RNA-Seq Kit and protocol (Life Technologies, Grand Island, NY).  Briefly, CF RNA was 
hybridized and ligated to SOLiD™ adaptors, followed by reverse transcription (RT) to 
synthesize complementary DNA (cDNA) utilizing adaptor-based priming.  Resulting cDNA was 
purified using gel extraction and amplified using PCR.  Amplified cDNA was tested for yield 
and size distribution using the NanoDrop spectrophotometer and the Agilent 2100 Bioanalyzer 
with the DNA 1000 kit (Agilent Technologies, Germany).  Once the cDNA had been amplified 
and passed gel and bioanalyzer QC assessment, fragments were ligated to template beads and 
deposited onto a glass slide for sequencing using the SOLiD EZ Bead kit (Life Technologies, 
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Grand Island, NY) (Figure 3.1).  The Next Generation Sequencing Core at CSU performed 
library preparation and sequencing. 
 
Figure 3.1 SOLiD sRNA library preparation.  RNA is hybridized and ligated to adapters followed by RT to 
produce cDNA.  cDNA is amplified using SOLiD specific primers to the adapters added in the beginning of library 
preparation.  Amplified cDNA is purified and ligated to magnetic beads before being deposited onto glass slides for 
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3.2.2 Library preparation for SOLiD sequencing: Quantitation bias study 
 The 45 M. tuberculosis tRNAs were synthesized as DNA oligonucleotides (stDNA 
oligos).  A mixture of the stDNA oligos was made to a final concentration of 5 µg, with groups 
of stDNA oligos at different concentrations.  At random, 33 of the stDNA oligos were chosen to 
be at a concentration of 0.15 µg.  The remaining stDNA oligos were split into groups of three for 
decreasing dilutions: 0.075 µg, 0.03 µg, 0.015 µg, and 0.003 µg (Table 3.1).  Sequencing 
libraries were prepared using the Applied Biosciences SOLiD Fragment Library DNA Kit and 
Oligo Primer Set, according to manufacturers instructions (Life Technologies, Grand Island, NY) 





Figure 3.2 SOLiD DNA oligo library preparation. DNA oligo is hybridized and ligated to adapters followed by 
amplification using SOLiD specific primers to the adapters added in the beginning of library preparation.  Amplified 
DNA is purified and ligated to magnetic beads before being deposited onto glass slides for sequencing (Figure 
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Table 3.1 stDNA oligonucleotides and concentration.  stDNA oligos grouped by concentration added to equal a 5 
























































3.2.3 Data Analysis 
 Colorspace data files (.csfasta) from SOLiD sequencing were uploaded to the NextGENe 
data analysis server (Soft Genetics, State College, PA) for analysis.  Once loaded into the 
NextGENe server, the 35 base sequence reads were aligned to the M. tuberculosis H37Rv 
GenBank reference genome (.gbk file) (NCBI reference sequence: NC_0009623) using the 
following parameters: the matching requirement parameters were base number >= 12 and base 
percentage >= 90%, with rigorous alignment.  The base number indicates the minimum number 
of bases in each read that must match the reference sequence, and 12 is a standard setting.  The 
base percentage for these studies was set high so that a minimum of 90% of each read much 
match the reference sequence.  Rigorous analysis parameters were necessary to have confidence 
in the location of each read along the reference sequence.   
Following alignment, a Peak Identification Report was generated for any peaks with five 
or more 35 base reads aligned to a region.  The report provided information on the chromosome 
region; length of the peak consensus sequence; depth of coverage, or reads; and the consensus 
sequence for each peak, or fragment, identified.  The whole data set was then split into three 
groups: tRNA, rRNA, and sRNA, using additional data analysis methods. 
First, the genomic tRNA database (GtRNAdb) was used was used to identify tRNAs 
within the data set by using the BLAST function for each consensus sequence obtained from the 
Peak Identification Report [9]. For the quantitation bias study, the GtRNAdb was used to identify 
the individual stDNA oligos [9]. 
Remaining sequences were visualized using the Artemis genome browser and annotation 
tool [10].  The H37Rv GenBank file was loaded onto Artemis as the reference genome, and each 
fragment identified in the peak identification report was entered as a new feature.  Each new 
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feature was then visualized on the genome browser, identifying the location on the genome in 
relation to specific genes.  The information gathered from this mapping allowed for the further 
division of the data set into rRNA and sRNA sequences.  An overview of the data analysis 
pipeline is shown in Figure 3.3. 
 
Figure 3.3 SOLiD Sequencing Data Analysis.  Workflow for NGS data analysis. 
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3.3.1 CF RNA sequencing data 
 Once the raw sequencing data were aligned to the H37Rv reference file, the Peak 
Identification Report with a cut off of five or greater reads, was generated and analyzed for each 
sample.  The large batch samples were analyzed first, and of the M. tuberculosis CF RNA 
concentrations tested, the 100 ng and 50 ng samples were found to be the optimal concentrations.  
Lower concentrations tested were lacking in depth of coverage, identifying few, if any sequences 
with five or greater reads (Table 3.2).  The 100 ng sample was preferentially used for analysis 
because of the depth of coverage obtained.   
 
Table 3.2 Number of unique fragments and average reads per fragment for large batch samples.  Displays the 
number of unique fragments as well as the average reads per fragment for each large batch sample sequenced.  The 
100 ng and 50 ng samples yielded the highest number of unique fragments of all concentrations tested.  The 5 ng, 1 
ng, and 0.5 ng samples had no unique fragments identified using the Peak Identification report. 
 
 
 The time course samples were submitted for sequencing at the same time as the large 
batch samples when it was hypothesized that 1-5 ng of sRNA would be sufficient for sequencing.  
Similar to what was observed in the large batch samples, the 5 ng and 1 ng concentrations had 
few unique fragments identified in each sample (Table 3.3).  Many of the time course samples 
Large Batch Sample 
Concentration (ng)
Number of Unique 
Fragments










had more unique fragments than what was detected with the large batch samples at the same 
concentrations.  It is likely that at such a low concentration the results would be variable and 
difficult to compare samples.  As such, very little data were obtained and they could not be 
compared with any confidence. 
 
Table 3.3 Number of unique fragments and average reads per fragment for time course samples.  Each time 
course sample was sequenced at two different concentrations (5 ng and 1 ng) with the exception of Day 14, as it was 
sequenced at multiple concentrations in the large batch experiment.  Time course Day 7: 1 ng and Day 10: 1ng, had 
no unique fragments detected using the Peak Identification report.  
 
 
 As shown in Figure 3.3, after Peak Identification Reports were generated, the whole data 
set for each concentration was split into three groups: tRNA, rRNA, and sRNA.  Table 3.4 shows 
the total reads, matched reads, number of reads per fragment, and average reads per fragment for 















3 5 19 8
3 1 1 8
7 5 6 12
7 1 0 0
10 5 15 13
10 1 0 0
14 1 7 8
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Table 3.4 Number of unique fragments and reads detected for each group.  A) Total reads, matched reads, 
number of unique fragments, and average reads per fragment from 100 ng sample.  B) Total reads, matched reads 






In sequencing analysis, matched reads, or total reads, provides an idea of relative 
abundance of each group.  The number of unique fragments gives an indication of the 
complexity or diversity within each group of RNA.  The average reads per fragment is another 
indicator of abundance, illustrating the relative abundance of each unique fragment in a 
particular group.  Although there are differences between the 50 ng and 100 ng samples, the 
numbers show the same trend.  tRNA fragments have the highest average reads per fragment, 
indicating that the tRNAs are relatively more abundant.  The sRNAs have the highest number of 
unique fragments and are therefore more diverse, although the average reads per fragment is 





100 ng Whole Data Set tRNA rRNA sRNA
Matched Reads 20615 7998 7178 5439
Number of Unique Fragments 297 25 33 239
Average Reads per Fragment 69 320 205 23
50 ng Whole Data Set tRNA rRNA sRNA
Matched Reads 21625 9223 9941 2461
Number of Unique Fragments 158 34 27 97
Average Reads per Fragment 659 342 292 25
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3.3.1.1 tRNAs detected in CF RNA 
 The tRNAs detected using this method were the most abundant group of CF RNAs 
identified.  Full lists of tRNA fragments from the 50 ng and 100 ng sample, with information on 
length, reads, genomic location, and consensus sequence, can be found in Appendix A and B 
respectively. 
 Table 3.5 shows all tRNA fragments identified in the 50 ng and 100 ng samples.  Of the 
45 tRNAs encoded in the M. tuberculosis H37Rv genome NGS identified 25 tRNAs present in 
the 100 ng CF RNA preparation.  The 50 ng sample displays the same general trend as the 100 
ng sample, although there were some outliers.  The previous study by Obregón-Henao et al. 














Table 3.5 tRNAs identified in 100 ng and 50 ng sample.  Each tRNA detected in the 100 ng and 50 ng sample 
with respective number of reads.  Highlighted tRNAs were also detected previously; tRNALys was the only tRNA 
identified in the previous study that was not found through Next Generation Sequencing [2]. 
 
 
The NextGENe software was used to visualize the coverage across each tRNA gene 
identified during the initial data analysis.  The length of the fragment is a consensus sequence, 
made up of 35 base reads aligned to the same region.  Based on the size seen with the 
Bioanalyzer (Chapter II) and previous studies [2], it was expected that the sequence coverage 
would span the majority of the gene region.  Figure 3.4 shows the top four individual tRNA gene 
sequence alignments for the 100 ng sample.  The tRNA fragments identified in the 100 ng 
sample generally do not span the entire gene and the majority of the fragments are located at the 
tRNA 100 ng Reads 
50 ng 
Reads 
SerT 2633 6309 
GlyU 2160 624 
AsnT 886 518 
ValU 731 114 
LeuU 533 918 
MetU 350 143 
GlnU 107 6 
ArgV 92 18 
HisT 80 154 
TrpT 55 0 
ThrT 52 23 
ThrV 47 32 
LeuT 44 32 
ThrU 39 30 
ValV 39 7 
ArgW 36 23 
ProT 32 9 
SerV 26 5 
CysU 11 8 
GlyV 11 41 
AlaT 10 5 
AspT 8 95 
IleT 6 52 
ProY 5 11 
ValT 5 0 
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3’ end of the gene (NextGENe outputs of each tRNA from the 100 ng sample can be found in 
Appendix C).  During NextGENe data analysis, a consensus sequence is constructed from all of 
the individual 35 base reads along a continuous area, and the area with the greatest depth is listed 
as the coverage in the Peak Identification Report.  For this reason, the consensus length listed is 
longer than the area of the greatest coverage, which can be seen in the sequence alignment for 
SerT in Figure 3.4. 
 
Figure 3.4 Top four individual tRNA gene sequence alignments for 100 ng sample. NGS data was aligned to the 
M. tuberculosis H37Rv GenBank reference genome.  Each tRNA gene was isolated in the NextGENe viewer to 
show coverage.  Grey regions show depth of coverage, the blue arrows are used to indicate gene locations within the 
reference file, and the green arrows are used to indicate mRNA.  Each tRNA is labeled with name, length of the 
fragment, and depth of coverage.  All tRNA gene sequence alignments for the 100 ng sample are displayed in 
Appendix C. 





















3.3.1.2 rRNA fragments detected in CF RNA 
 The rRNA group had the second-highest average reads per fragment.  Full lists of rRNA 
fragments with their respective sequences can be found in Appendix D (50 ng) and Appendix E 
(100 ng). 
 The Artemis genome browser was used to map each of the rRNA consensus fragments to 
the rRNA genes (Figure 3.5).  The rRNA consensus fragments for both the 100 and 50 ng 
samples were distributed across both the 16S and 23S rRNA genes without preference for gene 
location.  Additionally, the 5S rRNA gene was 99% covered in both samples, although no 
fragments had been found for this gene in the previous study [2]. 
 
 
Figure 3.5 Ribosomal RNA fragments.  All ribosomal consensus fragments from 100 ng and 50 ng samples, 
mapped using the Artemis genome browser [10].  Fragments are color-coded to show relative number of reads for 
each fragment. 
 
 Obregón-Henao et al. also identified rRNA fragments spanning the 16S and 23S rRNA 
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Figure 3.6 Alignments of rRNA fragments found in this study and in Obregón-Henao et al. Fragment contigs 
were generated using the software program Vector NTI in order to align sequences from rRNA fragments identified 
in this study (white arrows), with cloned RNA fragments identified in Obregón-Henao et al., 2012 (blue arrows); 
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rrs(+195): 196 » 276
1472121-1472165: 276 » 320
rrs(+322): 323 » 403
rrs(+675): 676 » 723
1472583-1472649 (c): 738 « 804 (complementary)
rrs(+735): 738 » 1178
1473051-1473109: 1206 » 1264
rrs(+1181): 1182 » 1289
rrs(+1294): 295 » 1405
rrs(+1413): 1414 » 1487
rRNA 16S: 1 » 1537
1 500 1000 1500
rrs(+61): 6 -174 
rrs(+19 ): 196-276 
rrs(+322): 323-403 
rrs(+735): 738- 178 
rrs(+1181): 1182-1289 
rrs(+1294): 1295-1405
rrs( 4 3): 1414-1487 
rRNA 16S 2005 MtRNA14: 114-182 
rRNA 16S 2004 2a: 170-230 
RNA 16S 2004 6b: 276-321 
rRNA 16S 2005 MtRNa23 and 13: 738-806 (complementary) 
rRNA 1 S 005 MtRNA18: 1206-1270 
rrs(+6 5): 6 6-723 
rRNA 6S 1471846-1473382: 1-1537  
0  5 0 5 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-261  
rRNA23S MtRNA11: 3061-3128 
rrl(+2744): 2745-2789 
rrl(+2818): 2819-2875 






rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
147435 -1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000
rRNA23S MtRNA12: 113-189 
rrl(+96): 97-146 
rrl(+271): 272-316 
rrl(+450): 451- 01 
rrl(+513): 514-585 




rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2 92
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782 61 25
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000





rRNA23S MtRNA2  and MtRNA5: 698-745 (complementary) 
rrl(+719): 20- 70 
rrl(+777): 778-83  
rrl(+843): 844-945 
rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202- 0 
rRNA23S MtRNA28: 255 -2618 
rRNA23S MtRNA1 : 3061-3128 








rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 69  « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 61
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000





rRNA23S MtRNA2  and MtRNA5: 698-745 (complementary) 
rrl(+719): 72 77  
rrl(+777): 778-834 
rrl(+843): 844-945 
rRNA23S MtRNA24: 1119-1 8  




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 255 -2618 
rRNA23S MtRNA11: 3061-3128 
rrl(+2744): 2745- 78  
rrl(+ 818): 819-2875 






rRNA23S MtRNA21: 3072-3135 (complementary)rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+ 201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 
rRNA23S MtRNA11: 3061-3128 
rrl(+2744): 2745-2789 
rrl(+ 818): 819-2875 
rrl(+2969): 2970-3059 
rrl(+3071): 3072-3140 




rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3 35  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 88
rrl(+271): 272 » 316
rrl(+450): 451 » 50
rrl(+513): 514 » 585
1474355-14 4400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 77  » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-147481 : 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 63
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 21 1
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 552 » 2614
rrl(+2677): 26 8 » 2733
rrl(+2744): 2745 » 27 9
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 30 2 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000
rRNA23S MtRNA1 : 113-189 
rrl(+96): 97-146 
rrl(+271): 272-316 
rrl(+450): 451- 01 
rrl(+513): 514-585 
rRNA23S MtRNA28 and MtRNA5: 698-745 (complementary) 
rrl(+719): 20- 70 
rrl(+777): 778-83  
rrl(+843): 844-945 
rRNA23S MtRNA24: 1119-1182 
rRNA23S 2004 3 086 56
rrl(+1102): 1103-1284
rrl(+1553): 1554- 56 
rrl(+1776): 1777-1863 
rRNA23S MtRNA25: 2059-2 25 
rrl(+2201): 2202- 0 
rRNA23S MtRNA28: 2552-2618
rRNA23S MtRNA1 : 3061-3128 








rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209 1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 9 0 » 059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
r l(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-313   
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 









rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 3072 « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1182 




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 
rRNA23S MtRNA11: 3061-3128 
rrl(+2744): 2745-2789 







rRNA23S MtRNA21: 3072-3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
rrl(+96): 97 » 146
1473772-1473845: 115 » 188
rrl(+271): 272 » 316
rrl(+450): 451 » 501
rrl(+513): 514 » 585
1474355-1474400 (c): 698 « 743 (complementary)
rrl(+719): 720 » 770
rrl(+777): 778 » 834
rrl(+843): 844 » 945
1474776-1474839: 1119 » 1182
1474743-1474813: 1086 » 1156
rrl(+1102): 1103 » 1284
rrl(+1419): 1420 » 1486
rrl(+1553): 1554 » 1756
rrl(+1776): 1777 » 1863
rrl(+1898): 1899 » 2020
1475716-1475778: 2059 » 2121
rrl(+2201): 2202 » 2390
rrl(+2397): 2398 » 2492
1476209-1476271: 2552 » 2614
rrl(+2677): 2678 » 2733
rrl(+2744): 2745 » 2789
rrl(+2818): 2819 » 2875
rrl(+2969): 2970 » 3059
rRNA 23S: 1 » 3135
1476729-1476792 (c): 307  « 3135 (complementary)
1476718-1476782: 3061 » 3125
rrl(+3071): 3072 » 3140
1 500 1000 1500 2000 2500 3000









rRNA23S MtRNA24: 1119-1 8  




rRNA23S MtRNA25: 2059-2125 
rrl(+2201): 2202-2390 
rRNA23S MtRNA28: 2552-2618 
rRNA23S MtRNA11: 3061-3128 
rrl(+2744): 2745-2789 
rrl(+ 18): 819-2875 
rrl(+2969): 2970-3059 
rrl(+3071): 3072-3140 




rRNA23S MtRNA 1: 307 -3135 (complementary) rRNA 23S 1473658-1476795: 1-3135  
 5 0 3 00 2500 00 500 0 
 99 
connected by dotted lines [2].  Boxes indicate fragments from the pervious study that were not identified here.  
Reference sequences were obtained from Tuberculist [11]. A) 16S rRNA fragments B) 23S rRNA fragments. 
 
The rRNA data analysis led to the question of why specific sections of the rRNA genes 
were present in the CF. One way of evaluating these consensus fragments is to use secondary 
structure predictions, which gives an idea of the stability of the fragments with the minimum free 
energy (MFE).  The RNAfold web server [12] was used to predict the secondary structure of the 

















Table 3.6 Secondary structure predictions of rRNA fragments found in the 100 ng sample. RNAfold web 
server was used to predict the secondary structure of the rRNA fragments found in the 100 ng sample.  Table shows 
the length of the consensus sequence, coverage, transcript site, and gene distance assigned by NextGENe.  For the 
secondary structure prediction, the table also displays the minimum free energy (MFE), free energy of the 
thermodynamic ensemble, as well as the ensemble diversity in each consensus fragment. 
 
 










35 5 1471780..1471814 rrf(0) -39.8 -39.13 10.06
48 6 1472521..1472568 rrl(+2397) -28.3 -29.47 9.54
39 7 1474276..1474314 rrl(-75) -2.2 -1.65 8.67
56 7 1476335..1476390 rrl(+2744) -18.8 -18.89 6.56
57 7 1474435..1474491 rrl(+2818) -13.6 -13.65 10.93
108 11 1473030..1473130 rrs(+1181) -29.9 -26.81 16.58
203 13 1475262..1475361 rrs(+675) -8.2 -6.4 4.35
102 18 1474501..1474601 rrs(-32) -1.3 -1.9 5.1
51 22 1474108..1474158 rrl(+2677) -13.2 -13.7 5.51
67 22 1475077..1475143 rrl(+2969) -26.7 -25.36 19.07
44 23 1472278..1472321 rrl(+1553) -72.4 -72.34 53.91
44 26 1473454..1473497 rrl(+1776) -15.3 -15.53 22.67
81 26 1472041..1472121 rrl(+618) -15.3 -15.71 3.28
35 29 1476276..1476310 rrl(-161) -9.1 -9.19 10.44
57 30 1476476..1476532 rrl(+2880) -10.6 -10.45 7.37
42 32 1476538..1476579 rrl(+1419) -23.9 -23.02 10.57
50 36 1473754..1473803 rrl(+2618) -7.3 -7.13 9.9
72 39 1474171..1474242 rrl(+450) -18.5 -19.53 4.02
45 41 1476402..1476446 rrl(+2201) -52.4 -54.08 25.5
69 41 1476729..1476797 rrl(+3071) -15 -14 18.86
81 42 1472168..1472248 rrl(+719) -12.2 -11.3 5.9
45 60 1473929..1473973 rrl(+1898) -37.9 -36.99 15.88
95 74 1476055..1476149 rrl(+96) -11.3 -9.59 13.3
51 75 1474377..1474427 rrl(+271) -20.4 -18.81 4.94
41 77 1473543..1473583 rrl(+1102) -55.9 -56.33 30.48
182 85 1474800..1474900 rrs(+432) -12.6 -11.13 1.26
113 94 1471913..1472012 rrs(+1413) -26.3 -24.69 18.17
90 134 1476627..1476716 rrl(+843) -29.8 -29.04 28.26
111 158 1473145..1473244 rrs(+1294) -37 -35.81 34.17
189 189 1475903..1476002 rrs(+61) -31.7 -29.32 20.22
122 205 1475566..1475666 rrs(+322) -23.8 -22.59 21.28
114 270 1476905..1477005 rrs(+195) -27.1 -27.07 13.69
74 409 1473259..1473332 rrl(+513) -18.5 -16.68 20.55
87 1303 1475434..1475520 rrl(+777) -10 -10.81 15.38
443 3562 1472752..1472851 rrs(+735) -166.6 -164.55 44.68
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Table 3.6 displays the length of each rRNA consensus sequence identified in the 100 ng 
sample, along with the maximum coverage for each sequence, transcript site, and gene distance 
assigned by the NextGENe program.  Results from the secondary structure predictions are also 
displayed on Table 3.6 including the minimum free energy (MFE), free energy of the 
thermodynamic ensemble, frequency of MFE structure in the ensemble, and the ensemble 
diversity for each consensus sequence entered in the program.  The RNAfold program used for 
this analysis uses a nearest-neighbor thermodynamic model to predict the MFE.  This type of 
modeling uses MFE to model the structure of regions that are energetically stable based on the 
second law of thermodynamics, which states that a system will always evolve toward 
thermodynamic equilibrium and that a closed system will come to thermal equilibrium with a 
minimum internal energy [13].  This model assumes that the energetically most stable structure 
is similar to the natural structure [14].  The free energy of thermodynamic ensemble is the 
overall free energy and sum of independent terms for different loops and base pairing 
interactions, or sum of all base pair free energies [14].  The MFE and free energy of the 
thermodynamic ensemble numbers are close to each other as they are two different methods of 
calculating the same thing, the stability of the RNA secondary structure.  Ensemble diversity is 
the average distance between all structures in the thermodynamic ensemble [15].  There are 
several problems with prediction programs including the neglect of the RNA pseudoknots 
structure, and that modifications are not accounted for; both of which can impact the stability of 
RNA [14]. 
Despite the uncertainty in RNA secondary structuring model, it can be valuable to gain 
some idea of how stable the RNA present in the CF might be.  All fragments examined were 
predicted to have varying degrees of secondary structure, although no correlations were apparent.  
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In an effort to try and better understand the results from the secondary structure predictions, the 
results were plotted in various ways to determine if any trends existed (Figure 3.7).  The MFE 
for each consensus sequence was plotted against the consensus fragment length (Figure 3.7 A) 
and although it has been shown that the number of possible structures increases with length (L) 
1.8L [16], there was no trend observed with the exception of the experimental outlier that was 
443 bases in length.    There was also no correlation observed for MFE vs. the amount of 
coverage for each consensus fragment  (Figure 3.7 B).  To further investigate, data analysis was 
preformed to normalize MFE by the amount of coverage and plot against coverage (Figure 3.7 
C).  The consensus length was normalized by the 35 base fragment obtained from sequencing to 
see if this would have any effect on the correlation with the MFE, and it did not (Figure 3.7 D).  
Finally, the consensus length of each fragment was normalized using the amount of coverage and 
plotted against the MFE, which also showed no correlation (Figure 3.7 E).  Based on these 
analyses there is no correlation between the stability of the RNA and the amount of coverage 
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Figure 3.7 rRNA fragments secondary structure prediction analysis. A) MFE vs. the consensus fragment length. 
B) MFE vs. coverage for each consensus fragment. C) MFE normalized by dividing by coverage for each consensus 
fragment, plotted vs. coverage.  D) MFE vs. consensus fragment length divided by the 35 base fragment size. E) 
MFE vs. consensus fragment length divided by the coverage for each consensus fragment. 
 
3.3.1.3 sRNAs detected in CF RNA 
 The sRNA group had the largest number of unique fragments.  Although there were 
many fragments, the average reads per fragment were much lower than those of the rRNA and 
tRNA groups, indicating a relatively low abundance overall.  Table 3.7 shows the top 20 sRNA 
fragments identified in the 100 ng sample.  Full lists of sRNA fragments for the 50 ng and 100 
ng samples can be found in Appendix F and G, respectively. 
sRNA fragments were compared with those reported in Arnvig et al., 2011 [4] and Miotto 
et al., 2012 [7] (Table 3.7).  Full lists of sRNAs from 50 ng and 100 ng samples compared to the 
literature can be found in Appendix H and I, respectively.  When sRNA fragments from the 100 
ng sample were compared to those found in Arnvig et al. [4], 193 of the 2943 total sRNAs 
identified were also found in this study.  When compared to the sRNAs from Miotto et al. [7], 43 
y = 8.8919ln(x) - 30.884 
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MFE vs. Consensus Length ÷ Coverage 
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of the 1948 identified were also found in this study.  Overall, 42 unique fragments were found in 
this study. 
 
Table 3.7 Top 20 sRNA fragments.  Top 20 sRNA fragments found in the 100 ng sample with genome location of 
each fragment.  Stars indicate the high abundance small RNA fragments that were also identified by Arnvig et al., 
2011 [4] and/or Miotto et al., 2012 [7].    
 
 
3.3.2 Quantitation bias study 
 Because there is a range in the number of reads found for different tRNAs and because 
this type of sequencing is considered quantitative, a study was designed to determine if bias was 
introduced into the sequencing of tRNAs.  The study was designed by synthesizing all 45 M. 
Loci Length  Reads Location 
IS1557-2 47 555 5' end of IS1557-2 
IS1081-2 72 504 5' end overlapping onto Rv1199c 
fadE35/Rv3798 43 424 Intergenic between fadE35 and Rv3798 
glyA 35 165 Towards the 5' end of glyA 
Rv3660c/Rv3661 64 152 Intergenic between Rv3660c and Rv3661 
Rv1733c/Rv1734c 82 129 Intergenic between Rv1733c and Rv1734c 
fas 34 128 In the middle of fas 
Rv2144c/wag31 56 123 5' end of Rv2144c and intergenic 
ideR 40 113 Towards the middle of ideR 
phoT 67 92 3' end of phoT 
Rv3894c 68 77 Towards the 3' end of Rv3894c 
ssr 40 71 In the middle of ssr 
Rv1147/Rv1148c 62 70 Intergenic between Rv1147 and Rv1148c 
rpsR 37 64 Towards the 3' end of rpsR 
esxA/Rv3876 36 62 Intergenic between esxA and Rv3876 
cydA 45 55 Towards the 3' end of cydA 
pykA 34 46 Towards the 5' end of pykA 
Rv3407 35 37 Towards the 3' end of Rv3407 
Rv3640c 57 35 Intergenic between Rv3640c and fic  
Rv3661/Rv3662c 167 32 Intergenic between Rv3661 and Rv3662c 
Also found in Arnvig et al., 2011 
Also found in Miotto et al., 2012 
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tuberculosis H37Rv tRNAs as stDNA oligos and sequencing a mixture of the oligos at different 
concentrations.     
stDNA oligos were identified from the SOLiD data and grouped based on the 
concentration added to the mixture (Figure 3.5).  It was expected that each stDNA oligo within a 
specific concentration group would have approximately the same number of reads.  As shown in 
Figure 3.5, some sort of bias seems to have occurred in this study.  Despite the bias seen, each of 
the 45 stDNA oligos added to the mixture were identified.  
 
Figure 3.8 stDNA Oligonucelotides from 5 µg sample.  Displays the number of reads for each of the stDNA 
oligos.  The numbers above some of the tRNAs indicate the top ten tRNAs found in the M. tuberculosis CF RNA 
samples. 
 
Several different types of bioinformatic analyses were performed in an attempt to identify 




















































































































































































extracellular tRNAs identified in the previous section (Figure 3.5).  The most prominent tRNA 
identified from the CF RNA, SerT, was one of the stDNA oligos with the lowest reads, so the 
bias does not follow that of secreted tRNA. 
Predicted melting temperatures of each stDNA oligo were examined to see if higher 
melting temperatures could be a factor in the observed bias.  No trend was seen, as the melting 
temperatures of all stDNA oligos were similar.  The bias also does not correlate with free energy 
predictions or tRNA length.  Because of the way the NextGENe software operates there was 
concern that the bias followed position on the genome.  The tRNAs have a high degree of 
homology to one another, and it was possible that the program would align a fragment to the first 
tRNA it encountered along the genome.  When the genome position of each tRNA gene was 
examined, the bias seen with the stDNA oligos did not correlate with genome position. 
When the 5 µg stDNA oligo mixture was made it was based on concentrations given by 
the company who synthesized them.  To help rule out a concentration issue, stDNA oligos were 
checked using the NanoDrop to be sure the concentrations given by IDT were correct, and that 
the concentration did not account for the bias (Table 3.8).  Although the expected concentration 
and the concentration acquired using the NanoDrop are not the same, all of the stDNA oligos 








Table 3.8 Expected concentrations of stDNA oligos vs. NanoDrop readings.  Each stDNA oligo was tested using 























































 The NGS pilot study provided us with a better understanding of the components of the 
secreted or released RNA, as well as the optimal concentrations for sequencing.  The 100 ng 
sample was found to be the optimal concentration based on the depth of coverage obtained.  
Results for the 50 ng sample were slightly different from those of the 100 ng sample, with some 
fragments appearing in the 50 ng sample, but not the 100 ng sample.  Despite some 
discrepancies, the two concentrations show the same trends and confirm relative abundance. 
The correlation between data from Obregón-Henao et al. [2], and the tRNAs identified in 
the NGS run is encouraging, displaying parallels between two different methods.  Only one of 
the tRNAs identified previously was not identified in this study, with 21 additional tRNAs 
identified here. This discrepancy in the number of tRNAs identified in the CF could be explained 
by the nature of the different methods used for detection.  The NGS approach used here is more 
sensitive than the cloning strategy used previously, allowing for the detection of additional 
tRNAs [2].  Additionally, tRNAs have a high level of homology to one another, and it is possible 
that the tRNALys from the previous study was incorrectly identified.   
The fragments that aligned to the tRNA genes did not cover the entire gene, with many 
tRNAs displaying greater coverage towards the 3’ ends of the genes (Figure 3.4 and Appendix 
C).  It is unknown whether the tRNAs are fragmented in this fashion in the CF, or if the 
fragmentation is an artifact of the sequencing.  The sequencing done by Obregón-Henao et al. 
found the tRNAs to be truncated at the 5’ and 3’ ends with a length between 30-70 bases, which 
was confirmed by the Bioanalyzer analysis discussed in Chapter II [2].  The possible 3’ bias 
observed with many of the tRNAs conflicts with the previous study, suggesting the possibility of 
a NGS sequencing issue.  The structure of tRNA could be problematic for library preparation, 
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and it is conceivable that an issue with library preparation would explain the apparent preference 
for the 3’ ends.  Also, the RNA preparation was not mechanically fragmented during the library 
preparation process.  Thus, if the majority of rRNAs were intact, a 3’ bias would be expected 
based on the process of library generation (ligation and cDNA generation) and the 35 nucleotide 
read of the SOLiD system.   
tRNAs are not typically sequenced using NGS, as many researches wish to remove tRNA 
and rRNA from their samples, so the protocol is not optimized for the secondary structure and 
stability of tRNAs.  Figure 3.9 outlines points in the library preparation process where the 
process could be optimized or problems could occur.  There have been several studies focused on 
library preparation for NGS, investigating where problems can arise and how this may affect bias 
[17-20].  Secondary structure, especially at the 3’ or 5’ end of the RNA can affect adapter 
ligation efficiency [17].  Toedling et al. found that SOLiD sequencing has a positive bias for 
reads with 3’ end secondary structures [19].  The initial denaturation temperature of the SOLiD 
library preparation protocol is 65°C, which cause problems in the initial hybridization and 
ligation of the RNA with SOLiD adaptors, as the average predicted melting temperature for the 
tRNAs is 76°C.  If either the 3’ or 5’ adaptor did not ligate properly, bias could occur at one end 
of the sequence during NGS, or the RNA would fail to be sequenced.  A prehybidization step, or 
an increase in the initial denaturation temperature could eliminate secondary structure, improving 
adaptor ligation [17].  The number of polymerase chain reaction cycles also has the potential to 
influence library preparation and NGS results [17].  As shown in Figure 3.9, there are multiple 
stages at which the denaturation temperature could be problematic for sequencing tRNAs.  These 
stages in the library preparation process could be optimized to ensure library preparation of the 
tRNAs works properly. 
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Figure 3.9 SOLiD library preparation with points where optimization and/or problems may occur.  RNA 
library preparation with the temperatures and conditions noted.  Points where optimization and/or problems may 
occur are indicated with suggestions for modification.  Figure adapted from the Applied Biosystems SOLiD total 
RNA-Seq kit protocol. 
 
The identification of rRNA fragments in the extracellular RNA also connects with the 
clones identified by Obregón-Henao et al. [2], with fragments distributed across the 16S and 23S 
rRNA genes.  This study also found nearly complete coverage of the 5S rRNA gene. 
It is unknown why specific fragments appear in the extracellular RNA.  One hypothesis 
for the presence of these fragments is that they are more stable sections of the rRNA gene, 
capable of surviving in the extracellular environment.  The RNA fold web server was used as a 
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method of testing this, and the fragments tested had varying levels of secondary structure, 
appearing to be relatively stable.  Secondary structure predictions were also made for regions of 
rRNA genes not represented by an aligned read.  The predictions for these uncovered areas had 
similar, if not higher levels of secondary structure and stability (Appendix J).  Secondary 
structure analysis indicates that stability alone is not likely to be the explanation for the presence 
of specific rRNA fragments in the CF. In trying to find any correlation between the secondary 
structures of rRNA consensus sequences and the NGS sequencing results, no correlation was 
identified.  Plotting the MFE of each predicted structure vs. the depth of coverage for that 
consensus sequence, yielded the inverse of what would be expected with the hypothesis that 
secondary structure would hinder the production of libraries.  If the secondary structure of a 
sequence was an issue in library preparation it would be expected that more stable structures 
(with a more negative MFE) would have less coverage, although this was not observed.   
The sRNA group contained the largest number of unique fragments, although the number 
of reads for each was relatively low, especially when compared to the tRNAs and rRNAs.  
sRNAs are of interest because they were not detected previously and have been studied in M. 
tuberculosis recently.  Many of the small RNAs in the extracellular material overlapped with 
those previously reported in the literature [4, 7]; however, novel small RNA sequences were also 
identified.  sRNAs were also compared with what was found by Pelly et al. from M. tuberculosis 
total RNA, discussed in Chapter I (Section 1.3.1.1) [8]. All of the clone types mentioned in Pelly 
et al. were detected, including the intergenic regions, although ncrMT1302 was not identified 
[8]. 
Secondary structure predictions of sRNA from the 100 ng sample using the RNAfold 
web server were also evaluated [12] (Appendix K).  Similar to what was seen with the rRNA 
 113 
consensus sequences analyzed, the sRNAs are relatively stable although there was no apparent 
correlation with the sequencing results.  There is some correlation with the size of the sRNAs 
and their stability, especially as many of the sRNAs are small in size (many are the size of a 
single 35 base fragment) and there is not much room for secondary structure to form.  The 
secondary structure predictions do support observations made by Obregón-Henao et al. that the 
CF RNA was susceptible to RNase V1, which would indicate that the CF RNA contained 
dsRNA hairpin structures [2]. 
Because of the homology of the tRNAs, an experiment was also designed to test the 
capabilities of our system, using stDNA oligos.  This experiment indicates that some bias occurs 
in the NGS, although the cause of that bias is unknown.  Ideally, the experiment would have 
been performed using synthesized RNA oligos to more accurately test the system, although this 
was unfortunately cost prohibitive.  Another flaw in the study design was that the stDNA oligos 
were isolated using only standard desalting, no HPLC purification.  It is possible that without the 
HPLC purification of the stDNA oligos, some may have degraded more than others causing 
differences in the library preparation and NGS.  To follow up in the future, the stDNA oligos 
could be run on an HPLC to see if they are degraded, possibly explaining the observed bias.   
The quantitative bias experiment was successful in identifying all of the stDNA oligos 
incorporated in the sample, even though some were at very low concentrations.  The 
identification of all stDNA oligos gives confidence that although the NGS data may not be 
quantitative, they could be considered qualitative.  However, based on the possibility of 
problems with library preparation and bias, it may be too generous to state that the technology is 
truly qualitative.  Based on these studies it is possible to say with confidence that what is 
identified is present, but not that things are not missed.   
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The bias displayed in the quantitative bias experiment does not appear to correlate with 
what was found in the CF RNA, as the tRNA with the highest number of reads from the CF 
(SerT) was not the same as the stDNA oligo with the highest number of reads (LeuU).  It is 
possible that the stDNA oligo bias does translate to the identification of tRNAs in the CF, for 
example, the SerT could be even more abundant than it appears.   
Despite questions of bias created by library preparation or sequencing, the data from this 
study indicates some selection occurs with the extracellular RNA, especially with the tRNAs.  
For the stDNA oligo study, technical variability could create the observed bias.  Future 
directions, possible methods for accounting for this variability, and the biological implications of 
these findings are further discussed in Chapter IV.  
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Final Discussion and Future Directions 
 
4.1 Final Discussion 
 The idea of M. tuberculosis RNA interacting with the host immune system is not new; 
described first in 1964 by Anne and Guy Youmans [1].  Studies were conducted throughout the 
1960s and 1970s to define the immunogenic component found in ruptured mycobacterial cells 
[2-8].  Through differential centrifugation, the immunologically active material was found in the 
ribosomal fraction [1].  When the active fraction was combined with Freund’s incomplete 
adjuvant and given to mice, the mice had a high degree of immunity to challenge with virulent 
M. tuberculosis [4].  In an effort to further define this material, it was found to be resistant to 
trace amounts of ribonuclease, indicating the RNA was relatively stable; likely double-stranded 
or having high degrees of secondary structure [8].  The M. tuberculosis RNA fraction was even 
tested as a means for tumor reduction in mice, further showing a strong immunogenic effect on 
the host [9, 10].  This work resonates with the sequencing work discussed in Chapter III, as well 
as the work done by Obregón-Henao et al. [11].  The studies documented in this thesis have 
provided a better understanding of the extracellular RNA population of M. tuberculosis.  Many 
of the tRNA and rRNA fragments identified by Obregón-Henao et al. were confirmed through 
NGS, with the discovery of additional RNAs.  Despite the advances made, there are many 
questions that remain unanswered, including the biological relevance and how the RNAs are 
being released.  This chapter will examine several possibilities for the mechanism of release, 
biological relevance, and future directions to answer these questions. 
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4.1.1 Active release of CF RNA 
One important area to investigate is how the RNA fragments are released from M. 
tuberculosis.  At this point the possibility that the extracellular RNA is released from cells 
through bacterial lysis cannot be ruled out, although there is some indications that this may not 
be the case.  The presence of the RNA in the CF as early as day three indicates active release, 
based on work done with secreted mycobacterial proteins.  In one particular study, the 
concentration of isocitrate dehydrogenase (ICD) in the medium was used as an indicator of 
autolysis [12].  ICD levels were very low early in growth, and found to rapidly increase during 
the late log phase of growth, peaking at day 14 [12].  The low level of ICD early in growth 
indicated that proteins released into the CF at that time were not a result of autolysis.  Studies 
also showed the population profile of proteins in the CF vary during the course of M. 
tuberculosis growth.  This could suggest that the extracellular RNA population also changes as a 
result of growth phase. 
The RNA fragments found in the CF are predicted to have high degrees of secondary 
structure.  Stability of the RNA fragments is a possible explanation as to why these specific 
fragments survive in the CF if their release is a result of cell lysis.  Complex secondary structure 
could protect against host, as well as bacterial, RNase activity in the extracellular environment 
[13].  While this is a possibility, it is complicated by the finding that not all of the M. 
tuberculosis tRNAs were present, even though all tRNAs possess similar secondary structure.  
The tRNAs identified were also compared to the codon/amino acid bias in the M. tuberculosis 
genome to see if there was any correlation.  M. tuberculosis has a statistically significant 
preference for amino acids that are encoded by G + C-rich codons including Ala, Gly, Pro, Arg, 
and Trp [14].  In contrast, M. tuberculosis has a reduction in A + T-rich codons like Asn, Ile, 
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Lys, Phe, and Tyr [14].  Although all of the preferred tRNAs were identified in the CF, the tRNA 
with the most reads (SerT) is not on the preferred list.  Two of the tRNAs identified, including 
the third most relatively abundant tRNA identified in the 100 ng CF RNA sample, are on the 
reduced list.  There were also, 15 of the 25 tRNAs identified that are neither preferred or 
reduced.  The specific tRNAs identified and differences in relative abundance lead to the 
hypothesis that there is selectivity in release of small extracellular RNA fragments.   
The predicted secondary structures of regions of rRNA genes not represented by an 
aligned read were also relatively stable, further indicating that stability may not be a factor in the 
presence of the extracellular RNA fragments.  If the RNA were being released through autolysis, 
it would be expected that rRNA fragments would make up the largest percentage of the 
extracellular RNA population, as rRNA makes up more than 95% of the RNA population within 
the bacterial cell [15].   
If the extracellular M. tuberculosis RNA is not released through autolysis, an active 
secretion system could be involved.  The Esx-1 M. tuberculosis secretion system has been well 
studied, and is responsible for the secretion of ESAT-6 and CFP-10, encoded on the RD1 gene.  
There is some evidence that the RD1 locus is involved in the transfer of DNA, as well as 
conjugation [16].  Obergón-Henao et al. evaluated the CF of the H37RvΔRD1 mutant for RNA, 
and found no change in the release of extracellular RNA [11].  The analysis of this particular 
mutant indicates the release is not linked to the Esx-1 secretion mechanism.  There are other Esx 
secretion mechanisms in the M. tuberculosis genome that could be involved in RNA release. 
The Sec secretion system is another possible route of RNA release from M. tuberculosis.  
L. monocytogenes is able to actively secrete small RNAs through its Sec secretion system, 
relying on SecA2 [17].  The mycobacterial Sec system also contains SecA2, which is often 
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associated with virulence [18].  The presence of SecA2 in both L. monocytogenes and M. 
tuberculosis leads to the idea that M. tuberculosis is actively releasing RNA through this 
mechanism. 
Another mechanism of RNA transport to consider is through membrane vesicles (MV).  
As discussed in Chapter I, MVs released by M. tuberculosis have been shown to contain TLR2 
lipoprotein agonists, which trigger a strong inflammatory response in the host [19].  Although the 
exact mechanism is unknown, the MVs are proposed to act as a delivery mechanism of 
mycobacterial molecules through compartments of infected host cells or released from the host 
cell [19].  It is possible that the small-stable RNA observed in the CF of M. tuberculosis could be 
packaged in these active MVs, and moved to the cytosol for recognition of PRRs, or released 
from the host cell.  
 
4.1.2 Biological Activity of CF RNA 
The biological significance of the extracellular RNA and its mode of action is not well 
understood.  Previous work found that the apoptotic activity induced by extracellular M. 
tuberculosis RNA was the result of a caspase-8, TNF-α and caspase-1 independent mechanism 
[11].  This knowledge gives some clues as to how the extracellular RNA interacts with the host 
cell, although many questions remain.  
If M. tuberculosis RNA release occurs in the early endosomal compartment of the host 
phagocytic cell, the extracellular RNA has the potential to interact with TLRs 3, 7, and 8.  TLR3 
recognizes dsRNA, leading to the production of a type I IFN response [20].  TLR7 and 8 also 
recognize dsRNAs, and research has been shown that they are able to detect bacterial RNA [21, 
22].  Although the M. tuberculosis extracellular RNA identified through NGS is single stranded 
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in nature, the secondary structure predictions described in Chapter III show that the ssRNA 
contain regions of dsRNA. 
TLR8 is an attractive candidate as a means of host recognition of the M. tuberculosis 
RNA, as activation of TLR8 can lead to apoptosis and caspase-8 activation [23, 24].  The 
mechanism through which TLR8 recognizes M. tuberculosis is unknown, and is of interest as 
human TLR8 polymorphisms have been associated with increased susceptibility to TB [25, 26].    
As discussed in Chapter I, M. tuberculosis tRNAs have sequence homology to sequences 
able to activate TLR7 and 8 [27].  The ability of TLR7 and 8 to recognize specific sequences 
could be a possible explanation for the presence of more tRNA fragments than other RNA 
species in the CF. All of the tRNAs in M. tuberculosis have at least one of the sequences able to 
activate TLR7 and 8 [27].  Ten of the tRNA fragments identified through sequencing had at least 
one of the sequences specific for activation of TLR8 [27].  The rRNA and sRNA fragments were 
also interrogated for the presence of any of the specific activating sequences.  Sequences that 
activate both TLR7 and 8 occurred in both the sRNA and rRNA fragment populations.  
Likewise, sequences that specifically activate TLR8 were found in both populations.  Many of 
the sRNA and rRNA fragments contained both TLR7/8 and the TLR8 reactive sequences.  While 
sequence homology could help explain how the extracellular RNA is recognized by the host cell, 
there is some evidence that the secondary structure itself may have more of an impact on 
immune stimulation than the specific sequence [21].  
If the M. tuberculosis RNA is able to translocate into the cytosol of the host cell, another 
group of PRRs could be responsible for recognition including PKRs, RIG-I, MDA5, Lgp2, and 
NOD2.  Although RNA is capable of activating an inflammasome response, these responses are 
dependent on caspase-1, so this pathway is unlikely [23]. 
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RNA modification is an important factor to consider when evaluating the biological 
significance of the M. tuberculosis extracellular RNA.  RNA nucleosides are often modified 
post-transcriptionally during maturation in both prokaryotes and eukaryotes [28].  Bacterial 
rRNA differs from eukaryotic rRNA in degree of methylation as well as the pseudouridine 
content [29].  Bacterial mRNA also differs from eukaryotic mRNA in the 3’-poly(A) tail, as 
eukaryotic mRNA has a long tail where bacterial mRNA has a short tail or none at all [30].  
tRNA is the most heavily modified subgroup of RNA, although it is modified less in prokaryotes 
than eukaryotes [28].  The differences in RNA modifications between eukaryotes and 
prokaryotes help to decrease the recognition of self-RNA, and the possibility of resulting 
autoimmunity.  tRNA and rRNA undergo multiple species-specific modifications that could alter 
their ability to activate different PRRs and signaling pathways.  Dephosphorylation and other 
modifications have been shown to change the host response to bacterial nucleic acid with fewer 
modifications generally leading to more immunogenic RNA [28].  Specific modified nucleosides 
including pseudouridine are able to abrogate the ability of RNA to signal through TLR3, TLR7, 
and TLR8 [28].  Modifications are also able to suppress the ability of RNA to activate DCs and 
induce production of TNFα and IL-12 [28]. Research performed with the mouse-specific TLR13 
helps illustrate the importance of RNA modifications and their interaction with the host immune 
system.  TLR13 was found to be a bacterial sensor that recognizes a ssRNA segment within the 
peptidyl transferase loop of the conserved 23S rRNA.  This loop binds antibiotics, and specific 
modifications of this segment leads to antibiotic resistance and the bacteria cannot be detected by 
TLR13 [31].   
RNA modifications in mycobacteria have not been widely studied, and little is known 
about which modifications they possess and how they may interact with the host immune system.  
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Chan et al. recently began investigating mycobacterial RNA modifications using a 
chromatography-coupled mass spectrometric approach to identifying ribonucleosides in BCG 
tRNA [32].  In this study, multiple candidates were identified, including a modification that had 
not been previously described in tRNA, N6,N6-Dimethyladenosine [32].  Identifying the types of 
modified ribonucleosides in mycobacteria is the first step in understanding their biological role. 
  
4.1 Future Directions 
Additional NGS would help to verify the information found in the study discussed here.  
As discussed in Chapter III, there are points of technical variability to overcome, requiring a well 
planned and directed research effort.  Specifically, the library preparation protocol would need to 
be optimized to ensure adaptors are properly ligating to the RNAs, especially the tRNAs.  It 
would be helpful to evaluate the population of small-stable extracellular RNAs with a 
complementary sequencing platform, which may provide more insight.   
There are several different sequencing platforms available, each with a unique library 
preparation protocol, which may have advantages or disadvantages for different types of material 
including small RNA [33-36].  There is a lot of debate as to which platform is best, which is 
complicated by the fact that there have been few studies independently testing platforms to 
determine details like error rate and yield [37-41].  For the continuation of these studies it will be 
important to consider the read length of each platform to get longer reads that will cover the 
entire fragment rather than the 35 base length provided by the SOLiD.  The newest SOLiD 
instrument (5500xi) has an improved read length of 85 bases [41].  The Illumina HiSeq and the 
Life Technologies Ion Proton systems are both possibilities for additional sequencing.  The 
Illumina has a read length of ≥100 bases, which would cover all of the CF RNA based on the 
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size observed using the Bioanalyzer [37, 41].  The Ion Proton sequencer utilizes semiconductor 
technology and does not require fluorescence/camera scanning leading to a higher speed and 
lower cost [40-42].  The Ion Proton would also be a good candidate for the CF RNA with a read 
length of up to 200 bases [41].   
Some studies have been done to look at NGS and the effect of both library preparation 
and platform on sRNAs specifically [33-36].  Linsen et al. argue that bias is generally 
independent of the platform used, and more dependent on the method used for sRNA library 
preparation [36].  Differences in library preparation protocols have been demonstrated to be 
responsible for differences in miRNA expression even when the same platform is used [35].  
Bias has been observed for sequences with end secondary structure using both the Illumina and 
SOLiD library preparation protocols, although SOLiD had a slightly larger bias [33, 35].  
Another study found different miRNA populations when compairing the SOLiD and Illumina 
platforms [34].  Deep sequencing technology continues to advance, and the amount of 
information that can be gained will continue to improve with the technology.  For example, 
sequencing platforms (so called “third generation sequencing”) are in development that do not 
require sequence amplification, which should significantly decrease the incidence of bias in the 
sequencing data [37].  Until then it is imperative that researchers not rely too heavily on the 
abilities of NGS, and carefully design experiments while being aware of the limitations of this 
technology. 
For a new NGS study, focus should be placed on biological replicates to confirm and gain 
confidence in the extracellular RNA population observed in the pilot study.  As discussed earlier, 
NGS could be used to evaluate time course samples to assess differences in RNA released during 
growth.  Differences in the extracellular RNA over time might indicate active versus passive 
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release.  Chapter II describes a method developed for isolating sRNA from M. tuberculosis cells, 
which could be used in NGS to compare CF RNA to low molecular weight cellular RNA.   
 Because of the questions of accuracy in the NGS, it is important to verify the information 
obtained from NGS using a different method.  Quantitative Real-Time PCR (qRT-PCR) and 
Northern blotting could both be used to confirm select sRNA fragments found using NGS [43].  
To evaluate the rRNA fragments, it would be valuable to use qRT-PCR or another method to 
examine areas of coverage observed for the rRNA genes, as well as for the uncovered areas of 
the genes.   
The development of a qRT-PCR assay would be beneficial as a way to evaluate selective 
release of RNA from M. tuberculosis.  This type of assay could be used to track specific RNA 
products over time and evaluate extracellular accumulation.  In addition, a qRT-PCR assay could 
be utilized to evaluate mutants for the absence of RNA secretion or release.  Mutants of M. 
tuberculosis secretion systems, including SecA2, could be evaluated in this manner in an attempt 
to identify a release mechanism.  In addition, MVs can be isolated and evaluated for RNA 
content.  
A method of fluorescent tagging could be used to visualize extracellular RNA location in 
the host cell, and even provide information on interaction with specific PRRs.  When 
investigating the role of TLR8 in B. burgdorferi infection, Cervantes et al. used confocal 
microscopy and a fluorescent version of the transfection agent polyethylenimine (PEI) to 
visualize the cellular location of the B. burgdorferi RNA.  TLR8 was stained red, and the PEI 
with B. burgdorferi RNA was stained green, so co-localization within the phagosomal vacuole 
could be observed [44].  Labeling was also used to identify L. monocytogenes RNA in the 
cytosol of infected host cells [45].  The new labeling technique described by Hagmann et al., is 
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non-radioactive and non-toxic, using 5’-ethynyluridine (EU) to label RNA [45].  The L. 
monocytogenes grown in the presence of EU were used to infect host cells, and the location of 
RNA could be tracked over time [45].  This technique could be beneficial in elucidating the 
release of M. tuberculosis extracellular RNA, and possibly the biological significance. 
It would also be important to evaluate different strains of M. tuberculosis for CF RNA 
composition.  While the presence of small extracellular RNA was found in both HN878 and 
CDC1551, the RNA population in each has not been defined.  Extracellular RNA was also 
detected, by visualization on TBE-Urea gel, in M. smegmatis.  The avirulent H37Ra should also 
be evaluated for extracellular RNA.  Because of the presence of extracellular RNA in M. 
smegmatis, H37Ra would be expected to also release RNA into the CF. 
 Immunological studies are important to many aspects of elucidating the role of the 
extracellular RNA fragments and answering the broader question of biological importance.  
Immunological studies are critical in the illumination of the mechanism of host cell activation 
and could be combined with the possibilities suggested here.  NGS would give some indication 
of differences over time and could be paired with immunological studies to look at changes in 
biological activity over time.  Induction of type I IFNs could indicate a possible receptor for the 
extracellular RNA based on studies indicating TLR signaling may not be involved in type I IFN 
in M. tuberculosis, implicating cytosolic receptors [46, 47].  A mycobacterial secretion system 
may be responsible for the translocation of the RNA into the cytosol, although secretion relying 
on the RD1 locus has been ruled out in previous work [11, 48].   
 Identification of a specific RNA population or species that contained the active material 
could be advantageous for immunological studies.  Chionh et al. recently developed a technique 
for targeted purification of a range of RNA species from total RNA, rRNA, tRNA, ncRNA, 
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using a multidimensional high-performance liquid chromatography (HPLC) platform [49].  Two 
ranges of size-exclusion chromatography (SEC) and ion-pair reverse-phase chromatography (IP 
RPC), allowing for the full separation of RNA species between 20 and 10,000 nucleotides in 
length.  An additional advantage of this method is that posttranscriptional modifications of 
nucleosides remain intact, especially important if the modifications do play a significant role in 
the biological activity as is suspected.   
Additional NGS, qRT-PCR, Northern blotting, and fragmentation could help identify 
specific fragments of interest, which could be synthesized for testing in immunological assays.  
Biological studies could also be used to investigate potential differences in biological activity 
between CDC1551, HN878, H37Ra, and M. smegmatis.  Together with the NGS data, the 
biological data could implicate specific small RNA species in different biological consequences.  
 A better understanding of the pathogenesis of M. tuberculosis is critical to the spread and 
control of TB.  Continued research of sRNAs in M. tuberculosis could lead to new targets for 
drugs, vaccines, or diagnostics.  sRNAs in M. tuberculosis are currently being studied by several 
groups, and there is still a lot unknown about the specific function of individual sRNAs.  
Continued study of M. tuberculosis sRNAs and their functions will also help to target specific 
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Appendix A:  tRNA fragments identified in 50 ng CF RNA sample.  Sequence reads from M. 
tuberculosis CF RNA 50 ng sample were mapped to the M. tuberculosis H37Rv GenBank 
reference file, and peak identification reports were exported in text format.  Peak identification 
report gives chromosome region, length of the fragment, depth of coverage, tRNA name, and the 









11149..11185 37 5 AlaTGC AlaT AGGCAGGGGTCAGGGGTTCGAGTCCCCTAGGCTCCAc
4168343..4168387 45 5 SerGGA SerV GCGGAGGATTCGCCTAGTGGCCTATGGCGCTCGCCTGGAACGCGg
3348659..3348693 35 6 GlnCTG GlnU CTGGGGTACCAGGACTCGAACCTAGAATGGCTGAa




2980965..2981000 36 7 ValGAC ValU AGTGAAACTGGTTCAATCCCAGTATCGCGCACCACg
2969894..2969928 35 8 CysGCA CysU CGTGCACACGGGTTCGATTCCCGTCTCCACCTCCa
1512767..1512809 43 9 LeuTAG LeuW GCCGGTGCTCGAAAGAGTTTGAGGGTTCGAGTCCCTCCGCCCg
1946652..1946687 36 9 ProGGG ProT TCAAGTGGTCGCAGGTTCAAATCCTGTCAGCCCGAc
2765331..2765366 36 9 ProTGG ProU TCGGGGTGACAGGATTTGAACCTGCGGCCTTCCGCt
4126582..4126616 35 11 ProCGG ProY AAGAGGCCGTGGGTTCAAATCCCGCCACCCCGACc
1446232..1446265 34 18 ArgCCG ArgV GAGGCAGACGCTCTATCCCCTGAGCTACGGGGGc
731510..731569 60 23 ThrGGT ThrT CGGCAGAGCGTTTCCATGGTAAGGAAAAGGTCAACGGTTCGATTCCGTTAGGGGGCTCGg
2794179..2794231 53 23 ArgTCT ArgW TCCGTAGCTCAGGTGGATAGAGCAAGGGCCTTCTAATCCCTAGGTCGCACGTt
924253..924286 34 28 PheGAA PheU CGGAAGGTCGGCGGTTCGATCCCGCCCCTGGCCa













25684..25727 44 32 LeuCAG LeuT CAGTGTCCTTCGGGACGTGGGGGTTCAAGTCCCCCTTCGCCCAc
850661..850710 50 32 ThrTGT ThrV ACTGACGACCGCTCGCTTACAAGGCGAGTGCTCTACCACTGAGCTAAGGa
2969754..2969787 34 41 GlyGCC GlyU CGGATGTAGCGCAGTTGGTAGCGCATCACCTTGc
10907..10961 55 52 IleGAT IleT TAGAGCGCTTCGCTGATAACGAAGAGGTCGGAGGTTCGAGTCCTCCTAGGCCCAc
924131..924187 57 95 AspGTC AspT AGCGCGCCGCCCTGTCACGGCGGAGGTCGCGGGTTCGAGTCCCGTCAGGGTCGCCAg
2969974..2970012 39 107 ValGAC ValU GACACGGAAGAGGTCACTGGTTCAATCCCAGTATCGCGc








2619405..2619461 57 518 AsnGTT AsnT TGCTCCCCCGGGAGGACTCGAACCTCCAACCCTTCGGTTAACAGCCGAACGCTCTGc




2402027..2402076 50 918 LeuGAG LeuU TAGTGCCCTACTAATGGGCGTGGGGGTTCAAGTCCCCCCTCGGACACAAc







Appendix B:  tRNA fragments identified in 100 ng CF RNA sample.  Sequence reads from 
M. tuberculosis CF RNA 100 ng sample were mapped to the M. tuberculosis H37Rv GenBank 
reference file, and peak identification reports were exported in text format.  Peak identification 
report gives chromosome region, length of the fragment, depth of coverage, tRNA name, and the 


























2402027..2402075 49 533 Leu GAG LeuU TAGTGCCCTACTAATGGGCGTGGGGGTTCAAGTCCCCCCTCGGACACAa




3348659..3348693 35 107 Gln CTG GlnU CTGGGGTACCAGGACTCGAACCTAGAATGGCTGAa
1446232..1446266 35 92 Arg CCG ArgV GAGGCAGACGCTCTATCCCCTGAGCTACGGGGGCg
























25684..25722 39 44 Leu CAG LeuT CAGTGTCCTTCGGGACGTGGGGGTTCAAGTCCCCCTTCg












1946652..1946687 36 32 Pro GGG ProT TCAAGTGGTCGCAGGTTCAAATCCTGTCAGCCCGAc




2969894..2969930 37 11 Cys GCA CysU CGTGCACACGGGTTCGATTCCCGTCTCCACCTCCAGg
2765541..2765595 55 11 Gly TCC GlyV GCGGGCGTAGCTCAATGGTAGAGCCCTAGTCTTCCAAACTAGCGACGCGGGTTCg
11145..11186 42 10 Ala TGC AlaT TGCAAGGCAGGGGTCAGGGGTTCGAGTCCCCTAGGCTCCACa
924131..924184 54 8 Asp GTC AspT AGCGCGCCGCCCTGTCACGGCGGAGGTCGCGGGTTCGAGTCCCGTCAGGGTCGc
10907..10964 58 6 Ile GAT IleT TAGAGCGCTTCGCTGATAACGAAGAGGTCGGAGGTTCGAGTCCTCCTAGGCCCACGAc
4126577..4126615 39 5 Pro CGG ProY GGACGAAGAGGCCGTGGGTTCAAATCCCGCCACCCCGAc







Appendix C: Individual tRNA gene sequence alignments for 100 ng sample.  NGS data was 
aligned to the M. tuberculosis H37Rv GenBank reference genome.  Each tRNA gene was 
isolated in the NextGENe viewer to show coverage.  Grey regions show depth of coverage, the 
blue arrows are used to indicate gene locations within the reference file, and the green arrows are 
























































































































































ProY (CGG)  Length: 39  Coverage: 5 
GGACGAAGAGGCCGTGGGTTCAAATCCCGCCACCCCGAc  
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Appendix D:  rRNA fragments identified in 50 ng CF RNA sample.  Sequence reads from M. tuberculosis CF RNA 50 ng sample 
were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification reports were exported in text format.  
Peak identification report gives chromosome region, length of the fragment, depth of coverage, gene name given by NextGENe, gene, 





Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence
1475756..1475806 51 5 rrl(+2098) rrl towards the middle TAACCCGCAAGGGTGAAGCGGAGAATTTAAGCCCCAGTAAACGGCGGTGGt
1476332..1476370 39 5 rrl(+2674) rrl towards the end GTACCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCc
1472989..1473023 35 5 rrs(+1143) rrs towards the end GAGAGACTGCCGGGGTCAACTCGGAGGAAGGTGGg
1474757..1474791 35 6 rrl(+1099) rrl close to the middle CGAAAGGGAAACAGCCCAGATCGCCGGCTAAGGCc
1476145..1476190 46 6 rrl(+2487) rrl towards the end GGGGCGGTTGCCTCCTAAAATGTAACGGAGGCGCCCAAAGGTTCCc
1474377..1474416 40 7 rrl(+719) rrl towards the middle GGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGACCc
1472388..1472432 45 7 rrs(+542) rrs towards the middle TGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTGTCGc
1475175..1475208 34 8 rrl(+1517) rrl middle GGGTTGATATTCCCGTACCCGTGTGTGGGCGCCc
1472053..1472121 69 10 rrs(+207) rrs towards the beginning
AGCGCTTTAGCGGTGTGGGATGAGCCCGCGGCCTATCAGCTTG
TTGGTGGGGTGACGGCCTACCAAGGc
1471704..1471738 35 11 rrs(-108) Intergenic
Intergenic region 
between murA and 
rrs
CAATAGTGTGTTTGGTGGTTTCACATTTTTGTTGt






Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence
1473453..1473499 47 17 rrl(-159) intergenic between rrs and rrl. Closer to rrs
GAGCCGGGTGCATGACAACAAAGTTGGCCACCAACACACTGT
TGGGt
1476208..1476271 64 17 rrl(+2550) rrl towards the end CAGGTGGCGAGTGTAAATGCACAAGGGAGCTTGACTGCGAGACTTACAAGTCAAGCAGGGACGa
1474108..1474150 43 18 rrl(+450) rrl towards the beginning CAATTCCCGAGTAGCAGCGGGCCCGTGGAATCCGCTGTGAATc





1474165..1474241 77 22 rrl(+507) rrl towards the beginning
GGTAAGCCTAAATACTCCTCGATGACCGATAGCGGATTAGTACC
GTGAGGGAATGGTGAAAAGTACCCCGGGAGGGg
1473754..1473812 59 30 rrl(+96) rrl close to the beginning GCGTGGATCCGAGGATTTCCGAATGGGGAAACCCAGCACGAGTGATGTCGTGCTACCCg












1472173..1472240 68 43 rrs(+327) rrs towards the beginning
ACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCA
CAATGGGCGCAAGCCTGATGCAGCg
1475071..1475128 58 45 rrl(+1413) rrl middle GAGAACCTTGCCCGCCGAAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGt








1476055..1476135 81 89 rrl(+2397) rrl towards the end CGTTGTTGAAATACCACTCTGATCGTATTGGGCATCTAACCTCGAACCCTGAATCGGGTTTAGGGACAGTGCCTGGCGGGt
1476625..1476708 84 89 rrl(+2967) rrl close to the end CGGTCAGGATAACCGCTGAAAGCATCTAAGCGGGAAACCTTCTCCAAGATCAGGTTTCTCACCCACTTGGTGGGATAAGGCCCc
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Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence
1474806..1474873 68 97 rrl(+1148) rrl middle AAGTGGGAAAGGATGTGCAGTCGCAAAGACAACCAGGAGGTTGGCTTAGAAGCAGCCACCCTTGAAAg




1473259..1473327 69 179 rrs(+1413) rrs close to the end CGGTAACACCCGAAGCCAGTGGCCTAACCCTCGGGAGGGAGCTGTCGAAGGTGGGATCGGCGATTGGGa


























Appendix E:  rRNA fragments identified in 100 ng CF RNA sample.  Sequence reads from M. tuberculosis CF RNA 100 ng 
sample were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification reports were exported in text 
format.  Peak identification report gives chromosome region, length of the fragment, depth of coverage, gene name given by 




Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence








1474276..1474314 39 7 rrl(-75) rrl close to the beginning CTTGGTGGTGGGGTGTGGTGTTTGAGAACTGGATAGTGGTt
1476335..1476390 56 7 rrl(+2744) rrl towards the end CGGCTCGTCGCATCCTGGGGCTGGAGCAGGTCCCAAGGGTTGGGc
1474435..1474491 57 7 rrl(+2818) rrl towards the middle GGGTTTAGAACGTCGTGAGACAGTTCGGTCTCTATCCGCCGCGCGCGTCAGAAACTt




1475262..1475361 203 13 rrs(+675) rrl towards the middle GTAGCGGTGGAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGc
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Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence
1474501..1474601 102 18 rrs(-32) rrl towards the middle GGCCGTTTGTTTTGTCAGGATATTTCTAAATACCt
1474108..1474158 51 22 rrl(+2677) rrl towards the beginning
CCCCGGGGATAACAGGCTGATCTTCCCCAAGAGTCCATATCGACG
GGATGGTTTGg









1473454..1473497 44 26 rrl(+1776) intergenic
intergenic between 




1472041..1472121 81 26 rrl(+618) rrs close to the beginning CCGTCAGAGCCTCCTTTTCCTCTCCGGAGGAGGGTGGTg
1476276..1476310 35 29 rrl(-161) rrl close to the end AGCCGGGTGCATGACAACAAAGTTGGCCACCAACACACTGTTGg
1476476..1476532 57 30 rrl(+2880) rrl towards the end AACCTGTCCCTAGTACGAGAGGACCGGGACGGACGAACCTCt
1476538..1476579 42 32 rrl(+1419) rrl close to the end CTTGCCCGCCGAAAGACCAAGGGTTCCTGGGCCAGGCCAGTCCGCCCAGGGTGAGTCGGGACCTAAg
1473754..1473803 50 36 rrl(+2618) rrl close to the beginning CGGGATTAGTGATCCGGCACCCCCGAGTGGAAGGg
1474171..1474242 72 39 rrl(+450) rrl towards the beginning
CAATTCCCGAGTAGCAGCGGGCCCGTGGAATCCGCTGTGAATCC
GCCGGGa





1476729..1476797 69 41 rrl(+3071) rrl end AGGTCAGACCTGGAAGCTCAGTAATGGGTGTAGGGAACTGGTGCTAACCGGCCGAAAACTTACAACACc
1472168..1472248 81 42 rrl(+719) rrs towards the beginning
GGGGTAGCCGCAGCGAAAGCGAGTCTGAATAGGGCGACCCACA
CGCGCATa




1476055..1476149 95 74 rrl(+96) rrl towards the end GCGTGGATCCGAGGATTTCCGAATGGGGAAACCCAGCACGAGTGATGTCg
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Transcript Site Length Coverage Gene Distance Gene Location on Gene Sequence
1474377..1474427 51 75 rrl(+271) rrl towards the middle AAACCGCACGCATGGGTAACCGGGTAGGGGTTGTGTGTGCGGGGt





1474800..1474900 182 85 rrs(+432) rrl towards the middle CTCTTTCACCATCGACGAAGGTCCGGGTTCTCTCGGATTGACGg
1471913..1472012 113 94 rrs(+1413) rrs close to the beginning
CGGTAACACCCGAAGCCAGTGGCCTAACCCTCGGGAGGGAGCT
GTCGAAGGTGGGATCGGCGATTGGGACGAAg












1475566..1475666 122 205 rrs(+322) rrl towards the middle GAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCg
1476905..1477005 114 270 rrs(+195) rrf nearly covers the whole gene
CTTGTGGTGGAAAGCGCTTTAGCGGTGTGGGATGAGCCCGCGGC
CTATCAGCTTGTTGGTGGGGTGACGGCCTACCAAGGc
1473259..1473332 74 409 rrl(+513) rrs very close to the end
CCTAAATACTCCTCGATGACCGATAGCGGATTAGTACCGTGAGGG
AATGGTGAAAAGTACCCCGGGAGGGGa
1475434..1475520 87 1303 rrl(+777) rrl towards the middle GTGAATAGTGGCGTGTTCTGGACCCGAAGCGGAGTGATCTACCCATGGCCAGGGTGa












Appendix F: sRNA fragments identified in 50 ng CF RNA sample with consensus sequence. Sequence reads from M. tuberculosis 
CF RNA 50 ng sample were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification reports were 
exported in text format.  Peak identification report gives chromosome region, length of the fragment, depth of coverage, gene name 
given by NextGENe, gene and the consensus sequence for each fragment. 
 
Chromosome Region Length Coverage Gene Distance Sequence
347393..347426 34 5 PE5(-2198) CTGCCGCCCATCCCGACACTGTTCGTGGTCGCCg
352230..352281 52 5 (+81) CCGTGGGTGCTGGCGATCACGATGCCCTATAGTGATGCCGCCCAGCGGGGTg
378209..378243 35 5 PPE6(-2498) TCCGATGGGGGTTTACAGCCTGGACTCCGCTTTTg
409681..409723 43 5 iniB(+319) TGGGTGCTGGGTTCCTGGGTCAGGGTGGCCTGGCTCTCGCCGc
989639..989673 35 5 citA(+188) TCGGCAGCGGGAACGGTTCAGCCGGCGGCAGCCCg
1466925..1466959 35 5 atpD(+1084) CCAGCTCGACCATCCTGGACCCCAGCGTTGTCGGg
1683101..1683134 34 5 mutA(+944) CCAGCGTGATCCGTGGGTGAACATGCTGCGCTGc
2277851..2277888 38 5 (+598) CTGCCGGAAGTCCCAAAACGACTCACCGACGGCCAGGa
2278147..2278182 36 5 (+304) CGGCGATGTCGCGCAGTTGCTGCGGTGTGATCCGCa
2502565..2502599 35 5 rnpB(-1814) GTCCAAACCGGCTATCAGGCCGCGGTATTCGGCGa
2626202..2626236 35 5 esxP(+283) ATTGTGCTGCAGCGGCTGACGTTAGCTGCTGAGGa
2692351..2692385 35 5 PE_PGRS41(-414) CCAAGCAGCTCCCTGCCGAACCAGCAGACGACGAc
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Chromosome Region Length Coverage Gene Distance Sequence
2951530..2951592 63 5 (-223) CGGGCGGTCGGCACGCTGTGCAGCGGCAGCGCAATGTCACCTACGCTGGTAGTGCTGCGCCGg
3023949..3023988 40 5 ideR(+384) GGCAACCCGATCCCGGGCCTGGTGGAACTTGGCGTGGGCc
3495854..3495897 44 5 tgs1(+469) CGACTGCATGGTCGTGTGGATGTTGCTCGCGAAGCTGTCGCTCa
3497036..3497070 35 5 (+521) TGTGGCGCAGGCTGTCTTGGACCACGTGACCGACg
3606901..3606935 35 5 None CGGCGGATGTAGCGGGCATCGCGTTCGCCGCGCGa
3826273..3826307 35 5 None GTGGAGGCAATCGGAATCCGAGAACTAAGACAGCa
4079769..4079807 39 5 None GCGTGCTTGGCGGTACACACCGACGATCTCGCCGACGGc
4100860..4100947 88 5 None TACAGCTAGAAGCGTCGCAAGATCGCCGAGGCCACCCACGCAACCCCAGGAGTGCACGCTTGGTAACCGAGAACCGTGTTGGTGGGCg
353331..353365 35 6 mycP3(-1133) CGACGGTGATCTGTTGGTGTTGCAGCCGGTGCCCg
619032..619065 34 6 (+727) ACTATCAGGCCGACCCGGCCACTGCTGACCTGAt
918303..918341 39 6 desA1(+409) GGCCCTGGTGGTTTTGGCCTGGGCTGAAGCCCCGGTTGa
1412992..1413025 34 6 (+1098) GGTGACGTCAGGCTTTTTCGAGTCCGGCGAGGGg
1987052..1987085 34 6 plcD(+611) GTTGAACGTTGACGTCATGTCGCCGGTCACACTg
2319295..2319328 34 6 cobN(+1425) CGTGGTAGATCGCCACCGGGTTCTCCCCGAAGCc
2483389..2483425 37 6 dlaT(+1424) CGACACCCCGATCCTGGTTCCGCCGCAGGCCGCCATg
2949955..2950022 68 6 TB31.7(+362) TGGGCGGTGGCCGGGCCGGCTGCTCGGTTCGGTCAGTTCCGGCCTGCTCCGCCACGCGCACTGTCCGg
2955616..2955660 45 6 (-4309) TTTGAGTTATGAAACCCGTGGGCACATACCCTTCCGCGTCGTACt
3499671..3499705 35 6 devR(+210) GTGAGGATCAGACAGCGCAGATCGGGCATGCGGGa
3705429..3705463 35 6 sdhA(+429) CTGCAGACGCTGTATCAGAACTGCGTCAAGCACGa
4314343..4314391 49 6 bfrB(+165) CGAAACCATGCAATGATGCTCGTGCAACACCTGCTCGACCGCGACCTTc
244740..244774 35 7 mmpL3(+2544) GTTGGTGGCGGCGTGGATGCTGGCGACTGCACGGa
345471..345505 35 7 PE5(-4119) GAGGCCCTTGGCCTGAACCCGCCCCCGGTCCCCAt
420761..420804 44 7 dnaK(+926) CGTTGTGCTCGTGGGTGGTTCGACCCGGATGCCCGCGGTGACCg
1080848..1080906 59 7 ctpV(+2171) CGCGATCGAACTCTCCAGGCAGACCCTGCGCACCATCTACCAGAATCTCGGCTGGGCCt
1391026..1391060 35 7 kgd(+1992) ATGGTGCCGCCGACGCGGTAGCCCGGCAGATTCGc
2955455..2955489 35 7 (-4148) TGCCGATCCGGTGGATGACTTTGGTCCCTATGCCt
274730..274769 40 8 None GGTCCTCTGGCGGTGCGGCGGCCAGCGTGTCGAGAGCGGc
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Chromosome Region Length Coverage Gene Distance Sequence
1220452..1220486 35 8 glyA(-52) TGCGGTGCAGACGTGCAACGGTGGATGGCGTGTGc
1338417..1338451 35 8 (+62) CCAGTTCCTCGATCCACTCCGGGCTGGGATTGAGg
1797585..1797619 35 8 nadC(+197) CCTGGGCACCAACGGTTATCGGGTGCTCGACCGCg
1824736..1824770 35 8 cydA(+1117) CGGGGCGGGCATGGTTAGCAGCGCCAGCCAGGAGa
1965776..1965820 45 8 (+119) GGGTGTTGGCCTGGCAAGGCTCAATCCGGCCGACCGCAACGTCCc
1965823..1965861 39 8 (+166) AGATCGGCGATGAACTCTCGGTCGCCCGAGCCTTGTCCg
2250949..2251015 67 8 otsB1(-987) GTGCCGTCGTTGGTCGGTGAGTCCATGGCGGTAGCCAAGCCAAGTAGTCACGACTGCCGTGCCACGa
2274682..2274716 35 8 None CCACCATGTGTACCGATCGACCCAGCCCAGCCAGa
2374240..2374279 40 8 lppK(-2292) AGGGACAGCGCTGGGTGATGCAGACGTGGAGTCAAGTGGt
2782771..2782805 35 8 (+1237) GGCCCGTGACGGCACTTCGGTTTGACCGACCTGGa
3046019..3046053 35 8 (-4558) GCATAGGCAGATTCGCGGGAGCTGGGCAGCGACGa
3414771..3414804 34 8 nrdH(+154) CCCGACCAGTGGTCGTTTCCGGCGACCACGACGg
1169366..1169429 64 9 (-3931) GGTCATCGCGTGATCCTTCGAAACGACCAGCAAAAGTCAATCGAAGGAAATGACGCAATGACCt
1340943..1340977 35 9 esxK(+284) CCTCAGCAGCTAACGTCAGCCGCTGCAGCACAATa
2314134..2314169 36 9 rpsR(+184) GCAGCAGCGCCATCTCGCGGGCGTTCTTGATCGCCt
3326014..3326063 50 9 (+80) CGACGCGTTCGATTTCCCTCGCTCGATGACGGAACCCGGCTTGGTCCGAa
3751654..3751688 35 9 PPE55(+1496) TGGTGATGGGGCCGACGCTGATAGGTATGGCCGTa
851642..851676 35 10 phoP(+34) CCCCAGGCGAAAACACCACACCGGAGGCTCGTGTc
1581101..1581136 36 10 (-679) CCGTTACGTGCTGGGACGACCCGACACAGGCCGGAt
4056124..4056158 35 10 ephA(-1575) GAGCTGACGATCGAGGTCTGCCAGTTCCTGGAAAa
15823..15857 35 11 pknB(+1613) CTGAATCGACCGGAACTGTGGTGCCTGCGGGTGGa
88190..88244 55 11 hycD(-4084) CGAAAGCCGAGCAGGTGGAACCGAAACGCAGTCGCCTCGTCGTATGTGCACCCGa
1166640..1166674 35 11 (-1205) AGGCCGAGGGTGCTCAGGTATCGGGAGAAATCTGc
2219456..2219490 35 11 None GTTGGTAAATCGGGTGCTCAGATCGGCCCTCCGGa
3826433..3826467 35 11 None CAGGTGTCCTGATTCCGGCTCGTCGTCCACAAAAc
474296..474330 35 12 ndhA(-1657) CCCGGTGCCGTTGCCGTGCCAAACGGTTGTTGTCg
806142..806176 35 12 rpsQ(+386) CGAGATCCTCGAGAAGGCTAAGTAAGCCTGACGAg
1962197..1962230 34 12 narX(+1956) GTCCTGTCCGCTCGCCGAAGACGCACTCCCGTCa
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Chromosome Region Length Coverage Gene Distance Sequence
1964687..1964721 35 12 narK2(+649) GTAGTTGCTGAACGCCACGAACCCGCCGAACACGa
2517341..2517396 56 12 fabD(+554) TGCACTGGGTGTCGCCGGAGCGTTCCACACCGAGTTCATGGCGCCCGCACTTGACg
3496799..3496837 39 12 (+284) AAACCGTTTCCCCGATCCCAAGGACCGCTGCCATCTGGc
3497203..3497248 46 12 (+688) CTCAGCCGTCCGACGTCTTACCCGCTGACGACGGCGCCGCGATCCt
3666695..3666729 35 13 accA3(+338) CGGCCCCAGCCCGCAGTCGATCCGCGACCTGGGCg
68848..68882 35 14 None GTGCTTGCTGCCCTACTGCTGGCGTATCGCTCGCg
2949865..2949899 35 14 TB31.7(+272) CCACAGTGAAATCGTTCCGGCGGCAGCCGTTCCCa
3468156..3468242 87 14 ssr(+177) AGGGTCCGGGCCGAGGGCGTTCCCGGTCTGACAGACTAGCCGTCGCTTAGGCAGCGAGAGCGTAGTCGCGCTGATGTGAATCGGCGc
3415123..3415167 45 16 nrdH(-165) CCCCGTGGATCTGGTGAGACCTGGTGAACCTGGGATCTGCCGGTa
4168234..4168282 49 16 (-106) GCCTTCCAGCCCTGGGGGAGTTCACAGGATAGACGCCGCGCGGGGTCCa
2238981..2239015 35 17 ctpF(-1144) ACACCCATGCAGAGGGGACGCCAATGTCAGCCCAa
164390..164424 35 18 cyp138(+1024) CGATCATTATCAATATCGCCCAGATACATGGCGAt
1187430..1187464 35 21 0 CTCCCGTGGTTATGCCTCTTGTCACGCCAACCACc
3468051..3468090 40 21 ssr(+329) GATCTCCCGGTCACGCGAACTAGCCGAGATGACGATCCCa
4262658..4262692 35 21 fadD32(+374) ACGGGGCACAGTCGTCGAGCACCGCGTGTAACCGa
2767686..2767719 34 22 (-21) GGGCACCGGCGGCGCTTCGTGGGTCCGTTCGTAc
80258..80292 35 24 glyA(-1362) GGCGGCCACGGGAAACGGACCCGCAGCAACGCGGg
1275613..1275673 61 27 None GGCGGTGACCGCGGCATTGTTTTCAGTTTGTGACAACTTCTCAATATGCCGCGGTCGCCGc
2040858..2040894 37 34 PPE28(+1405) ACGGCGACCCGGCCTATGGTTATTCGACCTCGCCGCc




1993213..1993246 34 41 (+60) GGGTTGGGGATTTCTGAACCGATCAGTCCCGGGt
3649468..3649502 35 48 ctpC(-1024) GCCACCGGTGAGCGCATCGAGCTATCCGCGGTGAc
754758..754793 36 54 atsD(-1344) CGTCGGAATGCGGTGCGTGGCAACGTATGAATGTTg
4099438..4099475 38 58 (-4524) CCGGGGGGTCGGACTGATACACCCTCGGCTATGGCCGa
2404472..2404549 78 63 (-2750) ACCAAGGCCAGGAGCCCAATCAGGGCCAAGACCAGCGCAATGATCAGCATCGGTCATCCTCCAACCGGCTAGCAGCGa
4352941..4352979 39 91 (-31) GAGTTCGACCTTCCGTCGGTCTCGCCCTTTCTCGTGTTt
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2844174..2844208 35 119 fas(+5124) CGCTCGGCGTTGAGCACTTCCACTGTGCTGTGGGc
1342600..1342663 64 338 0 GGTCATTGCGTCATTTCCTTCGATTGACTTTTGCTGGTCGTTTCGAAGGATCACGCGATGACCg
1469500..1469574 75 357 murA(-747) GCGCACGTCGTTGTCGGCTCCTTGTGTTTCTGATCCTTGACAAGCCAGAAACCTTAAGCCACAACGACGTGCGCc




Appendix H:  sRNA fragments identified in 100 ng CF RNA sample with consensus sequence.  Sequence reads from M. 
tuberculosis CF RNA 100 ng sample were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification 
reports were exported in text format.  Peak identification report gives chromosome region, length of the fragment, depth of coverage, 




Chromosome Region Length Coverage Location on geneome Gene Distance Sequence
303550..303583 34 5 argC nirB(+684) ATCGAGTCGGTGAAGCATTCGGATGGCTCGGTGt
337304..337337 34 5 Between Rv3750c and Rv3751 PE_PGRS4(+1736) CCCGCCGGTGTCCAGGCCAAACCCGCCGCTGCCg
601708..601741 34 5 ctpC hemA(+1267) TCTTCGAGCTTGACCAGACCGCCGTCGATGCCGt
1564447..1564480 34 5 fadD32 gmk(+46) AACCGGCGGCAGTGGGACGTGTGGTGGTGCTGTc
1577190..1577223 34 5 fusA1 (+260) CGTGGTGGCGATGTGCGTTGCGTCCGCGGGGCTg
2055657..2055690 34 5 gltB (-298) CTTCGGCTCGCTGGTTAGCGATTGTTAGTTGCAc
2239323..2239356 34 5 gmk ctpF(-803) TGCACGGCCAGATAGTGCCCACGCTGGCCAACAt
2289878..2289911 34 5 hemA lipT(+1309) GCACGGCGGTCGGCGGCGGCGGTCAGCAATGCGc
2827612..2827645 34 5 hemH orn(+455) CAAGGGGCTGACGCACCGGGCGCTGGCCGACATc
2978147..2978180 34 5 Inter geneic None GCTGGCAGTTCCTCGGTCTCAACGATCTTGCCGc
3022467..3022500 34 5 Inter geneic sigB(+6) GATGCACCCACAAGGGCCACCACAAGCCGGGTTg
4198611..4198644 34 5 Inter geneic tyrA(-1711) CGGGGGTGGAAGTACTGTCCGTTCCTGGACTGCg
4262779..4262812 34 5 kasA fadD32(+254) CAGGTTCTGCGGGCACAGGATGGCGACGCGGTCa
4302868..4302901 34 5 lipT (-79) GCACACATCGAGGTCAGGATCTCGGTCATATCGc
4334567..4334600 34 5 mbtB gltB(+1481) CGACAACACCGCAACTGGAGTGTCGGTGCCCATc
4369747..4369780 34 5 mmpL5 mycP2(+390) CAATGATCGAACTCACCACCGTGCCGTGCGCGTc
 150 
 
Chromosome Region Length Coverage Location on geneome Gene Distance Sequence
4398690..4398723 34 5 mycP2 sigM(-1463) GCTGGTTCCCGGCGCCCGCATCGCTAACGGCCGc
119170..119204 35 5 nadC (+1456) CGCACCCGATCACCGCATTCGTCCTCTTTGTGGCc
194242..194276 35 5 ndhA (+662) CAGCTGCCGATGACTGTTCACCGCGTCCGCGCCCc
269454..269488 35 5 nirB (-1690) CGACGATGTGACCAAACACCATGTGCTGCAAAGCt
274730..274764 35 5 orn None GGTCCTCTGGCGGTGCGGCGGCCAGCGTGTCGAGa
348462..348496 35 5 pckA PE5(-1128) TCAACACCCGTAATCCGTTGCTGGCCAGGGTAACc
474296..474330 35 5 PE_PGRS4 ndhA(-1657) CCCGGTGCCGTTGCCGTGCCAAACGGTTGTTGTCg
782891..782925 35 5 pepD fusA1(+406) TCGTCAACAAGATGGACAAGATCGGTGCGGACTTc
873531..873565 35 5 pks3 hemH(+188) CGTCGATGCCCCTAACCATCTGGCCGGGCCGCCGg
884318..884352 35 5 radE14 (-268) GCGGGCGGCGGTGGGTGCGTCGATGGTGGCGTCCa
1099314..1099348 35 5 rnpB pepD(+248) TCCGACCATGACGCCCCCTCCTGGGATGGTTCGCc
1511851..1511885 35 5 Rv0102 fadE14(+1005) CTTGTCGACGAAACGACGCTTGGCAAATGGTGGCg
1736341..1736375 35 5 Rv0165c ileS(-144) AGGCCCAGTAGAACCGAACGGGTTGGCCCGTCACa
1866320..1866354 35 5 Rv0225 argC(+744) GGCATCCTGGCCACCTGCACGGCACGCACCCGATc
1901178..1901212 35 5 Rv0284 dsbF(-536) GCCTACTCGATTGGCCCGCGGTGCGACCGTGCCGa
2032991..2033025 35 5 Rv0790c mycP5(-704) TGGGGATTTACACCACAATCGTCATCATCGGTGCg
2056276..2056310 35 5 Rv1349 erg3(-211) GGCTGCCCACCCACGGTGCTCGGTTCGGTCCGGGa
2477897..2477931 35 5 Rv1401 (+707) CGACGCCGCCGTCACCGACGTGGTGCATGCCGACg
2500503..2500537 35 5 Rv1676 rnpB(+214) CCGCAGGCTCGGGCGAGCAACCCTCAAGCGCCTGc
2502565..2502599 35 5 Rv1795 rnpB(-1814) GTCCAAACCGGCTATCAGGCCGCGGTATTCGGCGa
2519178..2519212 35 5 Rv1813c kasA(+1063) CGGTGCTCACGGTGCTGACGCTGCGCGACGGCGTc
2672020..2672054 35 5 Rv1996 mbtB(+3783) CGAGCGAACTCGAAGGCCACTATCGCACCCATGCa
2783947..2783981 35 5 Rv2144c (+61) GGCGCCCGGATAGAAACTCAACGTCACGTCGTCGa
2819339..2819373 35 5 Rv2212 scoA(+497) CCCCCTGCCAGGCATGCACCAGTGCGAAGTCGGTc
3020895..3020929 35 5 Rv2228c sigB(-1532) CGCTGGGCTTCTTGATCTCGCTGTGGGCAGGATCg
3651551..3651585 35 5 Rv2477c ctpC(+1025) CTCGGCCATCGCGTTGCTGATCACCGGCGACGTGc
3900311..3900345 35 5 Rv2626c cpsA(-2733) ATCAACGCACCAACGTGCATCATCGTGGTCGACGa
3953877..3953911 35 5 Rv2627c (+446) CGAGATGCTCGCCGAACGCTACCGGGGAAGCCGCg
4221473..4221507 35 5 Rv2655c (+384) CTGCTCGATGCCGCCCTCGCCAAACACGCCACAGc
4231808..4231842 35 5 Rv2707 None CGTGCTCGCCGCCGCATCGCGTCGATTGCTGCCCt
2404447..2404484 38 5 Rv3480c (-2725) CTGGTTGCTGGTGACCACCGCGAACACCAAGGCCAGGa
1797489..1797527 39 5 Rv3517 nadC(+101) GGTGCCTGCCAGTGCGACGACCACCGCATCGCTGGTGAc
2500383..2500425 43 5 Rv3776 (-4984) GGGCGGACGAGTTGGCCTGTAAGCCGGATTCTGTTCCGCGCCg
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2952672..2952716 45 5 Rv3785 (-1365) GCTCTGAGATGACCGGAACACGGCGGACCTGATGTTCTTCCATGa
2953710..2953754 45 5 Rv3828c (-2403) CGTAGATAAAGCGGCCCGGCATGGGCACCAGTGGCGTAAGTGAGa
1516874..1516919 46 5 Rv3910 fabG(-572) CTGTTCCACGGGACGATCCGCGACAACGTGTTCGCTGCAGACCCGg
1314313..1314361 49 5 Rv4006 pks3(+588) AGCGATCTCGCTCTTGCCGGTGGTGTGGTTGTCACGCTAGAACCGCGGa
251787..251840 54 5 scoA pckA(+5) CTCAGCGACCATCCCCGGTCTGGATACCGCGCCGACGAATCACCAGGGGTTGCt
776008..776071 64 5 sigB mmpL5(+2409) GTTGCCAGATCAGCACCGACAGCCCGAACGAGGCGCCCAGCGACAACACCACGGTGCCGACGAt
88211..88244 34 6 accA3 hycD(-4084) CGAAACGCAGTCGCCTCGTCGTATGTGCACCCGa
215774..215807 34 6 aceAb bglS(-462) GTTCGTCCGGACCTTGTTCGACCGCGTCACCGCa
326352..326385 34 6 ctaD fadE6(+2076) GGCTGGCTAGCAGGTACTCGCCCCACTTGCCGGg
352444..352477 34 6 ctpG (+295) AGCTGCTACGTGGCATCGTCGCGCTGCGCACCGg
420777..420810 34 6 dlaT dnaK(+942) GGTTCGACCCGGATGCCCGCGGTGACCGATCTGg
631410..631443 34 6 dnaK (-1679) CACGCCGGTGACCACGCCACCAACGACCGTCGCc
2162128..2162161 34 6 fadE6 aceAb(+562) GCTTGGTCGAATCTCCCTATCGCACACCGCAAAc
2276245..2276278 34 6 fas pfkB(+146) GACATGCACAATGCGGGCGACATTGATACCGCCg
2593248..2593281 34 6 Inter geneic rocE(+872) GATGGCCAGCCCGGCGGTTTCCTGCTCTGCGAAg
3497349..3497382 34 6 Inter geneic (+834) TGCCCGATCACCGAACCGCTGGAGATCGCCAAGa
3516906..3516939 34 6 lpqB nuoG(+160) TGGAGCCCGTCGGCGCCTGCCGGCAATGCCTGGt
3894312..3894345 34 6 narX PE31(+219) CAGTTTGTGACCACGCTGGCCACCAGCGCTAGTt
595932..595966 35 6 nuoG serB1(+619) TTCGCGGGTGCCGTCCCAGATCTTGTCGGCGATGa
707305..707339 35 6 otsB1 galTa(-4197) CACGCGATCCATCCGCGGTTCGCTGTTGGTTTCCa
1004881..1004915 35 6 PE31 prrB(+926) AGATCCGGGCCGCGTCGTGGGCGGCGCGGTCGAGc
1669140..1669174 35 6 pfkB moxR1(-109) ACTGAGCCAGGTGTGATTTGCCGGGCACCACCGCg
2150873..2150907 35 6 pks13 nanT(-599) CGGCGTGATGACGCTGACCTCCCGCCCTCCAATAc
2252256..2252290 35 6 prrB otsB1(+254) GGCCGCCCGCGGAATCAGGCTGCCGCCGGGCTCCc
2445035..2445069 35 6 rocE (-2718) CCTGCGCGGAGTCGGCATTGGTGCGGTCGATGGGa
2483389..2483423 35 6 Rv0079 dlaT(+1424) CGACACCCCGATCCTGGTTCCGCCGCAGGCCGCCa
2842511..2842545 35 6 Rv0185 fas(+6787) CGAGCCGGGCAGCACCACGTGCAGCCGCGACGCGa
3404859..3404893 35 6 Rv0284 ctaD(+28) GGTGCGGGCCGGGTAAGGACGAATGGCTTCGAGTt
3492964..3492998 35 6 Rv0289 (-842) CCAGTGACAGTCGTGACATCGTGCGGGGCCTGACg
3623406..3623440 35 6 Rv0538 lpqB(+1470) TCGTCACCGGTTCGCCAGGACAACGACACCACCGa
3666695..3666729 35 6 Rv0613c accA3(+338) CGGCCCCAGCCCGCAGTCGATCCGCGACCTGGGCg
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4222194..4222228 35 6 Rv1478 and intergenic (+1105) TCTGCGACATCGACCACACACTGCCCTACCCACTc
4258521..4258555 35 6 Rv2182c pks13(+2591) TCTGGGTGGGCGCGGCGTAGACACACACCTCCAGa
346439..346476 38 6 Rv2625c PE5(-3148) ATTCCCGGCCGCCTCGATGCGCTGGGCCCGGCCCGCAa
4056007..4056044 38 6 Rv2777c ephA(-1689) CGGGATGTAGGTCAGGTCCACAGCCACCGGGCGCACGa
1963271..1963312 42 6 Rv3127 narX(+874) TCAGCGGATCGGCACGGCGCAGCTCAGAGACCGTGCGCCCCa
2239872..2239913 42 6 Rv3127 ctpF(-246) GCTCAGTCAGCAGAGCGGTGGTCAATTCCGGTCAGGCTCCGg
1313412..1313455 44 6 Rv3131 pks3(-270) ATCACACGCGCGGTGCATGCTGCTGTGGCTGTCGAGCAGTGTTg
3084849..3084898 50 6 Rv3616c ald(-1922) AGCATGTCCAGCATCACGGGGTCTGCACCGACGGCATCGAGCTGCGGGGa
3493021..3493086 66 6 Rv3776 (-899) CCTTGATCCGGGTAGGGATAGCCCCGCCGTTGGCAGCAGTTCCCGCCCCCACACCACGGCGGCCGc
2952398..2952466 69 6 serB1 (-1091) ACATGGTCGCCAGACTCCAGGTGAACAACCACAGGATCACCAACACGCTCCAGTGGACGTTCACCACAa
662451..662484 34 7 acrA1 nrdZ(+1156) AGTCATGTAATCTCGGCTCGATCAACCTCGCCCg
2073625..2073658 34 7 desA2 (+544) CGCGGCATCTACGCGCCTTCCGCTCCGCGGCCGa
7449..7483 35 7 fumC gyrA(+147) CCCGTGCATCGCCGGGTGCTCTATGCAATGTTCGa
25117..25151 35 7 gyrA TB39.8(+293) GCTCGAATCGGACGACCACATCACCATACGTTTGc
349084..349118 35 7 Inter geneic PE5(-506) CCCCGACAACGAGTACACCGCCAACATCGATCGGa
867824..867858 35 7 ispF (+493) GGTGTCCAGCCGCTGGGTGTCCAATAGCGGAATGa
1222477..1222511 35 7 nrdZ desA2(+518) CGAAGAGCCCATCCTGGCCGGACTCATCGACCGCa
1227126..1227160 35 7 PPE3 fumC(+405) GTGGCCGTCGGGAAGGTGTCGTTGGACGACTGCGa
2017524..2017558 35 7 Rv0284 malQ(-48) CTGAGCCTTCCGTCAGCACAGCACGGTTGGCTACc
2278025..2278059 35 7 Rv0774c (+427) CATGCTTGCGCCGGTGGCCAAACCGTCATCGACGa
3806205..3806239 35 7 Rv0823c acrA1(+584) GTTCACCCCGATGCTGCTGCCGGACATTGGGCGCa
4346889..4346923 35 7 Rv0996 PE35(-3822) CTGTTGTCGATCGTCGGCACCCAACGGCAGTGGTc
1113102..1113140 39 7 Rv1828 (+718) TGATGGCGGTGATCCTGGTTGGCTCTGCCGCCGCGGCCt
917498..917537 40 7 Rv2030c (-1187) CCGACCTTCGACTGTTCCAGCTGACGACACAGCGCCCGGa
3468268..3468321 54 7 Rv3870 ssr(+98) GTGGTCTCTTGCCTGCACCGGCACGCTTCCCTTGATTCGATGCGCGAAGTCGAa
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4024199..4024262 64 7 ssr ispF(+85) TCGCACAGCGCATGAACGGCCACGTCACCGTCGGAGTGGCCCGCGCAACCGTCGGCGCTCGGGa




1796908..1796941 34 8 devR nadB(+1103) CGGGTTGCACGGCGCCAACCGCCTGGCCTCCAAc
1845595..1845628 34 8 devS uvrA(+1854) CGTTCCGTCGACCCCCGTCGTCAACTCACCGTCg
2484655..2484688 34 8 hspX lipB(+71) CGCGTGGCAGCTACAGCGAGAGCTAGCCGACGCc
2955616..2955649 34 8 hycD (-4309) TTTGAGTTATGAAACCCGTGGGCACATACCCTTc
4220050..4220083 34 8 Inter geneic between Rv2628 and Rv2629 lipE(+365) CTGCGAGTACCTGCCCTCCTACACCAGTCATGGc
88506..88540 35 8 kdpD hycD(-3788) CAGACTGGATCGACAGATCGTGCGGGCGTCGGCAc
851642..851676 35 8 lipB phoP(+34) CCCCAGGCGAAAACACCACACCGGAGGCTCGTGTc
1150652..1150686 35 8 lipE kdpD(+1000) GCCGACGACGAGCTGCGTGGCGTTCATCTCGCGGg
1235415..1235449 35 8 nadB xseA(+11) CCACCGCGCGAACCGGGAACGGATTCTCCGCTGAa
1796054..1796088 35 8 nadB nadB(+249) CCCGATGCGGTGTACTCGATCGTCGCCGACGGCTa
2979238..2979272 35 8 phoP clpC2(-4624) GTCTGCCATGCCGGGCCTTTCGGTCTCGTGAGAGa
3496869..3496903 35 8 pks16 (+354) CAGGCCGATGTCGCCTTGGCGGCGGCCATACCGCg
3499671..3499705 35 8 Rv0289 devR(+210) GTGAGGATCAGACAGCGCAGATCGGGCATGCGGGa
3606667..3606701 35 8 Rv0290 None TAGCGCCAGTGCTTGGACGATCCGCTCATGTCCCa
4029729..4029763 35 8 Rv2657c mutY(-730) TAGGTAGCGGGCCACGCGGTTCCAGATCCAGCACg
1132353..1132392 40 8 Rv3131 pks16(+728) CAAGTACCAGGGCACCATGACCGCGGCGCCCAACTTCGCc
3498580..3498619 40 8 Rv3229c devS(+646) CCGGACAACAACTCGGTGGCGATGTCACGGGTGGCCTCGa
353501..353542 42 8 Rv3587c / intergenic mycP3(-956) TGGCTACCGGTTTGACGGTGACCTATCGGGTTGCCACCGGTg
352199..352242 44 8 Rv3879c (+50) CATCGCTGAAACCATTGGGGCGGGGACCTTTCCGTGGGTGCTGg
2278606..2278652 47 8 uvrA hspX(+280) GTCAGCACCTACCGGCAGCGACACCGTGCGAACGAAGGAACCGTACg
4359090..4359155 66 8 xseA None CGTTGGTGTGATCGGAGTTACCGGCGCTCCCGGGATGGGTGTGATTGGGGTTCCCGGGGTGATCGg
1197094..1197127 34 9 cfp2 (+815) CAGTTATCTACAGAATGAGTAGCGCTCGTTGGCc
3589569..3589602 34 9 esxK (+175) CGCTGAAGCAGCTGTGGACCGCCGCCAGCCCAGc
356191..356225 35 9 Inter geneic (+311) CGCCCGGTATTTGGACCGATACGGCATCCGCGCCg
1340943..1340977 35 9 Inter geneic esxK(+284) CCTCAGCAGCTAACGTCAGCCGCTGCAGCACAATa
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2103054..2103088 35 9 Inter geneic ndh(-12) CCTGACGGGGTCACCTCGATGAGCGAGTTCAGTTa
3246358..3246392 35 9 PPE3 ppsA(+913) CCCCGGCGGTATTTCGCGGTTTCGACCAAGTCGGc
3548920..3548954 35 9 ppsA mesT(-3620) CGCCATATTTCAAGAGCAGGTTGGAGCTTCTGCCc
353322..353365 44 9 Rv0290 mycP3(-1133) CGGTGTCGTCGACGGTGATCTGTTGGTGTTGCAGCCGGTGCCCg
1965772..1965820 49 9 Rv0292 (+115) TGGTGGGTGTTGGCCTGGCAAGGCTCAATCCGGCCGACCGCAACGTCCc
2256537..2256600 64 9 Rv1072 fdxA(-109) GGGTGCAAGAAAACCGGGGCGGTTCACCCGACCGCCAGCGGGATTCACGCTCCCCCAGGCCATa
2655876..2655940 65 9 Rv1738 cfp2(+175) GCCCTTGTTCGCAAACGACACGTTGGGATCGGCGAGGCTGTTGAGCAGGCTGGTCAACTGGGCGg




2150918..2150951 34 10 ctaC None AGCACCTAACAGCACACGACGACGGGACTGCAAa
2954155..2954188 34 10 fas (-2848) GGCGCGGAACACCGCGAGATCCAACGGGGCCCTg
1413108..1413142 35 10 Inter geneic None GGGCAGACCCGGCGTGACTCTCGGGGGGCGTCTGa
2122411..2122445 35 10 Inter geneic lldD2(+706) GCCGACGGTGCCAGGCCAGCGATCCAGTGAAGCGa
2463741..2463775 35 10 lldD2 ctaC(+976) CGCCCGCAGGGCCTCGGCGTTTGTCTTCCCGTCGa
2847337..2847371 35 10 PPE56 fas(+1961) TGATCCATTGGTCGGTGCCCTGAGTGTCGACGAGc
3758308..3758342 35 10 Rv2627c PPE56(+8760) AGTGGGCCGGTGGCGTAGGGCGAACCGTCGGCCGa
32182..32215 34 11 atpD bioF2(-2080) CGCTGAGCTTTCGTCTAACACCGCCGAAACCGCc
1998195..1998228 34 11 desA1 PE_PGRS31(-2386) CACCCCAACCTGATCCAACGACAACCGCCCCTCc
1199075..1199109 35 11 fabD fadA3(+264) GCCATCCGGGTGGTCTGCAGCGACGACGAACAGTa
1220452..1220486 35 11 fadA3 glyA(-52) TGCGGTGCAGACGTGCAACGGTGGATGGCGTGTGc
1466925..1466959 35 11 fas atpD(+1084) CCAGCTCGACCATCCTGGACCCCAGCGTTGTCGGg
2517353..2517387 35 11 Inter geneic fabD(+566) CGCCGGAGCGTTCCACACCGAGTTCATGGCGCCCg
2845154..2845188 35 11 Inter geneic fas(+4144) GTGCACACCGCTGGCGATGATGCTGGTCGGGTTGt
4056753..4056787 35 11 Inter geneic ephA(-946) CGCCGGTGGCGCAATCAGGGCTGTGCTAACCCACc
378204..378242 39 11 Rv0029 PPE6(-2493) GCCACTCCGATGGGGGTTTACAGCCTGGACTCCGCTTTt
3093770..3093825 56 11 Rv0309 rpsO(-22) TCGCGATCATGGATATCAGGGCACGGCCACCGCGAACCGCAGCACGCACCGATGTc
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1389211..1389245 35 12 ctpG (-583) GATTGCGGACTTCGCCCAGTGGGACAACAGCCATa
2626202..2626236 35 12 Inter geneic esxP(+283) ATTGTGCTGCAGCGGCTGACGTTAGCTGCTGAGGa
3606901..3606935 35 12 IS1081-1 None CGGCGGATGTAGCGGGCATCGCGTTCGCCGCGCGa
2236394..2236438 45 12 Rv1247c ctpG(+868) CACGAATGATGCCGTCGGTGGCCAGGCGTTCGCCCGGTTTAACGa
1197139..1197190 52 12 Rv2345 None GTCCACCAGGCTGACCACTCGCACTTTTGCGTGGTAGACGCAGGATCAACGg
1169366..1169426 61 12 Rv3229c (-3931) GGTCATCGCGTGATCCTTCGAAACGACCAGCAAAAGTCAATCGAAGGAAATGACGCAATGa
2102731..2102764 34 13 Inter geneic ndh(+278) GAGCAATTCCGAGACGACGCACTGCCCGGCCAGg
1419706..1419740 35 13 lprA lprA(+8) TGGCGGTGGCGGCGGCAACAACGGAACAAGGTGGa
2646753..2646787 35 13 ndh (+301) CGGGTTACCTGCCCGATCGGTGACGATGATCGCAg
2756411..2756445 35 13 Rv1234 (-1665) GGGACGGTCACCGGCGGTCAGGATGTCGTAATCGg
2959794..2959828 35 13 Rv2365c None GCGCTTTAATACGTCGTAGGCATTCACTTCGTTGc
4119573..4119607 35 13 Rv2455c nth(-3679) GGCCGGGTTGTTGACGGCCGGGGTCAAGCTTCCCg
1376990..1377028 39 13 Rv2633c and intergenic lpqY(-496) CCAGCCCAGACAGGTTCCCGGTTCAACACCCGCCGCCGc




498846..498880 35 14 Inter geneic (+739) GGTCAGCGCAGTTCCCACCCACACCACCATGACGa
1666920..1666954 35 14 Inter geneic acn(-874) GATGCTTGTGGTGTCGTTGGCGTTGACCTGCGCTg
2728347..2728381 35 14 mycP3 PE25(-81) CACGTTGAGAAAACGCAACGACTTCACTGGCATAa
2782771..2782805 35 14 Rv0412c (+1237) GGCCCGTGACGGCACTTCGGTTTGACCGACCTGGa
2951533..2951573 41 14 Rv2477c (-226) GCGGTCGGCACGCTGTGCAGCGGCAGCGCAATGTCACCTAc
3496579..3496627 49 14 Rv2625c (+64) CCGTGCGAACGGTTCTCACCCTGGCCGTCCGGGCCCCCTCCATCCACAa
355733..355798 66 14 Rv3131 mycP3(+1235) CAAGCCGGTCGCCGATCCGCCGGTCCCGGCGCCCAAAGACACCACACCGCGCAACGTCGCATTCGc
3153388..3153421 34 15 ctpV efpA(+1210) GCCATGCCGATGCCAATCCCGCCGACGACGATCg
1166640..1166674 35 15 cysS (-1205) AGGCCGAGGGTGCTCAGGTATCGGGAGAAATCTGc
2624292..2624327 36 15 efpA (+471) TCGTCGAGTCGAGTGGTGTTGTTGGTCACGGTCGGc
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1080094..1080138 45 15 Rv1043c ctpV(+1417) CGAAGAAGATCGACACCGTGGTGTTCGACAAGACCGGCACCCTCa
2391717..2391761 45 15 Rv2345 cysS(+698) TGGATGTCGAGGCCGCTTCCGATACGACTGAGCGCGATGGCTGCg
1993213..1993246 34 16 bfrB (+60) GGGTTGGGGATTTCTGAACCGATCAGTCCCGGGt
2775535..2775568 34 16 Inter geneic (+263) AACTGGCCAGGCCTTACCTCGCACCGGGTAACCg
3496375..3496409 35 16 Rv1760 tgs1(-9) CCTTCCCCGGTGATCCGGATTATCTGCAACCGTCa
4314343..4314387 45 16 Rv2472 bfrB(+165) CGAAACCATGCAATGATGCTCGTGCAACACCTGCTCGACCGCGAc
2949865..2949938 74 16 TB31.7 TB31.7(+272) CCACAGTGAAATCGTTCCGGCGGCAGCCGTTCCCACATTGGTCGACATGTCCAAAGACGCAGTGCTGATGGTCg
2280314..2280348 35 17 fadD31 (+734) CGGTCCAGTCGCGTACTTGCGAACGGATGCGCCGc
2638357..2638391 35 17 hpx PPE40(+1144) GAAGAAGCCGATGTTTCCATCACCCGAGTTGAAGa
2885351..2885385 35 17 narK2 (+740) GGATCAACGGTATCCGCCGGATGCGGTCGATTCGc
3540695..3540729 35 17 PPE40 hpx(+16) CCCGAACACCTGGGTGTGTAACGGGGTGCCGTCCg
2177096..2177147 52 17 Rv2033c fadD31(+9) GGCTCCCGGCAGGAACTCAGGGTTCGTAGCGGCCTACTACAAATCGAGGACt
1964660..1964721 62 17 Rv2565 narK2(+649) GTAGATCGTGGTGATGTAGGTGGGCAGGTAGTTGCTGAACGCCACGAACCCGCCGAACACGa
1114988..1115021 34 18 lprQ arcA(-2164) GCGCTGCCGGGCATGATCGTCGGCGAAATCGCGc
2274682..2274716 35 18 Rv0998 None CCACCATGTGTACCGATCGACCCAGCCCAGCCAGa
571794..571838 45 18 Rv2028c lprQ(+84) CGGCGTCTGGCGTTGACGGCCCTTGGGTTTGGGGTGTTGGCACCg
65446..65480 35 19 efpA celA1(-72) ATTCCCGAGAACAGCCTGAAATCCTGTTCGGTTGa
3153949..3153983 35 19 Inter geneic efpA(+648) AGGGCGGTGCGGGCCAGGTAGATCATCACCAGCCc
3497199..3497253 55 19 Rv3131 (+684) CTGTCTCAGCCGTCCGACGTCTTACCCGCTGACGACGGCGCCGCGATCCTGGCAc
4100706..4100778 73 20 Inter geneic None GCTCGATCCAGAAGAGAAGGTTCGGTCTCCCGACCCGGGCGCCCAGCATGGTTCCCGGCACCCACGCGGAGTc




2279214..2279247 34 21 acg acg(+85) CCTGGCGCTGGATAGCCGAGGACCACACGGTTGc
4404606..4404640 35 23 Rv3131 None CCATCAAGAAGTTCGCGTCGATGATGCAGTGTTCg
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1965823..1965861 39 24 iniB (+166) AGATCGGCGATGAACTCTCGGTCGCCCGAGCCTTGTCCg
409680..409728 49 24 Rv1566c iniB(+318) CTGGGTGCTGGGTTCCTGGGTCAGGGTGGCCTGGCTCTCGCCGCGTCAa
3496517..3496571 55 24 Rv1738 (+2) GACCGCAGCCGTTGATGGGAAAGGCCCGGCAGCCATGAACACCCATTTCCCGGAc




2767686..2767728 43 26 Rv2465c (-21) GGGCACCGGCGGCGCTTCGTGGGTCCGTTCGTACTCGGCGAGa
50642..50676 35 27 inol ino1(+448) AGCACACTGGGCGTAGAACTTGTCGGCTTCCTCCg
3649468..3649502 35 27 Rv3268 ctpC(-1024) GCCACCGGTGAGCGCATCGAGCTATCCGCGGTGAc
916241..916275 35 28 Rv0822c (+36) CGGTCAACACCATCGGGGAATGCTGACTCGGAGAg
754760..754793 34 30 Rv0659c atsD(-1344) TCGGAATGCGGTGCGTGGCAACGTATGAATGTTg
3326014..3326063 50 31 Rv2970A (+80) CGACGCGTTCGATTTCCCTCGCTCGATGACGGAACCCGGCTTGGTCCGAa






Some on Rv3640c and 
some on intergenic 
region 
None GGATCTCCTTCGGTGCGTGCTTGGCGGTACACACCGACGATCTCGCCGACGGCCCCt
3826433..3826467 35 37 Rv3407 None CAGGTGTCCTGATTCCGGCTCGTCGTCCACAAAAc
1816201..1816234 34 46 pykA pykA(+12) GGGAAAATCGTCTGCACTCTCGGGCCGGCCACCc
1824726..1824770 45 55 cydA cydA(+1117) TGGCCAGGAACGGGGCGGGCATGGTTAGCAGCGCCAGCCAGGAGa
4352944..4352979 36 62 Inter geneic (-31) TTCGACCTTCCGTCGGTCTCGCCCTTTCTCGTGTTt
2314134..2314170 37 64 rpsR rpsR(+183) GCAGCAGCGCCATCTCGCGGGCGTTCTTGATCGCCTg
1275613..1275674 62 70 Inter geneic None GGCGGTGACCGCGGCATTGTTTTCAGTTTGTGACAACTTCTCAATATGCCGCGGTCGCCGCg
3468051..3468090 40 71 ssr ssr(+329) GATCTCCCGGTCACGCGAACTAGCCGAGATGACGATCCCa
4376405..4376472 68 77 Rv3894c (+3980) ACAACTGGGCCACTTTCGCCGAGGTCTGGGATTTCACCCAGGGGTCCATCGGCATCGTGGCCCAGTTc
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913457..913523 67 92 phoT phoT(+731) GAACCAGAAGGCCACCGAGGACTACATCTCCGGGCGCTTCGGCTAGGCCCGATGCCCTCGATGGCCa
3023949..3023988 40 113 ideR ideR(+384) GGCAACCCGATCCCGGGCCTGGTGGAACTTGGCGTGGGCc
2404494..2404549 56 123
some on Rv2144c and 
some on intergenic 
region
(-2772) GGGCCAAGACCAGCGCAATGATCAGCATCGGTCATCCTCCAACCGGCTAGCAGCGa
2844174..2844207 34 128 fas fas(+5125) CGCTCGGCGTTGAGCACTTCCACTGTGCTGTGGg




4099412..4099475 64 152 Inter geneic (-4498) GAGGCGAGGGTCGTCGTGCATCAGCCCCGGGGGGTCGGACTGATACACCCTCGGCTATGGCCGa
80258..80292 35 165 glyA glyA(-1362) GGCGGCCACGGGAAACGGACCCGCAGCAACGCGGg




4252929..4252971 43 424 Inter geneic (-22) ACGTCGTTGTGGCTTAAGGTTTCTGGCTTGTCAAGGATCAGAa
1342599..1342670 72 504 IS1081-2 0 AGGTCATTGCGTCATTTCCTTCGATTGACTTTTGCTGGTCGTTTCGAAGGATCACGCGATGACCGCCCACTa
1469528..1469574 47 555 IS1557-2 murA(-747) TCTGATCCTTGACAAGCCAGAAACCTTAAGCCACAACGACGTGCGCc
APPENDIX H 
 
Appendix I:  sRNA fragments identified in 50 ng CF RNA sample compared to literature.  Sequence reads from M. tuberculosis 
CF RNA 50 ng sample were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification reports were 
exported in text format.  Peak identification report gives chromosome region, length of the fragment, depth of coverage, and gene 
name given by NextGENe, gene.  All fragments were visualized using the Artemis genome browser to identify location on the genome 
[1].  Each fragment was compared to sRNAs reported in the literature: Arnvig et al., 2009 [2] and 2011 [3]; DiChiara et al., 2010 [4]; 
and the stable RNA list from Tuberculist [5]. 
 
Transcript Site Length Coverage Gene Distance Location ongeneome Location on gene Also Found In
1466925..1466959 35 5 atpD(+1084) atpD towards the end In Table 3 of the Arnvig et al, 2011 paper
989639..989673 35 5 citA(+188) citA towards the beginning
3023949..3023988 40 5 ideR(+384) ideR towards the middle
409681..409723 43 5 iniB(+319) iniB towards the beginning
2692351..2692385 35 5 PE_PGRS41(-414) intergenic Intergenic region between Rv2395 and PE_PGRS41
From Tuberculist Stable RNA list, found 
in DiChiara, 2010 paper. 
4100860..4100947 88 5 None intergenic Intergenic region between Rv3661 and Rv3662c
In Table 10 of the Arnvig et al, 2011 
paper.  sRNAs with Rv3661 and Rv3662c 
as flanking CDSs.  They annotate it as 
MTS2823.
2626202..2626236 35 5 esxP(+283) Intergenic and esxP
In the intergenic region between 
esxO and esxP.  Some on the end 
of esxP
4079769..4079807 39 5 None IS1553 and intergenic
At the end of IS1553 and some
on the intergenic region between 
IS1553 (and Rv3640c) and fic
IG2805 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
1683101..1683134 34 5 mutA(+944) mutA middle
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347393..347426 34 5 PE5(-2198) Rv0284 towards the middle
352230..352281 52 5 (+81) Rv0289 towards the beginning
378209..378243 35 5 PPE6(-2498) Rv0311 middle
2277851..2277888 38 5 (+598) Rv2030c towards the beginning In Table 4 of the Arnvig et al, 2011 paper
2278147..2278182 36 5 (+304) Rv2030c
towards the beginning.  Closer to 
the beginning of the gene than 
the (+598) fragment
In Table 4 of the Arnvig et al, 2011 paper
2502565..2502599 35 5 rnpB(-1814) Rv2228c towards the beginning
2951530..2951592 63 5 (-223) Rv2625c towards the end In Table 4 of the Arnvig et al, 2011 paper
3497036..3497070 35 5 (+521) Rv3131 middle In Table 4 of the Arnvig et al, 2011 paper
3606901..3606935 35 5 None Rv3229c close to the beginning
3826273..3826307 35 5 None Rv3407 close to the beginning
3495854..3495897 44 5 tgs1(+469) tgs1 towards the middle In Table 4 of the Arnvig et al, 2011 paper
4314343..4314391 49 6 bfrB(+165) bfrB towards the middle In Table 4 of the Arnvig et al, 2011 paper
2319295..2319328 34 6 cobN(+1425) cobN towards the middle
918303..918341 39 6 desA1(+409) desA1 towards the middle In Table 4 of the Arnvig et al, 2011 paper
3499671..3499705 35 6 devR(+210) devR towards the beginning
From Tuberculist Stable RNA list, found 
in the Arnvig and Young, 2009 paper.  
Also in Arnvig and Young, 2011 paper.
2483389..2483425 37 6 dlaT(+1424) dlaT towards the end
2955616..2955660 45 6 (-4309) intergenic
Intergenic region between 
Rv2628 and Rv2629.  Closer to 
the beginning of Rv2629.
IG2022 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
1987052..1987085 34 6 plcD(+611) plcD towards the end
353331..353365 35 6 mycP3(-1133) Rv0290 towards the beginning
619032..619065 34 6 (+727) Rv0528 middle
1412992..1413025 34 6 (+1098) Rv1264 close to the end
3705429..3705463 35 6 sdhA(+429) sdhA towards the beginning
2949955..2950022 68 6 TB31.7(+362) TB31.7 middle
1080848..1080906 59 7 ctpV(+2171) ctpV towards the end
420761..420804 44 7 dnaK(+926) dnaK middle
2955455..2955489 35 7 (-4148) intergenic
Intergenic region between 
Rv2628 and Rv2629.  Close to 
the end of Rv2628.
IG2022 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
1391026..1391060 35 7 kgd(+1992) kgd middle
244740..244774 35 7 mmpL3(+2544) mmpL3 towards the end
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345471..345505 35 7 PE5(-4119) Rv0283 close to the end
1824736..1824770 35 8 cydA(+1117) cydA towards the end
1220452..1220486 35 8 glyA(-52) intergenic
In the intergenic region between 
coaA and glyA.  Close to the 
beginning of glyA
In Table 10 of the Arnvig et al, 2011 
paper.  sRNAs with Rv3661 and Rv3662c 
as flanking CDSs.  They annotate it as 
MTS0858.
1797585..1797619 35 8 nadC(+197) nadC towards the beginning
3414771..3414804 34 8 nrdH(+154) nrdH Towards the end
274730..274769 40 8 None Rv0229c towards the middle
1338417..1338451 35 8 (+62) Rv1194c towards the beginning
1965776..1965820 45 8 (+119) Rv1738 middle In Table 4 of the Arnvig et al, 2011 paper
1965823..1965861 39 8 (+166) Rv1738 towards the end next to another fragment (+119) In Table 4 of the Arnvig et al, 2011 paper




Fragment covers the beginning of 
Rv2004c, the intergenic region 
between Rv2004c and Rv2005c, 
and the end of Rv2005c
2274682..2274716 35 8 None Rv2028c towards the end
2374240..2374279 40 8 lppK(-2292) Rv2114 towards the middle
2782771..2782805 35 8 (+1237) Rv2477c towards the end
3046019..3046053 35 8 (-4558) Rv2733c towards the beginning
1340943..1340977 35 9 esxK(+284) esxK and intergenic
At the end of esxK with 22bp 
into the intergenic region 
between esxK and esxL
1169366..1169429 64 9 (-3931) IS1081-1
At the beginning of Rv1047 and 
towards the beginning of the 
insertion sequence IS1081 moble 
element
3751654..3751688 35 9 PPE55(+1496) PPE55 towards the beginning
2314134..2314169 36 9 rpsR(+184) rpsR towards the end
3326014..3326063 50 9 (+80) Rv2970A towards the middle
1581101..1581136 36 10 (-679) intergenic Intergenic region between Rv1404 and Rv1405c
IG1101 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
851642..851676 35 10 phoP(+34) phoP towards the beginning
4056124..4056158 35 10 ephA(-1575) Rv3616c towards the beginning In Table 4 of the Arnvig et al, 2011 paper
 161
 
Transcript Site Length Coverage Gene Distance Location ongeneome Location on gene Also Found In
2219456..2219490 35 11 None intergenic Intergenic region between Rv1976c and Rv1977
IG1535 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
15823..15857 35 11 pknB(+1613) pknB towards the end
88190..88244 55 11 hycD(-4084) Rv0079
At the beginning of the gene, 
overlapping onto the intergenic 
region between Rv0078A and 
Rv0079
In Table 4 of the Arnvig et al, 2011 paper
1166640..1166674 35 11 (-1205) Rv1043c towards the beginning
3826433..3826467 35 11 None Rv3407 towards the end
2517341..2517396 56 12 fabD(+554) fabD towards the middle
1962197..1962230 34 12 narX(+1956) intergenic and narX
Intergenic region between 
Rv1735c and narX.  2bp on the 
end of narX
In Table 4 of the Arnvig et al, 2011 paper
1964687..1964721 35 12 narK2(+649) narK2 middle
806142..806176 35 12 rpsQ(+386) rpsQ
at the end of the gene with 10 bp 
hanging over into the intergenic 
region between rpsQ and atsA
474296..474330 35 12 ndhA(-1657) Rv0394c towards the end
3496799..3496837 39 12 (+284) Rv3131 towards the beginning In Table 4 of the Arnvig et al, 2011 paper
3497203..3497248 46 12 (+688) Rv3131 towards the end In Table 4 of the Arnvig et al, 2011 paper
3666695..3666729 35 13 accA3(+338) accA3 towards the beginning
68848..68882 35 14 None Rv0064 towards the beginning
3468156..3468242 87 14 ssr(+177) ssr towards the middle.  Next to another fragment (+329) From Tuberculist Stable RNA list.
2949865..2949899 35 14 TB31.7(+272) TB31.7 towards the middle
3415123..3415167 45 16 nrdH(-165) intergenic Intergenic region between nrdHand Rv3054c
IG2356 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
4168234..4168282 49 16 (-106) intergenic Intergenic region between Rv3722c and tRNA-Ser(GGA)
From Tuberculist Stable RNA list, (See
Arnvig and Young, 2009; DiChiara et al., 
2010
2238981..2239015 35 17 ctpF(-1144) Intergenic and Rv1996
intergenic region between 
Rv1995 and Rv1996 with some 
at the beginning of Rv1996
IG1550 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
164390..164424 35 18 cyp138(+1024) cyp138 towards the end
4262658..4262692 35 21 fadD32(+374) fadD32 towards the beginning
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1187430..1187464 35 21 0 Rv1065
At the beginning of Rv1065 with 
5bp overlapping onto the 
intergenic region between lpqV 
and Rv1065
3468051..3468090 40 21 ssr(+329) ssr middle From Tuberculist Stable RNA list.
2767686..2767719 34 22 (-21) Rv2465c close to the end
80258..80292 35 24 glyA(-1362) repeat region
close to the beginning of a repeat
region "MTV030.15, len:315bp. 
Probable REP'-1 pseudogene 
fragment, similar to many 
Mycobacterium proteins inside 
REP13E12 elements 
(Rv0071/Rv0072)
1275613..1275673 61 27 None intergenic
In the intergenic region between 
Rv1147 and Rv1148c.  Close to 
the end of Rv1147.
IG903 from Table S3 reads mapped to 
intergenic regions Arnvig 2011
2040858..2040894 37 34 PPE28(+1405) PPE28 towards the middle
1960675..1960774 113 37 (-878) intergenic
Intergenic region between 
Rv1733c and Rv1734c.  Very 
close to the end of Rv1734c, with 
one bp on the end of Rv1734c
In Table 10 of the Arnvig et al, 2011 
paper.  sRNAs with Rv3661 and Rv3662c 
as flanking CDSs.  They annotate it as 
MTS1338.
1993213..1993246 34 41 (+60) Rv1760 towards the beginning
3649468..3649502 35 48 ctpC(-1024) Rv3268 towards the beginning
754758..754793 36 54 atsD(-1344) Rv0659c towards the end
4099438..4099475 38 58 (-4524) intergenic Intergenic region between Rv3660 and Rv3661
From Tuberculist Stable RNA list, (See
Arnvig and Young, 2009; DiChiara et al., 
2010. 
2404472..2404549 78 63 (-2750) Rv2144c and intergenic
At the beginning of Rv2144c and 
into the intergenic region 
between Rv2144c and wag31
4352941..4352979 39 91 (-31) intergenic Intergenic region between esxA and Rv3876
IG3002 from Table S3 reads mapped to 
intergenic regions Arnvig 2011





Transcript Site Length Coverage Gene Distance Location ongeneome Location on gene Also Found In
1342600..1342663 64 338 0 IS1081-2
5 bp at the beginning of 
Rv1199c, with the rest towards 
the beginning of IS1081-2 
insertion sequence 
1469500..1469574 75 357 murA(-747) IS1557-2
5 bp at the beginning of Rv1313c
and the rest close to the 
beginning of Insertion sequence 
IS1557
4252929..4252971 43 431 (-22) intergenic Intergenic region between Rv3797 (fadE35) and Rv3798
IG2937 from Table S3 reads mapped to 
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Appendix I:  sRNA fragments identified in 100 ng CF RNA sample compared to literature.  Sequence reads from M. tuberculosis 
CF RNA 100 ng sample were mapped to the M. tuberculosis H37Rv GenBank reference file, and peak identification reports were 
exported in text format.  Peak identification report gives chromosome region, length of the fragment, depth of coverage, and gene 
name given by NextGENe, gene.  All fragments were visualized using the Artemis genome browser to identify location on the genome 
[1].  Each fragment was compared to sRNAs reported in the literature: Arnvig et al., 2009 [2] and 2011 [3]; DiChiara et al., 2010 [4]; 
and the stable RNA list from Tuberculist [5]. 
 
 
Chromosome Region Length Coverage Gene Distance Location ongeneome Location on gene Also Found In
119170..119204 35 5 (+1456) Rv0102 towards the end In TableS2 of Arnvig 2011.
194242..194276 35 5 (+662) Rv0165c towards the end In TableS2 of Arnvig 2011.
251787..251840 54 5 pckA(+5) pckA Very close to the beginning of thegene
In TableS2 of Arnvig 2011.  
Rv0211
269454..269488 35 5 (-1690) Rv0225 towards the end In TableS2 of Arnvig 2011.
274730..274764 35 5 None Rv4006 Towards the end
303550..303583 34 5 nirB(+684) nirB Close to the middle In TableS2 of Arnvig 2011.  Rv0252
337304..337337 34 5 PE_PGRS4(+1736) PE_PGRS4 close to the middle In TableS2 of Arnvig 2011.  Rv0279c
348462..348496 35 5 PE5(-1128) Rv0284 towards the middle In TableS2 of Arnvig 2011.
474296..474330 35 5 ndhA(-1657) ndhA towards the end In TableS2 of Arnvig 2011.  Rv0392c
601708..601741 34 5 hemA(+1267) hemA towards the end In TableS2 of Arnvig 2011.  Rv0509
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776008..776071 64 5 mmpL5(+2409) mmpL5 close to the end In TableS2 of Arnvig 2011.  Rv0676c
782891..782925 35 5 fusA1(+406) fusA1 Towards the beginning In TableS2 of Arnvig 2011.  Rv0684
873531..873565 35 5 hemH(+188) hemH Towards the beginning
884318..884352 35 5 (-268) Rv0790c towards the middle In TableS2 of Arnvig 2011.
1099314..1099348 35 5 pepD(+248) pepD Towards the beginning In TableS2 of Arnvig 2011.  Rv0983
1314313..1314361 49 5 pks3(+588) pks3 close to the middle In TableS2 of Arnvig 2011.  Rv1180
1511851..1511885 35 5 fadE14(+1005) radE14 towards the end
1516874..1516919 46 5 fabG(-572) Rv1349 towards the middle In TableS2 of Arnvig 2011.
1564447..1564480 34 5 gmk(+46) gmk Towards the beginning In Table 6 of the Arnvig et al, 2011 paper
1577190..1577223 34 5 (+260) Rv1401 middle In TableS2 of Arnvig 2011.
1736341..1736375 35 5 ileS(-144) Intergenic Intergenic region between Rv1535 and ileS
Table 8 of Arnvig 2011 paper 
(abundant 5' UTRs in intergenic 
regions) (?)
1797489..1797527 39 5 nadC(+101) nadC Towards the beginning In TableS2 of Arnvig 2011.  Rv1596
1866320..1866354 35 5 argC(+744) argC towards the end In TableS2 of Arnvig 2011.  Rv1652
1901178..1901212 35 5 dsbF(-536) Rv1676 Towards the beginning In TableS2 of Arnvig 2011.
2032991..2033025 35 5 mycP5(-704) Rv1795 middle In TableS2 of Arnvig 2011.
2055657..2055690 34 5 (-298) Rv1813c
at the end of the gene, and a little
over the region between Rv1813c 
and Rv1812c
In TableS2 of Arnvig 2011.
2056276..2056310 35 5 erg3(-211) Intergenic Intergenic region between Rv1813c and erg3
IG1406 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2239323..2239356 34 5 ctpF(-803) Rv1996 towards the middle Rv1996 isbefore ctpF
In Table 4 of the Arnvig et al, 
2011 paper
2289878..2289911 34 5 lipT(+1309) lipT towards the end In TableS2 of Arnvig 2011.  Rv2045c
2404447..2404484 38 5 (-2725) Rv2144c close to the beginning.  Very closeto another fragment (-2772) 
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2477897..2477931 35 5 (+707) Rv2212 towards the middle
2500383..2500425 43 5 (-4984) Intergenic very close to the end of Rv2226 and the end of rnpB (misc_RNA)
IG1727 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2500503..2500537 35 5 rnpB(+214) rnpB towards the end Ribonuclease P RNA. From Tuberculist Stable RNA list 
2502565..2502599 35 5 rnpB(-1814) Rv2228c Towards the beginning
2519178..2519212 35 5 kasA(+1063) kasA towards the end In TableS2 of Arnvig 2011.  Rv2245
2672020..2672054 35 5 mbtB(+3783) mbtB towards the end In TableS2 of Arnvig 2011.  Rv2383c
2783947..2783981 35 5 (+61) Rv2477c very close to the beginning of the gene
2819339..2819373 35 5 scoA(+497) scoA towards the middle In TableS2 of Arnvig 2011. Rv2504c
2827612..2827645 34 5 orn(+455) orn towards the end In TableS2 of Arnvig 2011.  Rv2511
2952672..2952716 45 5 (-1365) Rv2626c towards the middle In Table 4 of the Arnvig et al, 2011 paper
2953710..2953754 45 5 (-2403) Rv2627c towards the end In Table 4 of the Arnvig et al, 2011 paper
2978147..2978180 34 5 None Rv2655c towards the middle
3020895..3020929 35 5 sigB(-1532) Rv2707 towards the middle.
3022467..3022500 34 5 sigB(+6) sigB beginning In TableS2 of Arnvig 2011. Rv2710
3651551..3651585 35 5 ctpC(+1025) ctpC middle. "Cation transport ATPase" In TableS2 of Arnvig 2011.  Rv3270
3900311..3900345 35 5 cpsA(-2733) Rv3480c close to the beginning 
3953877..3953911 35 5 (+446) Rv3517 towards the middle
4198611..4198644 34 5 tyrA(-1711) Intergenic Between Rv3750c and Rv3751
IG1379 from Table S3 reads 




Chromosome Region Length Coverage Gene Distance Location on geneome Location on gene Also Found In
4221473..4221507 35 5 (+384) Rv3776
towards the beginning.  At the 
beginning of "domain of unknown 
function DUF 22"  fragments 
flanking both ends of this domain
4231808..4231842 35 5 None Rv3785 middle
4262779..4262812 34 5 fadD32(+254) fadD32 Towards the beginning In TableS2 of Arnvig 2011.  Rv3801c
4302868..4302901 34 5 (-79) Rv3828c towards the end
4334567..4334600 34 5 gltB(+1481) gltB towards the middle In TableS2 of Arnvig 2011.  Rv3859c
4369747..4369780 34 5 mycP2(+390) mycP2 Towards the beginning In TableS2 of Arnvig 2011.  Rv3886c
4398690..4398723 34 5 sigM(-1463) Rv3910 middle
88211..88244 34 6 hycD(-4084) Rv0079 Towards the beginning In Table 4 of the Arnvig et al, 2011 paper
215774..215807 34 6 bglS(-462) Rv0185 Towards the beginning In TableS2 of Arnvig 2011.
326352..326385 34 6 fadE6(+2076) fadE6 towards the end In TableS2 of Arnvig 2011.  Rv0271c
346439..346476 38 6 PE5(-3148) Rv0284 Towards the beginning In TableS2 of Arnvig 2011.
352444..352477 34 6 (+295) Rv0289 close to the middle In TableS2 of Arnvig 2011.
420777..420810 34 6 dnaK(+942) dnaK middle In TableS2 of Arnvig 2011.  Rv0350
595932..595966 35 6 serB1(+619) serB1 towards the middle In TableS2 of Arnvig 2011. Rv0505c
631410..631443 34 6 (-1679) Rv0538 towards the end In TableS2 of Arnvig 2011.
707305..707339 35 6 galTa(-4197) Rv0613c towards the end In TableS2 of Arnvig 2011.
1004881..1004915 35 6 prrB(+926) prrB towards the middle In TableS2 of Arnvig 2011.  Rv0902c
1313412..1313455 44 6 pks3(-270) Intergenic between Rv1179 and pks3
IG930 from Table S3 reads 




Chromosome Region Length Coverage Gene Distance Location on geneome Location on gene Also Found In
1669140..1669174 35 6 moxR1(-109) Rv1478 and intergenic
at the end of the the gene into the 
intergenic region between Rv1478 
and moxR1
IG1154 Starting on1669143, the
beginning of this fragment is not
intergenic (some other type of 
regulatory element?) from Table 
S3 reads mapped to intergenic 
regions Arnvig 2011
1963271..1963312 42 6 narX(+874) narX middle In Table 4 of the Arnvig et al, 2011 paper
2150873..2150907 35 6 nanT(-599) Intergenic Intergenic region between Rv1903 and Rv1904.  Closer to Rv1904
Also IG1484 from Table S3 
reads mapped to intergenic 
regions Arnvig 2011
2162128..2162161 34 6 aceAb(+562) aceAb in the middle In TableS2 of Arnvig 2011.  Rv1916
2239872..2239913 42 6 ctpF(-246) ctpG middle In TableS2 of Arnvig 2011.  Rv1992c
2252256..2252290 35 6 otsB1(+254) otsB1 Towards the beginning In TableS2 of Arnvig 2011.  Rv2006
2276245..2276278 34 6 pfkB(+146) pfkB Towards the beginning In TableS2 of Arnvig 2011.  Rv2029c
2445035..2445069 35 6 (-2718) Rv2182c towards the middle
2483389..2483423 35 6 dlaT(+1424) dlaT towards the end
2593248..2593281 34 6 rocE(+872) rocE towards the middle In TableS2 of Arnvig 2011.  Rv2320c
2842511..2842545 35 6 fas(+6787) fas towards the end In TableS2 of Arnvig 2011.  Rv2524c
2952398..2952466 69 6 (-1091) Rv2625c close to the beginning In Table 4 of the Arnvig et al, 2011 paper
3084849..3084898 50 6 ald(-1922) Rv2777c close to the middle
3404859..3404893 35 6 ctaD(+28) ctaD very close to the beginning of thegene
In TableS2 of Arnvig 2011.  
Rv3043c
3492964..3492998 35 6 (-842) Rv3127 towards the end of the gene.  Very close to another fragment (-899)
In Table 4 of the Arnvig et al, 
2011 paper
3493021..3493086 66 6 (-899) Rv3127 towards the end In Table 4 of the Arnvig et al, 2011 paper
3497349..3497382 34 6 (+834) Rv3131 towards the end In Table 4 of the Arnvig et al, 2011 paper
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3516906..3516939 34 6 nuoG(+160) nuoG Towards the beginning In TableS2 of Arnvig 2011.  Rv3151
3623406..3623440 35 6 lpqB(+1470) lpqB Towards the end of the gene. In TableS2 of Arnvig 2011.  Rv3244c
3666695..3666729 35 6 accA3(+338) accA3 Towards the beginning In TableS2 of Arnvig 2011.  Rv3285
3894312..3894345 34 6 PE31(+219) PE31 towards the end
Table 8 of Arnvig 2011 paper 
(abundant 5' UTRs in intergenic 
regions)
4056007..4056044 38 6 ephA(-1689) Rv3616c towards the end In Table 4 of the Arnvig et al, 2011 paper
4222194..4222228 35 6 (+1105) Rv3776
towards the end.  At the end of 
"domain of unknown function 
DUF 222"
4258521..4258555 35 6 pks13(+2591) pks13 middle In TableS2 of Arnvig 2011.  Rv3800c
7449..7483 35 7 gyrA(+147) gyrA Towards the beginning In TableS2 of Arnvig 2011.  Rv0006
25117..25151 35 7 TB39.8(+293) TB39.8 Towards the beginning In TableS2 of Arnvig 2011. Rv0020c
340528..340608 81 7 PPE3(+1164) PPE3 towards the end
349084..349118 35 7 PE5(-506) Rv0284 towards the end In TableS2 of Arnvig 2011.
662451..662484 34 7 nrdZ(+1156) nrdZ middle In TableS2 of Arnvig 2011.  Rv0570
867824..867858 35 7 (+493) Rv0774c middle In TableS2 of Arnvig 2011.
917498..917537 40 7 (-1187) Rv0823c Towards the beginning In TableS2 of Arnvig 2011.
1113102..1113140 39 7 (+718) Rv0996 towards the middle In TableS2 of Arnvig 2011.
1222477..1222511 35 7 desA2(+518) desA2 towards the middle In TableS2 of Arnvig 2011.  Rv1094
1227126..1227160 35 7 fumC(+405) fumC Towards the beginning In TableS2 of Arnvig 2011.  Rv1098c
2017524..2017558 35 7 malQ(-48) Intergenic Intergenic region between malQ and Rv1782
IG1379 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2073625..2073658 34 7 (+544) Rv1828 towards the end In TableS2 of Arnvig 2011.
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2278025..2278059 35 7 (+427) Rv2030c Towards the beginning In Table 4 of the Arnvig et al, 2011 paper
3468268..3468321 54 7 ssr(+98) ssr Towards the beginning.  Ssr isclassified as a misc RNA
From Tuberculist Stable RNA
list.
3806205..3806239 35 7 acrA1(+584) acrA1 towards the middle In Table 4 of the Arnvig et al, 2011 paper
4024199..4024262 64 7 ispF(+85) ispF Towards the beginning In TableS2 of Arnvig 2011.  Rv3581c
4346889..4346923 35 7 PE35(-3822) Rv3870 Towards the beginning
88506..88540 35 8 hycD(-3788) hycD towards the middle In TableS2 of Arnvig 2011.  Rv0084
352199..352242 44 8 (+50) Rv0289 close to the beginning of Rv0289 In TableS2 of Arnvig 2011.
353501..353542 42 8 mycP3(-956) Rv0290 towards the middle In TableS2 of Arnvig 2011.
851642..851676 35 8 phoP(+34) phoP Towards the beginning In TableS2 of Arnvig 2011.  Rv0757
1132353..1132392 40 8 pks16(+728) pks16 middle In TableS2 of Arnvig 2011.  Rv1013
1150652..1150686 35 8 kdpD(+1000) kdpD towards the middle In TableS2 of Arnvig 2011.  Rv1028c
1235415..1235449 35 8 xseA(+11) xseA at the beginning In TableS2 of Arnvig 2011. Rv1108c
1796054..1796088 35 8 nadB(+249) nadB Towards the beginning In TableS2 of Arnvig 2011.  Rv1595
1796908..1796941 34 8 nadB(+1103) nadB towards the end In TableS2 of Arnvig 2011.  Rv1595
1845595..1845628 34 8 uvrA(+1854) uvrA towards the middle In TableS2 of Arnvig 2011. Rv1638
2278606..2278652 47 8 hspX(+280) hspX towards the end In TableS2 of Arnvig 2011.  Rv2031c
2484655..2484688 34 8 lipB(+71) lipB Towards the beginning In TableS2 of Arnvig 2011.  Rv2217
2955616..2955649 34 8 (-4309) Intergenic Intergenic between Rv2628 and Rv2629
IG2022 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2979238..2979272 35 8 clpC2(-4624) Rv2657c Towards the beginning
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3496869..3496903 35 8 (+354) Rv3131 towards the middle In Table 4 of the Arnvig et al, 2011 paper
3498580..3498619 40 8 devS(+646) devS towards the middle In TableS2 of Arnvig 2011.  Rv3132c
3499671..3499705 35 8 devR(+210) devR towards the middle In TableS2 of Arnvig 2011.  Rv3133c
3606667..3606701 35 8 None Rv3229c towards the middle
4029729..4029763 35 8 mutY(-730) Rv3587c / intergenic
At the beginning of Rv3587c, over 
lapping a little into the intergenic 
region between Rv3587c and 
Rv3588c
3bp in IG2768 from Table S3 
reads mapped to intergenic 
regions Arnvig 2011
4220050..4220083 34 8 lipE(+365) lipE towards the middle In TableS2 of Arnvig 2011.  Rv3775
4359090..4359155 66 8 None Rv3879c Towards the beginning
340750..340826 77 9 PPE3(+1386) PPE3 closer to the end of PPE3 than PPE3(+1164)
353322..353365 44 9 mycP3(-1133) Rv0290 Towards the beginning In TableS2 of Arnvig 2011.
356191..356225 35 9 (+311) Rv0292 Towards the beginning In TableS2 of Arnvig 2011.
1197094..1197127 34 9 (+815) Rv1072 at the end In Table 3 of the Arnvig et al, 2011 paper
1340943..1340977 35 9 esxK(+284) esxK
at the end of Rv1247c into the
intergenic region between esxK 
and esxL
In TableS2 of Arnvig 2011.  
Rv1197
1965772..1965820 49 9 (+115) Rv1738 middle In Table 4 of the Arnvig et al, 2011 paper
2103054..2103088 35 9 ndh(-12) Intergenic
Intergenic region between ndh and 
Rv1855c.  Very close to the 
beginning of ndh
IG1440 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2256537..2256600 64 9 fdxA(-109) Intergenic
very close to the end of the gene
Rv2008c. between fdxA and 
Rv2008c
IG1562 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2655876..2655940 65 9 cfp2(+175) cfp2 towards the middle
In Table 5 of Arnvig et al 2011.  
Antisense transcripts deried 
from 3' UTRs (?)
3246358..3246392 35 9 ppsA(+913) ppsA Towards the beginning In TableS2 of Arnvig 2011.  Rv2931
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3548920..3548954 35 9 mesT(-3620) Intergenic 13 bp after the end of Rv3179
IG2451 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
3589569..3589602 34 9 (+175) Rv3212 Towards the beginning
1413108..1413142 35 10 None Intergenic
Intergenic region between Rv1264 
and Rv1265.  Very close to the end 
of Rv1264
mcr11, putative small regulatory 
RNA (ncRNA). From 
Tuberculist Stable RNA list, 
found in the DiChiara et al., 
2010 paper.  Same as MTs0997 
from Table 10 of Arnvig 2011 
paper
2122411..2122445 35 10 lldD2(+706) lldD2 middle In Table 4 of the Arnvig et al, 2011 paper
2150918..2150951 34 10 None Intergenic before the beginning of the gene Rv1904
IG1484 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2463741..2463775 35 10 ctaC(+976) ctaC close to the end In TableS2 of Arnvig 2011.  Rv2200c
2847337..2847371 35 10 fas(+1961) fas Towards the beginning In TableS2 of Arnvig 2011.  Rv2524c
2954155..2954188 34 10 (-2848) Rv2627c middle In Table 4 of the Arnvig et al, 2011 paper
3758308..3758342 35 10 PPE56(+8760) PPE56 Towards the end of the gene. In TableS2 of Arnvig 2011.  Rv3350c
32182..32215 34 11 bioF2(-2080) Rv0029 Towards the beginning In TableS2 of Arnvig 2011.  Rv0029
378204..378242 39 11 PPE6(-2493) Rv0309 towards the middle In TableS2 of Arnvig 2011.
918303..918380 78 11 desA1(+370) desA1 towards the middle
From Tuberculist Stable RNA
list, found in the Arnvig and 
Young, 2009 paper.  Also in 
Arnvig and Young, 2011 paper.
1199075..1199109 35 11 fadA3(+264) fadA3 Towards the beginning In TableS2 of Arnvig 2011.  Rv1074c
1220452..1220486 35 11 glyA(-52) Intergenic Intergenic close to the beginning of glyA.  Between coaA and glyA.
Table 10 of Arnvig 2011 paper, 
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1466925..1466959 35 11 atpD(+1084) atpD towards the end In Table 3 of the Arnvig et al, 2011 paper
1485598..1485663 66 11 fadA4(-199) Rv1322A towards the middle In TableS2 of Arnvig 2011.
1998195..1998228 34 11 PE_PGRS31(-2386) Rv1765c towards the middle In TableS2 of Arnvig 2011.
2517353..2517387 35 11 fabD(+566) fabD towards the middle In TableS2 of Arnvig 2011.  Rv2243
2845154..2845188 35 11 fas(+4144) fas middle In TableS2 of Arnvig 2011.  Rv2524c
3093770..3093825 56 11 rpsO(-22) Intergenic between rpsO and ribF
IG2148 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
4056753..4056787 35 11 ephA(-946) Intergenic
between Rv3616c and ephA. 
Closer to the beginning of 
Rv3616c.
IG2787 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
1169366..1169426 61 12 (-3931) IS1081-1 close to the beginning of insertion sequence of IS1081
1197139..1197190 52 12 None Intergenic between Rv1072 and Rv1073
IG841 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
1389211..1389245 35 12 (-583) Rv1247c
At the beginning of the gene, with 
one bp in the intergenic region 
between Rv1247 and kgd
In TableS2 of Arnvig 2011.
2236394..2236438 45 12 ctpG(+868) ctpG middle In TableS2 of Arnvig 2011.  Rv1992c
2626202..2626236 35 12 esxP(+283) Rv2345 towards the middle
3606901..3606935 35 12 None Rv3229c Towards the beginning
1376990..1377028 39 13 lpqY(-496) Rv1234 Towards the beginning.  Rv1234 isbefore lpqY In TableS2 of Arnvig 2011.
1419706..1419740 35 13 lprA(+8) lprA very close to the beginning of thegene
In TableS2 of Arnvig 2011.  
Rv1270c
2102731..2102764 34 13 ndh(+278) ndh Towards the beginning In TableS2 of Arnvig 2011.  Rv1854c
2646753..2646787 35 13 (+301) Rv2365c very close to the end of the gene
2756411..2756445 35 13 (-1665) Rv2455c Towards the beginning
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2959794..2959828 35 13 None Rv2633c and intergenic
At the beginning of Rv2633c and 
overlapping onto the intergenic 
region between Rv2633c and 
PE_PGRS46
10bp in IG2029 from Table S3 
reads mapped to intergenic 
regions Arnvig 2011
4119573..4119607 35 13 nth(-3679) Rv3679
towards the end.  Within a
predicted ATPase involved in 
chromosome partitioning
4168191..4168282 92 13 (-63) Intergenic
Between Rv3722c and Rvnt41.  
Rvnt41 is between Rv3722c and 
Rv3723.
From Tuberculist Stable RNA
list, (See Arnvig and Young, 
2009; DiChiara et al., 2010
355733..355798 66 14 mycP3(+1235) mycP3 close to the end In TableS2 of Arnvig 2011.  Rv0291
498846..498880 35 14 (+739) Rv0412c towards the middle In TableS2 of Arnvig 2011.
1666920..1666954 35 14 acn(-874) Intergenic Intergenic region between Rv1476 and Rv1477.  Closer to Rv1477
IG1152 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2728347..2728381 35 14 PE25(-81) Intergenic between PE25 and Rc2432c
IG1875 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2782771..2782805 35 14 (+1237) Rv2477c Towards the end
2951533..2951573 41 14 (-226) Rv2625c towards the end In Table 4 of the Arnvig et al, 2011 paper
3496579..3496627 49 14 (+64) Rv3131 towards the beginning, very closeto another segment (+2)
In Table 4 of the Arnvig et al, 
2011 paper
1080094..1080138 45 15 ctpV(+1417) ctpV towards the middle In TableS2 of Arnvig 2011.  Rv0969
1166640..1166674 35 15 (-1205) Rv1043c Towards the beginning In TableS2 of Arnvig 2011.
2391717..2391761 45 15 cysS(+698) cysS towards the middle In TableS2 of Arnvig 2011.  Rv2130c
2624292..2624327 36 15 (+471) Rv2345
Towards the beginning. At the end 
of a "domain of unknown function 
(DUF477)"
3153388..3153421 34 15 efpA(+1210) efpA towards the end In TableS2 of Arnvig 2011.  Rv2846c
1993213..1993246 34 16 (+60) Rv1760 Towards the beginning In TableS2 of Arnvig 2011.
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2775535..2775568 34 16 (+263) Rv2472 at the end In Table 3 of the Arnvig et al, 2011 paper
2949865..2949938 74 16 TB31.7(+272) TB31.7 towards the middle In TableS2 of Arnvig 2011. Rv2623
3496375..3496409 35 16 tgs1(-9) Intergenic
Very close to the beginning of 
tgs1.  In the intergenic region 
between tgs1 and Rv3131
IG2419 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
4314343..4314387 45 16 bfrB(+165) bfrB towards the middle In Table 4 of the Arnvig et al, 2011 paper
1964660..1964721 62 17 narK2(+649) narK2 towards the middle In TableS2 of Arnvig 2011.  Rv1737c
2177096..2177147 52 17 fadD31(+9) fadD31 Very close to the beginning of thegene
In TableS2 of Arnvig 2011.  
Rv1925
2280314..2280348 35 17 (+734) Rv2033c towards the end
2638357..2638391 35 17 PPE40(+1144) PPE40 towards the middle In TableS2 of Arnvig 2011.  Rv2356c
2885351..2885385 35 17 (+740) Rv2565 towards the middle
3540695..3540729 35 17 hpx(+16) hpx Very close to the beginning of thegene
In TableS2 of Arnvig 2011.  
Rv3171c
571794..571838 45 18 lprQ(+84) lprQ Towards the beginning In TableS2 of Arnvig 2011.  Rv0483
1114988..1115021 34 18 arcA(-2164) Rv0998 towards the middle In TableS2 of Arnvig 2011.
2274682..2274716 35 18 None Rv2028c towards the end In TableS2 of Arnvig 2011.
65446..65480 35 19 celA1(-72) Intergenic between Rv0061 and celA1, closer to the end of Rv0061
IG50 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
3153949..3153983 35 19 efpA(+648) efpA towards the middle In TableS2 of Arnvig 2011.  Rv2846c
3497199..3497253 55 19 (+684) Rv3131 towards the middle In Table 4 of the Arnvig et al, 2011 paper
3468146..3468234 89 20 ssr(+185) ssr towards the middle of ssr From Tuberculist Stable RNAlist.
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4100706..4100778 73 20 None Intergenic
behind another Intergenic 
fragment: 4100814.  between 
Rv3661 and Rv3662c.
In Table 10 of the Arnvig et al, 
2011 paper.  sRNAs with 
Rv3661 and Rv3662c as 
flanking CDSs.  They annotate 
it as MTS2823.
2279214..2279247 34 21 acg(+85) acg Towards the beginning In Table 4 of the Arnvig et al, 2011 paper
3496804..3496849 46 23 (+289) Rv3131 close to the middle, several other fragments on this gene
In Table 4 of the Arnvig et al, 
2011 paper
4404606..4404640 35 23 None Rv3916c towards the end
409680..409728 49 24 iniB(+318) iniB close to the beginning In TableS2 of Arnvig 2011.  Rv0341
1773938..1774017 80 24 (-109) Rv1566c Very close to the beginning of thegene In TableS2 of Arnvig 2011.
1965823..1965861 39 24 (+166) Rv1738 towards the end.  Next to another fragment (+115)
In Table 4 of the Arnvig et al, 
2011 paper
3496517..3496571 55 24 (+2) Rv3131 2bp into the beginning In Table 4 of the Arnvig et al, 2011 paper
2767686..2767728 43 26 (-21) Rv2465c close to the beginning 
50642..50676 35 27 ino1(+448) inol towards the middle In Table 6 of the Arnvig et al, 2011 paper
3649468..3649502 35 27 ctpC(-1024) Rv3268 Towards the beginning
916241..916275 35 28 (+36) Rv0822c beginning In TableS2 of Arnvig 2011.
754760..754793 34 30 atsD(-1344) Rv0659c towards the middle In TableS2 of Arnvig 2011.
3326014..3326063 50 31 (+80) Rv2970A middle/close to the end of the gene
4100814..4100913 167 32 None Intergenic Between Rv3661 and Rv3662c
In Table 10 of the Arnvig et al, 
2011 paper.  sRNAs with 
Rv3661 and Rv3662c as 
flanking CDSs.  They annotate 
it as MTS2823.






at the beginning of Rv3640c and I 
little on the intergenic region 
between Rv3640c and fic
IG2805 from Table S3 reads 
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3826433..3826467 35 37 None Rv3407
towards the end of the gene.  Also 
towards the end of "Phd YefM; 
Region: PhdYeFM; c109153"
In Table 3 of the Arnvig et al, 
2011 paper
1816201..1816234 34 46 pykA(+12) pykA close to the beginning In TableS2 of Arnvig 2011.  Rv1617
1824726..1824770 45 55 cydA(+1117) cydA towards the end In Table 4 of the Arnvig et al, 2011 paper
4352944..4352979 36 62 (-31) Intergenic between esxA and Rv3876
IG3002 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
2314134..2314170 37 64 rpsR(+183) rpsR towards the end In TableS2 of Arnvig 2011.  Rv0055
1275613..1275674 62 70 None Intergenic close to the end of Rv1147.  Between Rv1147 and Rv1148c
In Table 10 of the Arnvig et al, 
2011 paper.  sRNAs with 
Rv1147 and Rv1148c as 
flanking CDSs.  They annotate 
it as MTS0903.
3468051..3468090 40 71 ssr(+329) ssr towards the middle From Tuberculist Stable RNAlist.
4376405..4376472 68 77 (+3980) Rv3894c close to the end
913457..913523 67 92 phoT(+731) phoT at the end of the gene, a little over between phoT and phoY2
In TableS2 of Arnvig 2011.  
Rv0820
3023949..3023988 40 113 ideR(+384) ideR towards the middle In TableS2 of Arnvig 2011.  Rv2711






at the beginning of Rv2144c and 
overlapping onto intergenic region 
between Rv2144c and wag31
2844174..2844207 34 128 fas(+5125) fas towards the middle In TableS2 of Arnvig 2011.  Rv2524c. 
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1960700..1960781 82 129 (-909) Intergenic and on Rv1734c
Between Rv1733c and Rv1734c.  
Some of it overlaps with the end 
of Rv1734c
Probably MTS1338 from Table
10 of Arnvig 2011 paper, 
although the paper lists it as 
having 1733c and Rv1735c as 
flanking sequences, which 
excludes Rv1734c.
4099412..4099475 64 152 (-4498) Intergenic between Rv3660c and Rv3661
From Tuberculist Stable RNA
list, (See Arnvig and Young, 
2009; DiChiara et al., 2010.  
Also in Arnvig 2011 Table 10 as 
MTS2822
80258..80292 35 165 glyA(-1362) glyA Towards the beginning In TableS2 of Arnvig 2011.  Rv0070c
1473259..1473332 74 409 rrs(+1413) rrs very close to the end of the gene
4252929..4252971 43 424 . Intergenic between fadE35 and Rv3798.  Closer to the beginning of Rv3798
IG2937 from Table S3 reads
mapped to intergenic regions 
Arnvig 2011
1342599..1342670 72 504 0 IS1081-2
Towards the beginning, IS1081-2 
overlaps Rv119c except for the 
beginning
1469528..1469574 47 555 murA(-747) IS1557-2 close to the beginning of IS1557-2
IG1037 from Table S3 reads






1. Rutherford, K., et al., Artemis: sequence visualization and annotation. Bioinformatics, 
2000. 16(10): p. 944-945. 
2. Arnvig, K.B. and D.B. Young, Identification of small RNAs in Mycobacterium 
tuberculosis. Molecular microbiology, 2009. 73(3): p. 397-408. 
3. Arnvig, K.B., et al., Sequence-based analysis uncovers an abundance of non-coding RNA 
in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog, 2011. 7(11): p. 
e1002342. 
4. DiChiara, J.M., et al., Multiple small RNAs identified in Mycobacterium bovis BCG are 
also expressed in Mycobacterium tuberculosis and Mycobacterium smegmatis. Nucleic 
Acids Research, 2010. 38(12): p. 4067-4078. 






Appendix J:  Secondary structure predictions of regions of rRNA genes not represented by 
an aligned read. RNAfold web server was used to predict the secondary structure of the regions 
of rRNA genes not represented by an aligned read.  Table shows the chromosome region 
evaluated, along with the minimum free energy (MFE), free energy of the thermodynamic 
















1471846:1471910 -16.3 -17.52 10.81
1472010:1472052 -14 -14.35 1.96
1472122:1472172 -15.3 -15.68 3.95
1472241:1472387 -58.4 -60 27.15
1472433:1472603 -64.7 -61.17 11.84
1472704:1472988 -107.9 -112.06 33.52
1473024:1473036 0 -0.24 1.29
1473135:1473382 -93.4 -95.99 45.48
1473658:1473753 -26.8 -27.22 26.21
1473813:1473886 -18.9 -17.59 10.38
1473974:1474015 -12.1 -10.23 7
1474151:1474164 -2.4 -1.4 0.69
1474242:1474376 -40.6 -40.95 36.93
1474417:1474756 -138.1 -131.23 39.38
1474792:1474805 -1.2 -0.43 1.52
1474978:1475070 -33.3 -31.74 9.87
1475129:1475174 -11.8 -10.24 13.63
1475209:1475552 -110.2 -110.71 110.38
1475653:1475755 -27.1 -25.55 19.83
1475807:1476054 -73.2 -73.62 23.28
1476136:1476144 0 -0.04 0.28














1476272:1476331 -17.5 -17.7 8.54
1476371:1476624 -98.7 -95.56 71.88




Appendix K:  Secondary structure predictions of sRNA fragments found in the 100 ng sample. RNAfold web server was used to 
predict the secondary structure of the sRNA fragments found in the 100 ng sample.  Table shows the length, coverage, chromosome 
region, and location on the H37Rv genome.  For the secondary structure prediction, the table also displays the minimum free energy 
(MFE), free energy of the thermodynamic ensemble, as well as the ensemble diversity in each fragment. 
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Intergenic -10.60 -10.83 0.97
34 5 4262779..4262812 fadD32 Towards the beginning -8.70 -9.25 2.24
34 5 4334567..4334600 gltB towards the middle -7.70 -8.93 8.56
34 5 1564447..1564480 gmk Towards the beginning -8.90 -9.74 8.73
34 5 601708..601741 hemA towards the end -6.80 -6.90 0.54
34 5 2289878..2289911 lipT towards the end -10.60 -11.11 6.58
34 5 4369747..4369780 mycP2 Towards the beginning -5.10 -5.56 2.71
34 5 303550..303583 nirB 683 in -11.70 -12.32 1.45
34 5 2827612..2827645 orn towards the end -10.20 -10.52 2.04
34 5 337304..337337 PE_PGRS4 close to the middle -7.10 -8.00 8.47
34 5 1577190..1577223 Rv1401 middle -12.10 -12.23 0.87
34 5 2055657..2055690 Rv1813c
at the end of the gene, and a little 
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34 5 2239323..2239356 Rv1996 towards the middle Rv1996 is before ctpF -9.90 -10.50 2.13
34 5 2978147..2978180 Rv2655c towards the middle -8.10 -8.83 4.58
34 5 4302868..4302901 Rv3828c towards the end -7.50 -7.81 1.22
34 5 4398690..4398723 Rv3910 middle -7.90 -9.06 9.44
34 5 3022467..3022500 sigB beginning -7.20 -7.48 3.13
35 5 1866320..1866354 argC towards the end -5.70 -6.29 7.19
35 5 3651551..3651585 ctpC middle. "Cation transport ATPase" -15.30 -15.32 0.11
35 5 782891..782925 fusA1 Towards the beginning -5.00 -5.37 8.24
35 5 873531..873565 hemH Towards the beginning -9.20 -9.66 6.07
35 5 1736341..1736375 Inter geneic Intergenic region between Rv1535 and ileS -9.70 -9.81 1.89
35 5 2056276..2056310 Inter geneic Intergenic region between Rv1813c and erg3 -10.20 -10.43 4.16
35 5 2519178..2519212 kasA towards the end -13.50 -13.89 2.12
35 5 2672020..2672054 mbtB towards the end -5.20 -5.84 2.87
35 5 474296..474330 ndhA towards the end -6.60 -7.98 10.46
35 5 1099314..1099348 pepD Towards the beginning -9.00 -10.00 5.79
35 5 1511851..1511885 radE14 towards the end -6.40 -6.88 7.32
35 5 2500503..2500537 rnpB towards the end -11.60 -12.13 4.86
35 5 119170..119204 Rv0102 towards the end -5.40 -5.60 1.09
35 5 194242..194276 Rv0165c towards the end -6.30 -6.30 3.75
35 5 269454..269488 Rv0225 towards the end -3.30 -4.33 5.55
35 5 348462..348496 Rv0284 towards the middle -5.80 -6.52 4.36
35 5 884318..884352 Rv0790c towards the middle -10.20 -11.39 9.15
35 5 1901178..1901212 Rv1676 Towards the beginning -10.50 -11.22 9.30
35 5 2032991..2033025 Rv1795 middle -3.70 -5.04 9.72
35 5 2477897..2477931 Rv2212 towards the middle -10.40 -10.97 4.04
35 5 2502565..2502599 Rv2228c Towards the beginning -8.50 -9.58 5.98
35 5 2783947..2783981 Rv2477c very close to the beginning of the gene -4.80 -5.49 4.06
35 5 3020895..3020929 Rv2707 towards the middle. -7.40 -8.10 1.82
 186 
 
Length Coverage Chromosome region
Location on 











35 5 3900311..3900345 Rv3480c close to the beginning -7.10 -8.27 7.44
35 5 3953877..3953911 Rv3517 towards the middle -9.00 -9.65 2.24
35 5 4221473..4221507 Rv3776
towards the beginning.  At the 
beginning of "domain of unknown 
function DUF 22"  fragments 
flanking both ends of this domain
-1.00 -2.48 8.16
35 5 4231808..4231842 Rv3785 middle -6.70 -7.85 7.78
35 5 274730..274764 Rv4006 Towards the end -10.30 -10.60 3.45
35 5 2819339..2819373 scoA towards the middle -7.10 -7.78 8.21
38 5 2404447..2404484 Rv2144c close to the beginning.  Very close to another fragment (-2772) -13.80 -13.89 0.41
39 5 1797489..1797527 nadC Towards the beginning -11.20 -12.23 8.08
43 5 2500383..2500425 Inter geneic very close to the end of Rv2226 and the end of rnpB (misc_RNA) -18.20 -19.47 3.78
45 5 2952672..2952716 Rv2626c towards the middle -6.80 -8.07 8.50
45 5 2953710..2953754 Rv2627c towards the end -8.50 -9.56 6.05
46 5 1516874..1516919 Rv1349 towards the middle -9.90 -11.01 7.95
49 5 1314313..1314361 pks3 close to the middle -15.30 -17.12 6.77
54 5 251787..251840 pckA Very close to the beginning of the gene -14.00 -15.59 11.47
64 5 776008..776071 mmpL5 close to the end -13.60 -14.41 9.77
34 6 2162128..2162161 aceAb in the middle -2.80 -3.57 5.04
34 6 420777..420810 dnaK middle -10.90 -11.49 3.05
34 6 326352..326385 fadE6 towards the end -10.60 -11.10 3.05
34 6 3516906..3516939 nuoG Towards the beginning -11.70 -12.58 10.84
34 6 3894312..3894345 PE31 towards the end -9.40 -9.87 2.64
34 6 2276245..2276278 pfkB Towards the beginning -7.10 -7.64 3.33
34 6 2593248..2593281 rocE towards the middle -7.00 -7.76 8.79
34 6 88211..88244 Rv0079 Towards the beginning -5.10 -5.71 2.48
34 6 215774..215807 Rv0185 Towards the beginning -5.80 -6.67 4.93
34 6 352444..352477 Rv0289 close to the middle -11.10 -11.23 1.27
34 6 631410..631443 Rv0538 towards the end -7.00 -7.33 5.18
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34 6 3497349..3497382 Rv3131 towards the end -8.30 -8.69 1.24
35 6 3666695..3666729 accA3 Towards the beginning -12.30 -13.14 9.40
35 6 3404859..3404893 ctaD very close to the beginning of the gene -6.00 -7.22 4.37
35 6 2483389..2483423 dlaT towards the end -6.20 -6.91 4.98
35 6 2842511..2842545 fas towards the end -12.90 -13.14 2.05
35 6 2150873..2150907 Inter geneic Intergenic region between Rv1903 and Rv1904.  Closer to Rv1904 -9.10 -9.12 0.13
35 6 3623406..3623440 lpqB Towards the end of the gene. -5.50 -5.71 5.29
35 6 2252256..2252290 otsB1 Towards the beginning -14.60 -15.34 2.95
35 6 4258521..4258555 pks13 middle -7.90 -8.44 4.61
35 6 1004881..1004915 prrB towards the middle -18.90 -19.48 10.51
35 6 707305..707339 Rv0613c towards the end -8.40 -9.29 4.10
35 6 1669140..1669174 Rv1478 and intergenic
at the end of the the gene into the 
intergenic region between Rv1478 
and moxR1
-8.10 -8.48 3.88
35 6 2445035..2445069 Rv2182c towards the middle -9.50 -9.86 2.69
35 6 3492964..3492998 Rv3127 towards the end of the gene.  Very close to another fragment (-899) -4.50 -6.14 6.38
35 6 4222194..4222228 Rv3776
towards the end.  At the end of 
"domain of unknown function DUF 
222"
0.00 -0.54 2.14
35 6 595932..595966 serB1 towards the middle -6.10 -7.38 11.71
38 6 346439..346476 Rv0284 Towards the beginning -12.30 -13.01 8.42
38 6 4056007..4056044 Rv3616c towards the end -7.60 -8.39 12.01
42 6 2239872..2239913 ctpG middle -9.80 -10.36 11.47
42 6 1963271..1963312 narX middle -11.20 -11.90 7.46
44 6 1313412..1313455 Inter geneic between Rv1179 and pks3 -13.10 -13.77 12.57
50 6 3084849..3084898 Rv2777c close to the middle -13.50 -14.05 5.57
66 6 3493021..3493086 Rv3127 towards the end -21.20 -22.00 7.81
69 6 2952398..2952466 Rv2625c close to the beginning -23.30 -23.58 1.28
34 7 662451..662484 nrdZ middle -3.10 -3.63 4.79
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34 7 2073625..2073658 Rv1828 towards the end -10.60 -10.81 5.83
35 7 3806205..3806239 acrA1 towards the middle -11.80 -11.89 0.54
35 7 1222477..1222511 desA2 towards the middle -7.70 -8.18 3.42
35 7 1227126..1227160 fumC Towards the beginning -7.90 -8.97 9.24
35 7 7449..7483 gyrA Towards the beginning -10.20 -10.31 0.76
35 7 2017524..2017558 Inter geneic Intergenic region between malQ and Rv1782 -12.30 -12.64 1.14
35 7 349084..349118 Rv0284 towards the end -5.50 -5.87 1.24
35 7 867824..867858 Rv0774c middle -8.20 -9.72 5.39
35 7 2278025..2278059 Rv2030c Towards the beginning -10.40 -10.52 0.85
35 7 4346889..4346923 Rv3870 Towards the beginning -7.30 -8.31 8.51
35 7 25117..25151 TB39.8 Towards the beginning -3.40 -3.50 1.87
39 7 1113102..1113140 Rv0996 towards the middle -15.10 -15.85 1.74
40 7 917498..917537 Rv0823c Towards the beginning -7.00 -7.44 9.08
54 7 3468268..3468321 ssr Towards the beginning.  Ssr is classified as a misc RNA -10.70 -11.91 10.41
64 7 4024199..4024262 ispF Towards the beginning -20.50 -22.40 14.95





inter genic -3.00 -3.77 7.03
34 8 2484655..2484688 lipB Towards the beginning -14.60 -14.89 1.02
34 8 4220050..4220083 lipE towards the middle -3.40 -4.19 4.46
34 8 1796908..1796941 nadB towards the end -11.30 -11.59 3.12
34 8 1845595..1845628 uvrA towards the middle -3.70 -4.16 4.18
35 8 3499671..3499705 devR towards the middle -4.30 -4.71 3.80
35 8 88506..88540 hycD towards the middle -8.90 -9.26 4.75
35 8 1150652..1150686 kdpD towards the middle -10.80 -11.19 4.87
35 8 1796054..1796088 nadB Towards the beginning -10.90 -10.99 0.74
35 8 851642..851676 phoP Towards the beginning -3.10 -4.14 9.50
35 8 2979238..2979272 Rv2657c Towards the beginning -10.90 -11.16 2.53
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35 8 3606667..3606701 Rv3229c towards the middle -5.70 -6.89 4.74
35 8 4029729..4029763 Rv3587c / intergenic
At the beginning of Rv3587c, over 
lapping a little into the intergenic 
region between Rv3587c and 
Rv3588c
-6.20 -6.89 7.14
35 8 1235415..1235449 xseA at the beginning -8.70 -9.08 2.05
40 8 3498580..3498619 devS towards the middle -10.00 -10.62 15.09
40 8 1132353..1132392 pks16 middle -10.80 -11.34 2.27
42 8 353501..353542 Rv0290 towards the middle -18.20 -18.57 1.09
44 8 352199..352242 Rv0289 close to the beginning of Rv0289 -10.30 -11.55 9.61
47 8 2278606..2278652 hspX towards the end -10.20 -10.41 1.90
66 8 4359090..4359155 Rv3879c Towards the beginning -22.30 -23.45 12.32
34 9 1197094..1197127 Rv1072 at the end -5.10 -5.76 4.41
34 9 3589569..3589602 Rv3212 Towards the beginning -10.20 -10.78 3.19
35 9 1340943..1340977 esxK
at the end of Rv1247c into the 
intergenic region between esxK and 
esxL
-9.30 -9.64 1.46
35 9 2103054..2103088 Inter geneic
Intergenic region between ndh and 
Rv1855c.  Very close to the 
beginning of ndh
-5.90 -7.00 10.23
35 9 3548920..3548954 Inter geneic 13 bp after the end of Rv3179 -6.10 -6.30 2.72
35 9 3246358..3246392 ppsA Towards the beginning -8.60 -0.96 6.27
35 9 356191..356225 Rv0292 Towards the beginning -9.40 -9.81 9.10
44 9 353322..353365 Rv0290 Towards the beginning -13.10 -13.91 3.52
49 9 1965772..1965820 Rv1738 middle -18.90 -19.58 7.29
64 9 2256537..2256600 Inter geneic
very close to the end of the gene 
Rv2008c. between fdxA and 
Rv2008c
-27.00 -27.33 2.74
65 9 2655876..2655940 cfp2 towards the middle -20.70 -22.70 17.70
77 9 340750..340826 PPE3 closer to the end of PPE3 than PPE3(+1164) -45.30 -46.46 5.59
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34 10 2150918..2150951 Inter geneic before the beginning of the gene Rv1904 -2.00 -2.77 6.57
34 10 2954155..2954188 Rv2627c middle -8.80 -9.73 3.85
35 10 2463741..2463775 ctaC close to the end -10.80 -10.93 0.44
35 10 2847337..2847371 fas Towards the beginning -7.00 -7.67 1.70
35 10 1413108..1413142 Inter geneic
Intergenic region between Rv1264 
and Rv1265.  Very close to the end of 
Rv1264
-9.90 -11.00 13.05
35 10 2122411..2122445 lldD2 middle -4.30 -4.99 8.02
35 10 3758308..3758342 PPE56 Towards the end of the gene. -14.90 -15.58 1.98
34 11 32182..32215 Rv0029 Towards the beginning -2.60 -0.32 2.89
34 11 1998195..1998228 Rv1765c towards the middle 0.00 -0.45 1.91
35 11 1466925..1466959 atpD towards the end -11.70 -11.90 0.83
35 11 2517353..2517387 fabD towards the middle -10.70 -11.11 2.13
35 11 1199075..1199109 fadA3 Towards the beginning -6.40 -6.69 4.01
35 11 2845154..2845188 fas middle -12.50 -13.08 2.01
35 11 1220452..1220486 Inter geneic inter genic close to the beginning of glyA.  Between coaA and glyA. -8.00 -8.84 10.89
35 11 4056753..4056787 Inter geneic between Rv3616c and ephA. Closer to the beginning of Rv3616c. -9.90 -10.52 2.96
39 11 378204..378242 Rv0309 towards the middle -7.80 -8.58 8.15
56 11 3093770..3093825 Inter geneic between rpsO and ribF -11.20 -11.88 4.78
66 11 1485598..1485663 Rv1322A towards the middle -14.60 -16.75 16.75
78 11 918303..918380 desA1 towards the middle -34.10 -35.16 4.61
35 12 1389211..1389245 Rv1247c
At the beginning of the gene, with 
one bp in the intergenic region 
between Rv1247 and kgd
-5.90 -6.54 4.07
35 12 2626202..2626236 Rv2345 towards the middle -15.00 -15.71 2.61
35 12 3606901..3606935 Rv3229c Towards the beginning -14.40 -15.23 8.32
45 12 2236394..2236438 ctpG middle -13.10 -13.39 6.29
52 12 1197139..1197190 Inter geneic between Rv1072 and Rv1073 -12.10 -13.10 13.68
 191 
 
Length Coverage Chromosome region
Location on 











61 12 1169366..1169426 IS1081-1 close to the beginning of insertion sequence of IS1081 -21.40 -22.42 1.59
34 13 2102731..2102764 ndh Towards the beginning -1.90 -3.00 7.13
35 13 1419706..1419740 lprA very close to the beginning of the gene -4.40 -5.12 6.19
35 13 2646753..2646787 Rv2365c very close to the end of the gene -11.50 -11.98 5.03
35 13 2756411..2756445 Rv2455c Towards the beginning -7.20 -7.78 10.47
35 13 2959794..2959828 Rv2633c and intergenic
At the beginning of Rv2633c and 
overlapping onto the intergenic 
region between Rv2633c and 
PE_PGRS46
-1.50 -3.05 8.96
35 13 4119573..4119607 Rv3679
towards the end.  Within a predicted 
ATPase involved in chromosome 
partitioning
-14.00 -14.54 6.37
39 13 1376990..1377028 Rv1234 Towards the beginning.  Rv1234 is before lpqY -5.20 -6.18 7.85
92 13 4168191..4168282 Inter geneic
Between Rv3722c and Rvnt41.  
Rvnt41 is between Rv3722c and 
Rv3723.
-38.90 -40.30 19.32
35 14 1666920..1666954 Inter geneic Intergenic region between Rv1476 and Rv1477.  Closer to Rv1477 -9.50 -9.97 1.45
35 14 2728347..2728381 Inter geneic between PE25 and Rc2432c -4.90 -5.03 1.17
35 14 498846..498880 Rv0412c towards the middle -1.90 -2.50 3.04
35 14 2782771..2782805 Rv2477c Towards the end -8.50 -9.05 4.10
41 14 2951533..2951573 Rv2625c towards the end -14.90 -15.01 0.81
49 14 3496579..3496627 Rv3131 towards the beginning, very close to another segment (+2) -12.70 -12.91 6.60
66 14 355733..355798 mycP3 close to the end -17.00 -17.50 5.96
34 15 3153388..3153421 efpA towards the end -1.50 -2.61 8.28
35 15 1166640..1166674 Rv1043c Towards the beginning -6.50 -7.70 11.91
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36 15 2624292..2624327 Rv2345
Towards the beginning. At the end of 
a "domain of unknown function 
(DUF477)"
-8.00 -9.19 3.12
45 15 1080094..1080138 ctpV towards the middle -8.10 -8.92 5.41
45 15 2391717..2391761 cysS towards the middle -7.80 -9.58 16.90
34 16 1993213..1993246 Rv1760 Towards the beginning -8.70 -9.49 6.87
34 16 2775535..2775568 Rv2472 at the end -7.50 -7.94 8.96
35 16 3496375..3496409 Inter geneic
Very close to the beginning of tgs1.  
In the intergenic region between tgs1 
and Rv3131
-6.00 -6.52 6.42
45 16 4314343..4314387 bfrB towards the middle -7.30 -8.23 11.96
74 16 2949865..2949938 TB31.7 towards the middle -18.10 -19.49 11.13
35 17 3540695..3540729 hpx Very close to the beginning of the gene -9.60 -10.16 8.93
35 17 2638357..2638391 PPE40 towards the middle -3.10 -3.67 4.38
35 17 2280314..2280348 Rv2033c towards the end -11.40 -12.50 5.42
35 17 2885351..2885385 Rv2565 towards the middle -14.90 -14.95 0.20
52 17 2177096..2177147 fadD31 Very close to the beginning of the gene -8.90 -10.26 16.65
62 17 1964660..1964721 narK2 towards the middle -17.60 -19.07 17.70
34 18 1114988..1115021 Rv0998 towards the middle -11.50 -12.44 3.27
35 18 2274682..2274716 Rv2028c towards the end 0.00 -0.79 3.85
45 18 571794..571838 lprQ Towards the beginning -17.10 -17.57 1.85
35 19 3153949..3153983 efpA towards the middle -11.10 -11.68 2.91
35 19 65446..65480 Inter geneic between Rv0061 and celA1, closer to the end of Rv0061 -6.80 -7.37 7.90
55 19 3497199..3497253 Rv3131 towards the middle -15.70 -16.78 13.47
73 20 4100706..4100778 Inter geneic
behind another inter geneic fragment: 
4100814.  between Rv3661 and 
Rv3662c.
-22.90 -23.54 7.23
89 20 3468146..3468234 ssr towards the middle of ssr -33.20 -34.80 12.54
34 21 2279214..2279247 acg Towards the beginning -10.80 -11.12 1.50
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35 23 4404606..4404640 Rv3916c towards the end -5.80 -5.99 2.28
46 23 3496804..3496849 Rv3131 close to the middle, several other fragments on this gene -15.10 -15.50 5.03
39 24 1965823..1965861 Rv1738 towards the end.  Next to another fragment (+115) -9.40 -11.25 5.98
49 24 409680..409728 iniB close to the beginning -18.10 -19.38 18.12
55 24 3496517..3496571 Rv3131 2bp into the beginning -12.60 -12.88 6.80
80 24 1773938..1774017 Rv1566c Very close to the beginning of the gene -43.30 -44.21 6.54
43 26 2767686..2767728 Rv2465c close to the beginning -14.00 -14.97 6.48
35 27 50642..50676 inol towards the middle -4.20 -4.74 5.58
35 27 3649468..3649502 Rv3268 Towards the beginning -11.10 -11.90 8.11
35 28 916241..916275 Rv0822c beginning -6.90 -7.55 5.45
34 30 754760..754793 Rv0659c towards the middle -6.70 -7.47 8.44
50 31 3326014..3326063 Rv2970A middle/close to the end of the gene -12.20 -12.80 4.84






at the beginning of Rv3640c and I 
little on the intergenic region 
between Rv3640c and fic
-20.60 -21.08 1.84
35 37 3826433..3826467 Rv3407
towards the end of the gene.  Also 
towards the end of "Phd YefM; 
Region: PhdYeFM; c109153"
-4.20 -4.85 4.22
34 46 1816201..1816234 pykA close to the beginning -6.50 -7.04 3.64
45 55 1824726..1824770 cydA towards the end -12.60 -13.20 13.41
36 62 4352944..4352979 Inter geneic between esxA and Rv3876 -4.90 -5.34 5.66
37 64 2314134..2314170 rpsR towards the end -10.30 -11.02 9.69
62 70 1275613..1275674 Inter geneic close to the end of Rv1147.  Between Rv1147 and Rv1148c -36.60 -37.37 5.94
40 71 3468051..3468090 ssr towards the middle -6.10 -6.92 10.36
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67 92 913457..913523 phoT at the end of the gene, a little over between phoT and phoY2 -27.90 -28.49 3.63






at the beginning of Rv2144c and 
overlapping onto intergenic region 
between Rv2144c and wag31
-9.20 -10.63 14.82
34 128 2844174..2844207 fas towards the middle -10.80 -11.49 1.25
82 129 1960700..1960781 Inter geneic and on Rv1734c
Between Rv1733c and Rv1734c.  
Some of it overlaps with the end of 
Rv1734c
-25.90 -27.54 20.12
64 152 4099412..4099475 Inter geneic between Rv3660c and Rv3661 -24.50 -25.52 18.79
35 165 80258..80292 glyA Towards the beginning -10.90 11.15 6.42
74 409 1473259..1473332 rrs very close to the end of the gene -26.30 -27.07 15.92
43 424 4252929..4252971 Inter geneic between fadE35 and Rv3798.  Closer to the beginning of Rv3798 -7.40 -8.23 10.42
72 504 1342599..1342670 IS1081-2
Towards the beginning, IS1081-2 
overlaps Rv119c except for the 
beginning
-35.60 -35.82 0.82
47 555 1469528..1469574 IS1557-2 close to the beginning of IS1557-2 -6.40 -7.03 2.39
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35 5 3900311..3900345 Rv3480c close to the beginning -7.10 -8.27 7.44
35 5 3953877..3953911 Rv3517 towards the middle -9.00 -9.65 2.24
35 5 4221473..4221507 Rv3776
towards the beginning.  At the 
beginning of "domain of unknown 
function DUF 22"  fragments 
flanking both ends of this domain
-1.00 -2.48 8.16
35 5 4231808..4231842 Rv3785 middle -6.70 -7.85 7.78
35 5 274730..274764 Rv4006 Towards the end -10.30 -10.60 3.45
35 5 2819339..2819373 scoA towards the middle -7.10 -7.78 8.21
38 5 2404447..2404484 Rv2144c close to the beginning.  Very close to another fragment (-2772) -13.80 -13.89 0.41
39 5 1797489..1797527 nadC Towards the beginning -11.20 -12.23 8.08
43 5 2500383..2500425 Inter geneic very close to the end of Rv2226 and the end of rnpB (misc_RNA) -18.20 -19.47 3.78
45 5 2952672..2952716 Rv2626c towards the middle -6.80 -8.07 8.50
45 5 2953710..2953754 Rv2627c towards the end -8.50 -9.56 6.05
46 5 1516874..1516919 Rv1349 towards the middle -9.90 -11.01 7.95
49 5 1314313..1314361 pks3 close to the middle -15.30 -17.12 6.77
54 5 251787..251840 pckA Very close to the beginning of the gene -14.00 -15.59 11.47
64 5 776008..776071 mmpL5 close to the end -13.60 -14.41 9.77
34 6 2162128..2162161 aceAb in the middle -2.80 -3.57 5.04
34 6 420777..420810 dnaK middle -10.90 -11.49 3.05
34 6 326352..326385 fadE6 towards the end -10.60 -11.10 3.05
34 6 3516906..3516939 nuoG Towards the beginning -11.70 -12.58 10.84
34 6 3894312..3894345 PE31 towards the end -9.40 -9.87 2.64
34 6 2276245..2276278 pfkB Towards the beginning -7.10 -7.64 3.33
34 6 2593248..2593281 rocE towards the middle -7.00 -7.76 8.79
34 6 88211..88244 Rv0079 Towards the beginning -5.10 -5.71 2.48
34 6 215774..215807 Rv0185 Towards the beginning -5.80 -6.67 4.93
34 6 352444..352477 Rv0289 close to the middle -11.10 -11.23 1.27
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